| Q24634502 | "Splicing up" drug discovery. Cell-based expression and screening of genetically-encoded libraries of backbone-cyclized polypeptides |
| Q39766431 | 'Metabolic mapping' of drugs: rapid screening techniques for xenobiotic metabolites with m.s./m.s. techniques |
| Q30978056 | 2 minute non-invasive screening for cardio-vascular diseases: relative limitation of C-Reactive Protein compared with more sensitive L-Homocystine as cardio-vascular risk factors; safe and effective treatment using the selective drug uptake [...] |
| Q35252215 | 3'-Azido-3'-deoxythymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/10 mice infected with LP-BM5 murine leukemia viruses, a possible animal model for antiretroviral drug screening |
| Q41055848 | 3-Dimensional micropillar drug screening identifies FGFR2-IIIC overexpression as a potential target in metastatic giant cell tumor |
| Q38832448 | 3D Printing of Tissue Engineered Constructs for In Vitro Modeling of Disease Progression and Drug Screening |
| Q38811797 | 3D descriptors calculation and conformational search to investigate potential bioactive conformations, with application in 3D-QSAR and virtual screening in drug design |
| Q38154340 | 3D in vitro tissue models and their potential for drug screening |
| Q63246944 | 3D tissue engineering, an emerging technique for pharmaceutical research |
| Q34650300 | 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. |
| Q39902631 | A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase. |
| Q41518143 | A Biomimetic Microfluidic Tumor Microenvironment Platform Mimicking the EPR Effect for Rapid Screening of Drug Delivery Systems |
| Q35626674 | A Brief Screening Tool to Assess the Risk of Contracting HIV Infection Among Active Injection Drug Users |
| Q33628472 | A Digital Tool to Promote Alcohol and Drug Use Screening, Brief Intervention, and Referral to Treatment Skill Translation: A Mobile App Development and Randomized Controlled Trial Protocol. |
| Q33201766 | A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases |
| Q41767658 | A Gas Chromatographic Screening Procedure for the detection of Non-steroidal Anti-inflammatory Drugs in horse urine |
| Q41990847 | A High Throughput Screening Method for Systematic Surveillance of Drugs of Abuse by Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry. |
| Q41132294 | A High Throughput, 384-Well, Semi-Automated, Hepatocyte Intrinsic Clearance Assay for Screening New Molecular Entities in Drug Discovery |
| Q36009841 | A High-Throughput Drug Screening Strategy for Detecting Rhodopsin P23H Mutant Rescue and Degradation |
| Q37474413 | A Microchip for High-throughput Axon Growth Drug Screening. |
| Q35916110 | A Mismatch between High-Risk Behaviors and Screening of Infectious Diseases among People Who Inject Drugs in Dar es Salaam, Tanzania |
| Q38799329 | A Multi-Modality CMOS Sensor Array for Cell-Based Assay and Drug Screening. |
| Q33652588 | A Natural Products Approach to Drug Discovery: Probing Modes of Action of Antitumor Agents by Genome-Scale cDNA Library Screening |
| Q44632143 | A Novel In Vitro Model for Screening and Evaluation of Anti-asthenopia Drugs |
| Q37710715 | A Novel Method for Screening Adenosine Receptor Specific Agonists for Use in Adenosine Drug Development. |
| Q41925849 | A Plasmodium falciparum screening assay for anti-gametocyte drugs based on parasite lactate dehydrogenase detection |
| Q35837615 | A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening |
| Q27308741 | A Recombinant Human Pluripotent Stem Cell Line Stably Expressing Halide-Sensitive YFP-I152L for GABAAR and GlyR-Targeted High-Throughput Drug Screening and Toxicity Testing |
| Q27692126 | A Synthetic Biology Project - Developing a single-molecule device for screening drug-target interactions |
| Q39701557 | A Systematic Comparison Identifies an ATP-Based Viability Assay as Most Suitable Read-Out for Drug Screening in Glioma Stem-Like Cells |
| Q41938185 | A Unique Antinuclcic Acid Approach to the Mass Screening of Antimalarial Drugs |
| Q41587038 | A biochemical screening test for the photosensitizing potential of drugs and disinfectants |
| Q35868287 | A biomimetic Schlemm's canal inner wall: A model to study outflow physiology, glaucoma pathology and high-throughput drug screening. |
| Q34793715 | A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide. |
| Q39189380 | A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization. |
| Q64055450 | A cell-based high-throughput screen identifies tyrphostin AG 879 as an inhibitor of animal cell phospholipid and fatty acid biosynthesis |
| Q37241812 | A clinical evaluation of the Janus Web Application, a software screening tool for drug-drug interactions |
| Q44148145 | A combination of new screening assays for prioritization of transmission-blocking antimalarials reveals distinct dynamics of marketed and experimental drugs |
| Q35342234 | A combined HPLC-immunoenzymatic comprehensive screening for suspected drug poisoning in the emergency department. |
| Q38123757 | A commentary on iPS cells: potential applications in autologous transplantation, study of illnesses and drug screening |
| Q31035854 | A comparison of an opioid abuse screening tool and prescription drug monitoring data in the emergency department. |
| Q39917831 | A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management |
| Q36738500 | A comprehensive review of the psychometric properties of the Drug Abuse Screening Test |
| Q42697074 | A comprehensive screening platform for aerosolizable protein formulations for intranasal and pulmonary drug delivery. |
| Q33206987 | A computer program for automated data evaluation to support in vitro higher-throughput screening for drug metabolism and pharmacokinetics attributes |
| Q39335214 | A computer system for on-line drug screening |
| Q43556833 | A computer-based system for screening outpatient drug utilization |
| Q34129808 | A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity |
| Q28482183 | A drug screening method based on the autophagy pathway and studies of the mechanism of evodiamine against influenza A virus |
| Q35270008 | A drug-repositioning screening identifies pentetic acid as a potential therapeutic agent for suppressing the elastase-mediated virulence of Pseudomonas aeruginosa. |
| Q40047018 | A functional temporal association mining approach for screening potential drug-drug interactions from electronic patient databases |
| Q44130467 | A general screening method for acidic, neutral, and basic drugs in whole blood using the Oasis MCX column |
| Q30886898 | A general unknown screening procedure for drugs and toxic compounds in serum using liquid chromatography-electrospray-single quadrupole mass spectrometry |
| Q31119978 | A generally applicable, high-throughput screening-compatible assay to identify, evaluate, and optimize antimicrobial agents for drug therapy |
| Q43528067 | A high content screening assay to predict human drug-induced liver injury during drug discovery |
| Q36122722 | A high throughput drug screening assay to identify compounds that promote oligodendrocyte differentiation using acutely dissociated and purified oligodendrocyte precursor cells |
| Q34199223 | A high-coverage artificial chromosome library for the genome-wide screening of drug-resistance genes in malaria parasites |
| Q34364856 | A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine |
| Q40256942 | A high-throughput drug screening system for HIV-1 transcription inhibitors |
| Q28484556 | A high-throughput fluorescence-based assay system for appetite-regulating gene and drug screening |
| Q64075831 | A high-throughput ratiometric method for imaging hypertrophic growth in cultured primary cardiac myocytes |
| Q36495979 | A high-throughput screening assay for the identification of flavivirus NS5 capping enzyme GTP-binding inhibitors: implications for antiviral drug development |
| Q30863787 | A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates |
| Q40730733 | A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein |
| Q28477495 | A human TREK-1/HEK cell line: a highly efficient screening tool for drug development in neurological diseases |
| Q42208724 | A knowledge-based approach for identification of drugs against vivapain-2 protein of Plasmodium vivax through pharmacophore-based virtual screening with comparative modelling |
| Q34132195 | A lethal combination for cancer cells: synthetic lethality screenings for drug discovery |
| Q40565801 | A mechanism-based in vitro anticancer drug screening approach for phenolic phytochemicals |
| Q33613032 | A method for post-marketing screening of adverse reactions to drugs: initial results. |
| Q44150585 | A method for screening antimalarial drugs in the mosquito host. |
| Q41941065 | A method for screening drugs against the liver stages of malaria using Plasmodium gallinaceum and Aedes mosquitos |
| Q35205302 | A method to enhance the hit ratio by a combination of structure-based drug screening and ligand-based screening. |
| Q36022803 | A microfluidic device for whole-animal drug screening using electrophysiological measures in the nematode C. elegans |
| Q30539555 | A microfluidic platform for high-sensitivity, real-time drug screening on C. elegans and parasitic nematodes |
| Q38998051 | A microfluidic-based platform for tumour spheroid culture, monitoring and drug screening |
| Q40186769 | A modified screening system to select new cytostatic drugs |
| Q35546916 | A modified version of the Drug Abuse Screening Test among undergraduate students. |
| Q40688694 | A multichannel ultrasonic activity monitor forin-vitro screening of antischistosomal drugs |
| Q28222071 | A multiparameter test of clot formation and fibrinolysis for in-vitro drug screening |
| Q40008083 | A near-infrared-fluorescence-quenched gold-nanoparticle imaging probe for in vivo drug screening and protease activity determination |
| Q31775960 | A new drug-screening procedure for photosensitizing agents used in photodynamic therapy for CNV. |
| Q42154642 | A new fluorescent based screening system for high throughput screening of drugs targeting HBV-core and HBsAg interaction |
| Q28534314 | A new in vivo screening paradigm to accelerate antimalarial drug discovery |
| Q24304169 | A new mechanism of 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one dihydrochloride (TAS-103) action discovered by target screening with drug-immobilized affinity beads |
| Q33388600 | A new method for in-silico drug screening and similarity search using molecular dynamics maximum volume overlap (MD-MVO) method |
| Q41579262 | A new microperfusion system for the cultivation of tumor-cells invitro - approach to integrate pharmacokinetic parameters in screening assays for cytostatic drugs. |
| Q41645899 | A new screening assay for antigiardial compounds: effects of various drugs on the adherence of Giardia duodenalis to Caco2 cells |
| Q41730699 | A new screening system for nonsteroidal anti-inflammatory drugs based upon inhibition of chemiluminescence produced from human cells (granulocytes) |
| Q42038302 | A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions |
| Q34535992 | A new system for parallel drug screening against multiple-resistant HIV mutants based on lentiviral self-inactivating (SIN) vectors and multi-colour analyses |
| Q44059740 | A new, rapid and sensitive bioluminescence assay for drug screening on Leishmania |
| Q33723750 | A novel Caenorhabditis elegans allele, smn-1(cb131), mimicking a mild form of spinal muscular atrophy, provides a convenient drug screening platform highlighting new and pre-approved compounds |
| Q34669706 | A novel Leishmania major amastigote assay in 96-well format for rapid drug screening and its use for discovery and evaluation of a new class of leishmanicidal quinolinium salts |
| Q37588526 | A novel assay for high-throughput screening of anti-Alzheimer's disease drugs to determine their efficacy by real-time monitoring of changes in PC12 cell proliferation |
| Q36308567 | A novel assay to determine acetylcholinesterase activity: The application potential for screening of drugs against Alzheimer's disease |
| Q41761865 | A novel diet-induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis |
| Q38848195 | A novel hanging spherical drop system for the generation of cellular spheroids and high throughput combinatorial drug screening. |
| Q28476171 | A novel high throughput assay for anthelmintic drug screening and resistance diagnosis by real-time monitoring of parasite motility |
| Q31105814 | A novel high-through-put assay for screening of pro-apoptotic drugs |
| Q33425353 | A novel high-throughput cell-based method for integrated quantification of type I interferons and in vitro screening of immunostimulatory RNA drug delivery |
| Q39655614 | A novel immunoassay for quantitative drug abuse screening in serum. |
| Q36081191 | A novel intravenous vehicle for preclinical cardiovascular screening of small molecule drug candidates in rat. |
| Q43628749 | A novel microphysiometer based on MLAPS for drugs screening |
| Q37907001 | A novel multicenter preclinical drug screening and biomarker consortium for experimental traumatic brain injury: operation brain trauma therapy |
| Q36922558 | A novel non-radioactive assay for HIV-RT (RdDp) based on pyrosequencing for high-throughput drug screening |
| Q37284537 | A novel reporter system for molecular imaging and high-throughput screening of anticancer drugs. |
| Q43714511 | A novel screening for inhibitors of a pleiotropic drug resistant pump, Pdr5, in Saccharomyces cerevisiae |
| Q31135604 | A novel screening method to establish tumor-targeting antibodies reliable for drug delivery system |
| Q34262700 | A novel zebrafish human tumor xenograft model validated for anti-cancer drug screening |
| Q39669970 | A polymer microstructure array for the formation, culturing, and high throughput drug screening of breast cancer spheroids |
| Q34687788 | A potential model for drug screening by simulating the effect of shear stress in vivo on endothelium |
| Q41309387 | A potential screening test for minor tranquilizing drug action |
| Q40001741 | A preliminary report on spinal muscular atrophy lymphoblastoid cell lines: are they an appropriate tool for drug screening? |
| Q39372646 | A programmable microfluidic cell array for combinatorial drug screening |
| Q39231668 | A proposed screening paradigm for discovery of covalent inhibitor drugs |
| Q33240484 | A protein recycling system for nuclear magnetic resonance-based screening of drug candidates |
| Q44039646 | A random survey of drug screening proficiency |
| Q38764637 | A randomized study of the use of screening, brief intervention, and referral to treatment (SBIRT) for drug and alcohol use with jail inmates |
| Q41647232 | A rapid anticancer drug screening assay by [14C] thymidine uptake in cultured human cancer cells |
| Q33200528 | A rapid in vitro screening for delivery of peptide-derived peptidase inhibitors as potential drug candidates via epithelial peptide transporters |
| Q44667757 | A rapid screening procedure for acidic and neutral drugs in blood by high resolution gas chromatography |
| Q33200894 | A rapid screening procedure for drugs and poisons in gastric contents by direct injection-HPLC analysis |
| Q30884640 | A rapid spectrofluorimetric technique for determining drug-serum protein binding suitable for high-throughput screening |
| Q39037776 | A real-time impedance-based screening assay for drug-induced vascular leakage |
| Q41775860 | A research for screening anti-hepatitis B virus drugs with the 2.2.15 cell line |
| Q36566235 | A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards |
| Q35164037 | A screening pattern recognition method finds new and divergent targets for drugs and natural products |
| Q38716425 | A screening strategy for the discovery of drugs that reduce C/EBPβ-LIP translation with potential calorie restriction mimetic properties |
| Q37316562 | A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel |
| Q44330227 | A screening survey of dyslipoproteinemias associated with prescription drug use. The Lipid Research Clinics Program Prevalence Study |
| Q44026793 | A semiautomated multiparameter approach for anti-HIV drug screening |
| Q43741828 | A semiautomated radioimmunoassay for mass screening of drugs of abuse |
| Q38599275 | A signalome screening approach in the autoinflammatory disease TNF Receptor Associated Periodic Syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing |
| Q38943963 | A simple screening system for anti-HIV drugs: syncytium formation assay using T-cell line tropic and macrophage tropic HIV env expressing cell lines--establishment and validation. |
| Q30846735 | A simple technique for high-throughput screening of drugs that modulate normal and psoriasis-like differentiation in cultured human keratinocytes |
| Q38740982 | A simple, reliable method for high-throughput screening for diabetes drugs using 3D β-cell spheroids |
| Q33631031 | A single-question screening test for drug use in primary care |
| Q35606501 | A small-fish model for behavioral-toxicological screening of new antimalarial drugs: a comparison between erythro- and threo-mefloquine |
| Q64387374 | A small-molecule inhibitor of the DNA recombinase Rad51 from synergizes with the antimalarial drugs artemisinin and chloroquine |
| Q31806373 | A solid-phase glycosyltransferase assay for high-throughput screening in drug discovery research |
| Q38968948 | A spatiotemporally defined in vitro microenvironment for controllable signal delivery and drug screening. |
| Q30844551 | A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials |
| Q41512776 | A statistical-heuristic methods for automated selection of drugs for screening |
| Q34143251 | A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening. |
| Q40936372 | A strategy for screening anti-tumor drugs utilizing oncogenes encoded in retroviral vectors |
| Q44518328 | A study on mechanism of skin penetration by cercaria of S. japonicum and screening of preventive drugs |
| Q36422566 | A system for screening and epidemiologic monitoring of HIV infection in drug addicts. A working model and analysis of data related to 1517 subjects from the Veronese area |
| Q36565940 | A system of screening for the presence of a number of common drugs |
| Q34084900 | A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening. |
| Q38827863 | A systematic approach to prioritize drug targets using machine learning, a molecular descriptor-based classification model, and high-throughput screening of plant derived molecules: a case study in oral cancer. |
| Q35025905 | A three-stage biophysical screening cascade for fragment-based drug discovery. |
| Q40519669 | A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system |
| Q36250562 | A vascularized and perfused organ-on-a-chip platform for large-scale drug screening applications. |
| Q41137409 | A versatile 3D tissue matrix scaffold system for tumor modeling and drug screening |
| Q44700854 | A vertical flow chamber for Xenopus oocyte electrophysiology and automated drug screening |
| Q35397122 | AN APPRAISAL OF ANIMAL DRUG SCREENING TECHNIQUES USED IN PSYCHOPHARMACOLOGY. |
| Q41496032 | ARQiv-HTS, a versatile whole-organism screening platform enabling in vivo drug discovery at high-throughput rates. |
| Q41905691 | AUTOMATED QUANTIFICATION OF ZEBRAFISH TAIL DEFORMATION FOR HIGH-THROUGHPUT DRUG SCREENING. |
| Q38801066 | Abstinence-Conflict Model: Toward an Optimal Animal Model for Screening Medications Promoting Drug Abstinence |
| Q40480372 | Acanthamoeba castellanii: A new high-throughput method for drug screening in vitro. |
| Q36107703 | Accelerated cytotoxicity mechanism screening using drug metabolising enzyme modulators |
| Q31001861 | Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis |
| Q41874952 | Achievement of constitutive fluorescent pLEXSY-egfp Leishmania braziliensis and its application as an alternative method for drug screening in vitro |
| Q33397254 | Actinomycin D identified as an inhibitor of discoidin domain receptor 2 interaction with collagen through an insect cell based screening of a drug compound library |
| Q40347903 | Activators of viral gene expression in polarized epithelial monolayers identified by rapid-throughput drug screening. |
| Q41652677 | Active screening of multi-drug resistant bacteria effectively prevent and control the potential infections |
| Q36741418 | Activity based probes for proteases: applications to biomarker discovery, molecular imaging and drug screening. |
| Q40210891 | Adaptation and optimization of a fluorescence-based assay for in vivo antimalarial drug screening. |
| Q35719340 | Adaptation of high-throughput screening in drug discovery-toxicological screening tests. |
| Q28082595 | Adapting Screening, Brief Intervention, and Referral to Treatment for Alcohol and Drugs to Culturally Diverse Clinical Populations |
| Q38911199 | Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers |
| Q40250258 | Adjuvant polyarthritis in rats: is this a satisfactory model for screening anti-arthritic drugs? |
| Q38552408 | Advancements in in vitro hepatic models: application for drug screening and therapeutics |
| Q36641739 | Advances and perspectives in Leishmania cell based drug-screening procedures |
| Q38028568 | Advances in flow cytometry for drug screening. |
| Q28256965 | Advances in high content screening for drug discovery |
| Q37232926 | Advances in parallel screening of drug candidates. |
| Q33269368 | Advances in small animal mesentery models for in vivo flow cytometry, dynamic microscopy, and drug screening |
| Q38777366 | Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis. |
| Q30597676 | Advantages and application of label-free detection assays in drug screening |
| Q38211210 | Advantages of cell-based high-volume screening assays to assess nuclear receptor activation during drug discovery |
| Q35848043 | Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery |
| Q36968696 | Affinity selection-mass spectrometry screening techniques for small molecule drug discovery |
| Q39426492 | Alcohol and drug abuse in an urban trauma center: predictors of screening and detection |
| Q39888019 | Alcohol and drug screening of newborns: would women consent? |
| Q24241010 | Alcohol and drug screening of occupational drivers for preventing injury |
| Q24246014 | Alcohol and drug screening of occupational drivers for preventing injury |
| Q24201802 | Alcohol and drug screening of occupational drivers for preventing work-related injury |
| Q34001595 | Alcohol screening and brief intervention among drug users in primary care: a discussion paper |
| Q39912189 | Alcohol, tobacco, and other drugs: future directions for screening and intervention in the emergency department |
| Q39874849 | Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells |
| Q35454522 | Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. |
| Q38139529 | Alzheimer's disease drug discovery: in vivo screening using Caenorhabditis elegans as a model for β-amyloid peptide-induced toxicity |
| Q41977858 | An Algorithm for the Preclinical Screening of Anticancer Drugs Effective against Brain Tumors. |
| Q41938192 | An Automated Method of Mass Drug Testing Applied to Screening for Antimalarial Activity |
| Q42291062 | An Integrating Approach for Genome-Wide Screening of MicroRNA Polymorphisms Mediated Drug Response Alterations. |
| Q40043376 | An RNA polymerase II-driven Ebola virus minigenome system as an advanced tool for antiviral drug screening |
| Q39394159 | An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs. |
| Q43268346 | An allele specific PCR assay for screening for drug resistance among Wuchereria bancrofti populations in India |
| Q37069597 | An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein |
| Q44461918 | An amperometric biosensor with human CYP3A4 as a novel drug screening tool |
| Q41899314 | An analysis of the activating system including its use for screening antiParkinson drugs. |
| Q34372525 | An aptamer-based bio-barcode assay with isothermal recombinase polymerase amplification for cytochrome-c detection and anti-cancer drug screening |
| Q28484953 | An assay suitable for high throughput screening of anti-influenza drugs |
| Q37211885 | An assessment of anxiolytic drug screening tests: hormetic dose responses predominate |
| Q33694152 | An automated screening method for drugs and toxic compounds in human serum and urine using liquid chromatography-tandem mass spectrometry |
| Q39783960 | An axenic amastigote system for drug screening |
| Q34075283 | An efficient high-throughput screening method for MYST family acetyltransferases, a new class of epigenetic drug targets |
| Q37762497 | An emerging role for kinase screening in GPCR drug discovery |
| Q44170646 | An ex vivo culture model for screening drug activity against in vivo phenotypes of Mycobacterium tuberculosis |
| Q44039513 | An examination of the relative impact of type I and type II error rates in phase II drug screening trial queues |
| Q35163145 | An exhaustive yet simple virtual screening campaign against Sortase A from multiple drug resistant Staphylococcus aureus |
| Q43203148 | An improved formulation screening and optimization method applied to the development of a self-microemulsifying drug delivery system |
| Q38947257 | An in silico functional annotation and screening of potential drug targets derived from Leishmania spp. hypothetical proteins identified by immunoproteomics. |
| Q39767325 | An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells. |
| Q41611674 | An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1 |
| Q39283886 | An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents |
| Q44252111 | An in vitro system for screening anti-hepatitis B virus drugs |
| Q34407919 | An in vivo C. elegans model system for screening EGFR-inhibiting anti-cancer drugs |
| Q41926337 | An in vivo drug screening model using glucose-6-phosphate dehydrogenase deficient mice to predict the hemolytic toxicity of 8-aminoquinolines |
| Q36683116 | An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery. |
| Q44237626 | An in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying drugs. |
| Q35665032 | An inducible kras(V12) transgenic zebrafish model for liver tumorigenesis and chemical drug screening. |
| Q39739416 | An instrument-based screening assay for DNA-targeted anticancer drugs using resonance light scattering |
| Q34187856 | An integrated surrogate model for screening of drugs against Mycobacterium tuberculosis |
| Q33393822 | An ion channel library for drug discovery and safety screening on automated platforms |
| Q42168297 | An optical approach for drug screening based on light-harvesting conjugated polyelectrolytes |
| Q38873342 | An optimized InCell Western screening technique identifies hexachlorophene as a novel potent TDP43 targeting drug |
| Q35690408 | An optimized lactate dehydrogenase release assay for screening of drug candidates in neuroscience |
| Q28534870 | An over expression APP model for anti-Alzheimer disease drug screening created by zinc finger nuclease technology |
| Q42170717 | An overview of acetic acid ulcer models and their utility for drug screening |
| Q37241157 | An overview of drug screening using primary and embryonic stem cells. |
| Q38020237 | An update of novel screening methods for GPCR in drug discovery |
| Q38840796 | An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs |
| Q30583965 | Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives |
| Q39820326 | Analysis of nonadherent apoptotic cells by a quantum dots probe in a microfluidic device for drug screening |
| Q34314602 | Analysis of synthetic cannabinoids using high-resolution mass spectrometry and mass defect filtering: implications for nontargeted screening of designer drugs |
| Q31163078 | Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses |
| Q41318010 | Analytical strategies for the screening of veterinary drugs and their residues in edible products (review), by Aerts et al.: an addendum |
| Q40476270 | Analytical strategies for the screening of veterinary drugs and their residues in edible products. |
| Q36351405 | Animal models as tools for screening candidate drugs |
| Q26781104 | Animal models for screening anxiolytic-like drugs: a perspective |
| Q43816527 | Animal models for screening hypolipidemic drugs. II. Response to nicotinic acid in the Mongolian gerbil. Short communication |
| Q37998707 | Animal models of working memory: a review of tasks that might be used in screening drug treatments for the memory impairments found in schizophrenia. |
| Q34091800 | Animal models used in the screening of antiepileptic drugs |
| Q28477320 | Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease |
| Q41276044 | Anti-Tat MTT assay: a novel anti-HIV drug screening system using the viral regulatory network of replication |
| Q33720784 | Anti-tubercular drug designing by structure based screening of combinatorial libraries |
| Q35538634 | Antiarrhythmic Drug Target Choices and Screening |
| Q37233054 | Antibodies against G-protein coupled receptors: novel uses in screening and drug development |
| Q39437562 | Antibody binding shift assay for rapid screening of drug interactions with the human ABCG2 multidrug transporter |
| Q34626275 | Anticancer drug development incorporating high-content screening and RNAi: synergistic approaches to improve target identification and validation |
| Q35535446 | Anticancer drug screening and discovery in the 1990s: a European perspective |
| Q42030108 | Anticancer drug screening test with LDH in nude mouse bearing bone and soft part sarcoma |
| Q40382361 | Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer |
| Q28473835 | Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds |
| Q35790381 | Antimalarial drug discovery: efficacy models for compound screening |
| Q43466173 | Antineoplastic drug screening belongs in the laboratory, not in the clinic |
| Q36858299 | Antipsychotic Drug Use and Screening for Delirium in Mechanically Ventilated Patients in Canadian Intensive Care Units: An Observational Study |
| Q39311040 | Application of Combination High-Throughput Phenotypic Screening and Target Identification Methods for the Discovery of Natural Product-Based Combination Drugs |
| Q43879127 | Application of EU guidelines for the validation of screening methods for veterinary drugs |
| Q34191709 | Application of LC-high-resolution MS with 'intelligent' data mining tools for screening reactive drug metabolites |
| Q35061199 | Application of NMR screening in drug discovery |
| Q40067191 | Application of PatchXpress planar patch clamp technology to the screening of new drug candidates for cardiac KCNQ1/KCNE1 (I Ks) activity |
| Q41677182 | Application of Raman spectroscopy in type 2 diabetes screening in blood using leucine and isoleucine amino-acids as biomarkers and in comparative anti-diabetic drugs efficacy studies |
| Q36237723 | Application of Snyder-Dolan classification scheme to the selection of "orthogonal" columns for fast screening of illicit drugs and impurity profiling of pharmaceuticals--I. Isocratic elution |
| Q36366308 | Application of a laser-induced endothelial injury model in the screening of antithrombotic drugs |
| Q33213621 | Application of accurate mass measurement to urine drug screening |
| Q43189665 | Application of an in vitro drug screening assay based on the release of phosphoglucose isomerase to determine the structure-activity relationship of thiazolides against Echinococcus multilocularis metacestodes. |
| Q44069611 | Application of cell-free hemolymph of horseshoe crab in antimicrobial drug screening |
| Q37692438 | Application of chemistry-based functional proteomics to screening for novel drug targets |
| Q37669369 | Application of cytochrome P450 drug interaction screening in drug discovery |
| Q30986274 | Application of data screening to drug exposure in large risk factor studies of birth defects. |
| Q33433609 | Application of direct urine LC-MS-MS analysis for screening of novel substances in drug abusers |
| Q33938910 | Application of high-throughput screening techniques to drug discovery. |
| Q34594910 | Application of high-throughput, molecular-targeted screening to anticancer drug discovery |
| Q31734229 | Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s |
| Q33259931 | Application of linear discriminant analysis in the virtual screening of antichagasic drugs through trypanothione reductase inhibition |
| Q33485906 | Application of screening methods, shape signatures and engineered biosensors in early drug discovery process |
| Q43756624 | Application of solid-phase micro-extraction technology to drug screening and identification |
| Q44020593 | Application of the CEDIA 6-MAM assay to routine drugs-of-abuse screening |
| Q31120463 | Applications of SHAPES screening in drug discovery. |
| Q28656335 | Applications of chemogenomic library screening in drug discovery |
| Q36749967 | Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions |
| Q37823231 | Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease |
| Q44478112 | Applications of recombinant Leishmania amazonensis expressing egfp or the beta-galactosidase gene for drug screening and histopathological analysis |
| Q38600008 | Approach to Modeling, Therapy Evaluation, Drug Selection, and Biomarker Assessments for a Multicenter Pre-Clinical Drug Screening Consortium for Acute Therapies in Severe Traumatic Brain Injury: Operation Brain Trauma Therapy |
| Q38127474 | Approaches to protozoan drug discovery: phenotypic screening. |
| Q37380627 | Arbitrarily Accessible 3D Microfluidic Device for Combinatorial High-Throughput Drug Screening |
| Q44026065 | Are drunk-driving offenders referred for screening accurately reporting their drug use? |
| Q33734763 | Aroma WaterLOGSY: a fast and sensitive screening tool for drug discovery |
| Q37286428 | Arthritis screening and support program to be delivered by pharmacists at Shoppers Drug Mart |
| Q39109900 | Ascidians: An Emerging Marine Model for Drug Discovery and Screening. |
| Q27489371 | Assay development and high-throughput antiviral drug screening against Bluetongue virus |
| Q41934438 | Assay for screening for six antimalarial drugs and one metabolite using dried blood spot sampling, sequential extraction and ion-trap detection |
| Q43172183 | Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care |
| Q42112205 | Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening |
| Q28552630 | Assessment of Anti-TNF-α Activities in Keratinocytes Expressing Inducible TNF- α: A Novel Tool for Anti-TNF-α Drug Screening |
| Q28373277 | Assessment of drugs against Cryptosporidium parvum using a simple in vitro screening method |
| Q41900287 | Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria Sybr green I-based fluorescence assay |
| Q33746847 | Assessment of re-aggregated human pancreatic islets for secondary drug screening |
| Q34233988 | Athletic trainers' attitudes toward drug screening of intercollegiate athletes. |
| Q33385063 | Atom- and bond-based 2D TOMOCOMD-CARDD approach and ligand-based virtual screening for the drug discovery of new tyrosinase inhibitors. |
| Q42628459 | Atomic force microscopy-based screening of drug-excipient miscibility and stability of solid dispersions |
| Q40252076 | Attempts to Standardize the Screening for Antiviral Drugs by <i>in vitro</i> Tests |
| Q36429431 | Attitudes of matriculating first-year pharmacy students toward a mandatory, random drug-screening program |
| Q39677414 | Attitudes, perceptions and practice of alcohol and drug screening, brief intervention and referral to treatment: a case study of New York State primary care physicians and non-physician providers |
| Q35967022 | Automated Fast Screening Method for Cocaine Identification in Seized Drug Samples Using a Portable Fourier Transform Infrared (FT-IR) Instrument |
| Q33247029 | Automated analysis of behavior: a computer-controlled system for drug screening and the investigation of learning |
| Q24629251 | Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts |
| Q35296383 | Automated fast perfusion of Xenopus oocytes for drug screening |
| Q21562132 | Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z |
| Q36821789 | Automated imaging and quantitation of tumor cells and CFU-GM colonies in microcapillary cultures: toward therapeutic index-based drug screening |
| Q33534587 | Automated mass spectral deconvolution and identification system for GC-MS screening for drugs, poisons, and metabolites in urine |
| Q37370171 | Automated planar electrode electrophysiology in drug discovery: examples of the use of QPatch in basic characterization and high content screening on Na(v), K(Ca)2.3, and K(v)11.1 channels |
| Q33251750 | Automated screening for drug metabolites with high-performance liquid chromatography UV-visible diode array detection and spectra library search |
| Q39786685 | Automated tracking of unmarked cells migrating in three-dimensional matrices applied to anti-cancer drug screening |
| Q33749271 | BEAR, a novel virtual screening methodology for drug discovery. |
| Q36131412 | Bacterial Transcription Inhibitor of RNA Polymerase Holoenzyme Formation by Structure-Based Drug Design: From in Silico Screening to Validation |
| Q36601834 | Baculoviruses and mammalian cell-based assays for drug screening |
| Q37496984 | Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study |
| Q37875030 | Behavioral screening for neuroactive drugs in zebrafish |
| Q39094539 | Benchmarking of multivariate similarity measures for high-content screening fingerprints in phenotypic drug discovery |
| Q33650254 | Beta-adrenergic receptor blocking drugs: tear lysozyme and immunological screening for adverse reaction |
| Q24611403 | Beyond reverse pharmacology: Mechanism-based screening of Ayurvedic drugs |
| Q41649015 | Beyond risky alcohol use: screening non-medical use of prescription drugs at National Alcohol Screening Day. |
| Q38848565 | Bi-content micro-collagen chip provides contractility-based biomechanical readout for phenotypic drug screening with expanded and profiled targets |
| Q30359656 | Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased μ opioid receptor agonists |
| Q44233694 | Big Data and New Drug Discovery: Tackling "Big Data" for Virtual Screening of Large Compound Databases |
| Q41932504 | Bioanalytical Screening of Riboflavin Antagonists for Targeted Drug Delivery - A Thermodynamic and Kinetic Study |
| Q34421141 | Biochanin A reduces drug-induced p75NTR expression and enhances cell survival: a new in vitro assay for screening inhibitors of p75NTR expression |
| Q38593990 | Biochemical Screening for in utero Drug Exposure |
| Q39026114 | Bioengineered 3D Scaffolds in Cancer Research: Focus on Epithelial to Mesenchymal Transition and Drug Screening |
| Q28654365 | Bioinformatic screening of autoimmune disease genes and protein structure prediction with FAMS for drug discovery |
| Q37411273 | Bioinformatics tools for screening of antiparasitic drugs. |
| Q64807197 | Biological Collection of Kidney Cells |
| Q23922568 | Biological monitoring screening of patients provided antineoplastic drugs including adriamycin, cyclophosphamide, 5-fluorouracil, methotrexate, and vincristine |
| Q36732518 | Biological screening of natural products and drug innovation in China |
| Q35184192 | Bioluminescence and chemiluminescence in drug screening |
| Q28379005 | Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery |
| Q33928270 | Bioluminescent Mycobacterium aurum expressing firefly luciferase for rapid and high throughput screening of antimycobacterial drugs in vitro and in infected macrophages |
| Q35694549 | Biomimetic 3D Tissue Models for Advanced High-Throughput Drug Screening. |
| Q64065786 | Biomimetic Membranes with Transmembrane Proteins: State-of-the-Art in Transmembrane Protein Applications |
| Q44251312 | Biomimetic membrane platform containing hERG potassium channel and its application to drug screening |
| Q27676919 | Biophysical Fragment Screening of the β 1 -Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug Design |
| Q37542558 | Biophysical techniques for ligand screening and drug design |
| Q36515199 | Biosensor screening for veterinary drug residues in foodstuffs |
| Q37480101 | Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening? |
| Q66024328 | Blood Sampling for Research Related to Sickle Cell Disease |
| Q41946744 | Blood schizontocidal activity of azithromycin and its combination with alpha/beta arteether against multi-drug resistant Plasmodium yoelii nigeriensis, a novel MDR parasite model for antimalarial screening |
| Q41058669 | Bond-based bilinear indices for computational discovery of novel trypanosomicidal drug-like compounds through virtual screening |
| Q34056343 | Brief intervention to increase emergency department uptake of combined rapid human immunodeficiency virus and hepatitis C screening among a drug misusing population |
| Q39919747 | Brief screening and intervention for alcohol and drug use in a college student health clinic: feasibility, implementation, and outcomes. |
| Q39126913 | Bringing new dimensions to drug discovery screening: impact of cellular stimulation technologies |
| Q33524425 | Broad spectrum drug screening using electron-ionization gas chromatography-mass spectrometry (EI-GCMS). |
| Q33444870 | Broad spectrum drug screening using liquid chromatography-hybrid triple quadrupole linear ion trap mass spectrometry. |
| Q35867467 | Broad-Spectrum Drug Screening Using Liquid Chromatography-Hybrid Triple-Quadrupole Linear Ion Trap Mass Spectrometry |
| Q42975289 | Broad-spectrum drug screening of meconium by liquid chromatography with tandem mass spectrometry and time-of-flight mass spectrometry |
| Q38803953 | C-SPADE: a web-tool for interactive analysis and visualization of drug screening experiments through compound-specific bioactivity dendrograms |
| Q43215833 | CAS Enhances Chemotherapeutic Drug-Induced p53 Accumulation and Apoptosis: Use of CAS for High-Sensitivity Anticancer Drug Screening |
| Q39388607 | CMHC practices related to tardive dyskinesia screening and informed consent for neuroleptic drugs |
| Q33253907 | Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings |
| Q30594778 | Caenorhabditis elegans dnj-14, the orthologue of the DNAJC5 gene mutated in adult onset neuronal ceroid lipofuscinosis, provides a new platform for neuroprotective drug screening and identifies a SIR-2.1-independent action of resveratrol. |
| Q37768092 | Calcium channelopathies in inherited neurological disorders: relevance to drug screening for acquired channel disorders. |
| Q43636770 | Can 2 screening questions accurately detect alcohol and other drug abuse in the primary care setting? |
| Q39008498 | Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy |
| Q39116630 | Cancer Stem Cells (CSCs) as a Rational Therapeutic Cancer Target, and Screening for CSC-targeting Drugs |
| Q38495033 | Cancer cell spheroids for screening of chemotherapeutics and drug-delivery systems |
| Q39801897 | Cancer stem cells and escape from drug-induced premature senescence in human lung tumor cells: implications for drug resistance and in vitro drug screening models |
| Q36286435 | Candida albicans biofilm chip (CaBChip) for high-throughput antifungal drug screening |
| Q43692784 | Canine heartworm disease in Japan: screening of selected drugs against Dirofilaria immitis in vivo |
| Q36258383 | Capsule Commentary on McNeely et al., Validation of Self-Administered Single Item Screening Questions (SISQs) for Unhealthy Alcohol and Drug use in Primary Care Patients. |
| Q34111355 | Cardiac Arrhythmia: In vivo screening in the zebrafish to overcome complexity in drug discovery |
| Q37978068 | Cardiomyocytes derived from human pluripotent stem cells for drug screening |
| Q37481432 | Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates |
| Q37030257 | Cardiovascular complications among individuals with amphetamine-positive urine drug screening admitted to a tertiary care hospital in Riyadh |
| Q43933338 | Catalepsy, Sedation and Hypothermia Induced by Alpha-Methyl-p-Tyrosine in the Rat. An Ideal Tool for Screening of Drugs Active on Central Catecholaminergic Receptors**) |
| Q39064343 | Cell culture monitoring for drug screening and cancer research: a transparent, microfluidic, multi-sensor microsystem |
| Q41068603 | Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs |
| Q36284754 | Cell lines as in vitro models for drug screening and toxicity studies |
| Q28084264 | Cell-Based Assay Design for High-Content Screening of Drug Candidates |
| Q39137189 | Cell-based drug combination screening with a microfluidic droplet array system |
| Q30786727 | Cell-based screening approach for antitumor drug leads which exploits sensitivity differences between normal and cancer cells: identification of two novel cell-cycle inhibitors. |
| Q42810446 | Cells Cultured on Core-Shell Photonic Crystal Barcodes for Drug Screening |
| Q27021118 | Cellular Biomechanics in Drug Screening and Evaluation: Mechanopharmacology |
| Q42710078 | Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity |
| Q35487937 | Cellular impedance biosensors for drug screening and toxin detection. |
| Q37825825 | Cellular models for disease exploring and drug screening |
| Q35717303 | Centrifugal microfluidic platform for single-cell level cardiomyocyte-based drug profiling and screening |
| Q40476505 | Ceramic Hydroxylapatite as a Plaque Growth and Drug Screening Substrate |
| Q38682415 | Challenges for Detecting Valproic Acid in a Nontargeted Urine Drug Screening Method. |
| Q36144731 | Characteristics Associated with HIV Drug Resistance Among Women Screening for an HIV Prevention Trial in KwaZulu-Natal, South Africa |
| Q38931985 | Characterization of a new small bowel adenocarcinoma cell line and screening of anti-cancer drug against small bowel adenocarcinoma. |
| Q28369412 | Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening |
| Q44191382 | Characterization of mixtures of recombinant human cytochrome p450s as a screening model for metabolic stability in drug discovery |
| Q38336860 | Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CLpro protease: basis for the in vitro screening of anti-SARS drugs |
| Q41122113 | Charting the epidemic: the case study of HIV screening of injecting drug users in San Francisco, 1985-1990. |
| Q28542718 | Cheburator software for automatically calculating drug inhibitory concentrations from in vitro screening assays |
| Q40472636 | Chemical & RNAi screening at MSKCC: a collaborative platform to discover & repurpose drugs to fight disease. |
| Q37950610 | Chemical genetics and drug screening in Drosophila cancer models |
| Q33833426 | Chemical library screening identifies a small molecule that downregulates SOD1 transcription for drugs to treat amyotrophic lateral sclerosis |
| Q30492821 | Chemical microarray: a new tool for drug screening and discovery |
| Q38139531 | Chemical screening platforms for autophagy drug discovery to identify therapeutic candidates for Huntington's disease and other neurodegenerative disorders. |
| Q28290688 | Chemogenomics profiling of drug targets of peptidoglycan biosynthesis pathway in Leptospira interrogans by virtual screening approaches |
| Q41238161 | Chemosensitization and drug accumulation assays as complementary methods for the screening of multidrug resistance reversal agents |
| Q39464331 | Child Restraint Use and Driver Screening in Fatal Crashes Involving Drugs and Alcohol |
| Q37845739 | Chlamydia screening in young people as an outcome of a HEADSS; Home, Education, Activities, Drug and alcohol use, Sexuality and Suicide youth psychosocial assessment tool |
| Q33708992 | Chlamydia's quick cure. Fight against 'silent' STD includes new screening test, one-dose drug. |
| Q64119879 | Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer's Disease Neurons |
| Q36559992 | Clinical Note: Urine Screening of Arrestees as a Source of Drug Abuse Indicator Data |
| Q34917423 | Clinical Validation of a Highly Sensitive GC-MS Platform for Routine Urine Drug Screening and Real-Time Reporting of up to 212 Drugs |
| Q34339946 | Clinical case discussion: screening and brief intervention for drug use in primary care. |
| Q44495442 | Clinical characteristics according to depression screening tools in patients with Alzheimer's disease: view from self, caregiver-reported and drug-intervention pattern |
| Q33616140 | Clinical evaluation and use of urine screening for drug abuse |
| Q42748942 | Cochrane reviews--in their own words. Alcohol and drug screening of people whose job involves driving |
| Q40053125 | Colworth prize lecture 2016: exploiting new biological targets from a whole-cell phenotypic screening campaign for TB drug discovery. |
| Q39864781 | Combination of cell culture and quantitative PCR for screening of drugs against Cryptosporidium parvum |
| Q38722564 | Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities |
| Q38712272 | Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor |
| Q30819299 | Combinatorial chemistry and high-throughput screening in drug discovery: different strategies and formats |
| Q30277902 | Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas |
| Q30418057 | Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms |
| Q42553000 | Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma |
| Q35537690 | Combinatorial screening for specific drug solubilizers with switchable release profiles. |
| Q64274970 | Combining TIR and FRET in Molecular Test Systems |
| Q33991624 | Combining biophysical screening and X-ray crystallography for fragment-based drug discovery |
| Q42428707 | Comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells". |
| Q40838051 | Community-based screening: a motivating experience for drug users |
| Q41525387 | Comparative Analysis of 3D Bladder Tumor Spheroids Obtained by Forced Floating and Hanging Drop Methods for Drug Screening. |
| Q37268884 | Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions |
| Q37632187 | Comparative drug screening in NUT midline carcinoma |
| Q39172040 | Comparison between drug screening by immunoassay and ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry in post-mortem urine |
| Q42656132 | Comparison between xCELLigence biosensor technology and conventional cell culture system for real-time monitoring human tenocytes proliferation and drugs cytotoxicity screening |
| Q39468626 | Comparison of Cryptosporidium parvum development in various cell lines for screening in vitro drug testing. |
| Q40446524 | Comparison of Information-Dependent Acquisition on a Tandem Quadrupole TOF vs a Triple Quadrupole Linear Ion Trap Mass Spectrometer for Broad-Spectrum Drug Screening |
| Q41920365 | Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations |
| Q36444505 | Comparison of Objective Screening and Self-Report for Alcohol and Drug Use in Traumatically Injured Patients |
| Q28552275 | Comparison of a New In-House and Three Published HLA-B*15:02 Screening Methods for Prevention of Carbamazepine-Induced Severe Drug Reactions |
| Q44426494 | Comparison of a preliminary procedure for the general unknown screening of drugs and toxic compounds using a quadrupole-linear ion-trap mass spectrometer with a liquid chromatography–mass spectrometry reference technique |
| Q41345517 | Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system: an in vitro method of screening new drugs |
| Q43682780 | Comparison of eight commercial on-site screening devices for drugs-of-abuse testing |
| Q44406101 | Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery |
| Q30617388 | Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines |
| Q28475069 | Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening |
| Q43774601 | Comparison of point-of-collection screening of drugs of abuse in oral fluid with a laboratory-based urine screen |
| Q34663837 | Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening |
| Q40273624 | Comparison of three cell-based drug screening platforms for HSV-1 infection |
| Q43139798 | Comparison of triple quadrupole, hybrid linear ion trap triple quadrupole, time-of-flight and LTQ-Orbitrap mass spectrometers in drug discovery phase metabolite screening and identification in vitro--amitriptyline and verapamil as model compounds |
| Q35212443 | Complete genome-wide screening and subtractive genomic approach revealed new virulence factors, potential drug targets against bio-war pathogen Brucella melitensis 16M. |
| Q30381239 | Composite Sequence-Structure Stability Models as Screening Tools for Identifying Vulnerable Targets for HIV Drug and Vaccine Development. |
| Q30989686 | Comprehensive drug screening by integrated use of gas chromatography/mass spectrometry and Remedi HS. |
| Q35339149 | Comprehensive drug screening in decision making of patients attending the emergency department for suspected drug overdose |
| Q36739658 | Comprehensive screening and quantification of veterinary drugs in milk using UPLC-ToF-MS. |
| Q35707383 | Comprehensive screening of genes resistant to an anticancer drug in esophageal squamous cell carcinoma |
| Q43312451 | Comprehensive screening of veterinary drugs in honey by ultra-high-performance liquid chromatography coupled to mass spectrometry |
| Q33204525 | Comprehensive two-dimensional gas chromatography with time-of-flight mass spectrometry (GC x GC-TOFMS) for drug screening and confirmation |
| Q39357510 | Computation-based virtual screening for designing novel antimalarial drugs by targeting falcipain-III: a structure-based drug designing approach |
| Q37414273 | Computational Drug Target Screening through Protein Interaction Profiles |
| Q37465002 | Computational Systems Bioinformatics and Bioimaging for Pathway Analysis and Drug Screening |
| Q36462289 | Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs |
| Q33377132 | Computational chemistry, data mining, high-throughput synthesis and screening--informatics and integration in drug discovery |
| Q64096640 | Computational modeling of the olfactory receptor Olfr73 suggests a molecular basis for low potency of olfactory receptor-activating compounds |
| Q35989427 | Computational protein-ligand docking and virtual drug screening with the AutoDock suite |
| Q38779114 | Computational proteome-wide screening predicts neurotoxic drug-protein interactome for the investigational analgesic BIA 10-2474. |
| Q42005228 | Computational screening of molecular targets in Plasmodium for novel non resistant anti-malarial drugs |
| Q34158472 | Computer-aided drug design of falcipain inhibitors: virtual screening, structure-activity relationships, hydration site thermodynamics, and reactivity analysis |
| Q37281804 | Computer-delivered screening and brief intervention (e-SBI) for postpartum drug use: a randomized trial |
| Q36553043 | Computerized Tailored Interventions to Enhance Prevention and Screening for Hepatitis C Virus Among People Who Inject Drugs: Protocol for a Randomized Pilot Study. |
| Q44175622 | Computerized drug-drug interaction screening system |
| Q36859556 | Computerized screening for alcohol and drug use among adults seeking outpatient psychiatric services |
| Q39031335 | Concave microwell array-mediated three-dimensional tumor model for screening anticancer drug-loaded nanoparticles |
| Q34347602 | Concise review: a high-content screening approach to stem cell research and drug discovery |
| Q43862565 | Concordance analysis of an in vitro micronucleus screening assay and the regulatory chromosome aberration assay using pharmaceutical drug candidates |
| Q33476900 | Conditional drug screening shows that mitotic inhibitors induce AKT/PKB-insensitive apoptosis |
| Q40923746 | Conditionally adherent growth of serum-independent CHO cells for automated drug screening and biopharmaceutical production |
| Q33755473 | Confidence from uncertainty--a multi-target drug screening method from robust control theory |
| Q36179203 | Conjugate-SELEX: A High-throughput Screening of Thioaptamer-liposomal Nanoparticle Conjugates for Targeted Intracellular Delivery of Anticancer Drugs |
| Q37550214 | Conjugated polyelectrolytes as new platforms for drug screening |
| Q41908136 | Construction of yeast strains useful for screening drugs that inhibit glucose uptake and glycolysis |
| Q40178422 | Contribution and limits of clinical specimens for the screening of intestinal multi-drug-resistant bacteria in view of laboratory automation. |
| Q37055825 | Corneal epithelial cell cultures as a tool for research, drug screening and testing |
| Q28538346 | Correction: Prevalence of HIV-1 Drug Resistance among Women Screening for HIV Prevention Trials in KwaZulu-Natal, South Africa (MTN-009) |
| Q37446970 | Correlative effect between in vivo hollow fiber assay and xenografts assay in drug screening |
| Q36715136 | Cost Effectiveness Associated with Helicobacter pylori Screening and Eradication in Patients Taking Nonsteroidal Anti-Inflammatory Drugs and/or Aspirin |
| Q28483820 | Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users |
| Q28359547 | Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program |
| Q37731402 | Costs of screening and brief intervention for illicit drug use in primary care settings. |
| Q33454558 | Coupling laser ablation/desorption electrospray ionization to atmospheric pressure drift tube ion mobility spectrometry for the screening of antimalarial drug quality. |
| Q36217016 | Covalent Immobilization of Human Placental 17β-Hydroxysteroid Dehydrogenase Type 1 onto Glutaraldehyde Activated Silica Coupled with LC-TOF/MS for Anti-Cancer Drug Screening Applications. |
| Q43242748 | Criterion for excipients screening in the development of nanoemulsion formulation of three anti-inflammatory drugs |
| Q42097867 | Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids |
| Q35210165 | Crystallography, NMR and virtual screening: integrated tools for drug discovery. |
| Q38034129 | Current status of drug screening and disease modelling in human pluripotent stem cells. |
| Q34149545 | Current use of high-resolution mass spectrometry in drug screening relevant to clinical and forensic toxicology and doping control |
| Q38900601 | Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise? |
| Q36900653 | Cutaneous leishmaniasis in the dorsal skin of hamsters: a useful model for the screening of antileishmanial drugs |
| Q41176129 | Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. |
| Q28544810 | DISIS: prediction of drug response through an iterative sure independence screening |
| Q31066558 | DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program |
| Q39476913 | DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening |
| Q35051906 | DSE-FRET: A new anticancer drug screening assay for DNA binding proteins |
| Q28546078 | Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia |
| Q42373485 | Data from roadside screening for psychoactive substances, alcohol and illicit drugs, among Spanish drivers in 2015. |
| Q31147766 | Data mining a small molecule drug screening representative subset from NIH PubChem |
| Q34967840 | Database screening of herbal monomers regulating autophagy by constructing a "disease-gene-drug" network |
| Q40368392 | Decatamariic acid, a new mitochondrial respiration inhibitor discovered by pesticidal screening using drug-sensitive Saccharomyces cerevisiae. |
| Q40209539 | Derivation of a novel SARS-coronavirus replicon cell line and its application for anti-SARS drug screening |
| Q34106427 | Design and use of electrochemical sensors in enantioselective high throughput screening of drugs. A minireview |
| Q43109673 | Design of self-microemulsifying drug delivery systems using a high-throughput formulation screening system |
| Q31130509 | Design of small molecule libraries for NMR screening and other applications in drug discovery |
| Q37401820 | Design or screening of drugs for the treatment of Chagas disease: what shows the most promise? |
| Q39256194 | Design, development, and validation of a high-throughput drug-screening assay for targeting of human leukemia |
| Q28817173 | Designing and screening of universal drug from neem (Azadirachta indica) and standard drug chemicals against influenza virus nucleoprotein |
| Q33506859 | Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets |
| Q39995071 | Desorption electrospray ionisation mass spectrometry: A rapid screening tool for veterinary drug preparations and forensic samples from hormone crime investigations |
| Q39914742 | Detecting depressive disorders in drug abusers: a comparison of screening instruments |
| Q33529161 | Detection and identification of 700 drugs by multi-target screening with a 3200 Q TRAP LC-MS/MS system and library searching |
| Q39591373 | Detection of EPO-Fc fusion protein in human blood: screening and confirmation protocols for sports drug testing |
| Q36827828 | Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data |
| Q42726154 | Detection of drug abusers by urine screening |
| Q44201557 | Detection of drug interactions with single dose acenocoumarol: new screening method? |
| Q34191793 | Detection, characterization, and screening of heme-binding molecules by mass spectrometry for malaria drug discovery |
| Q36332263 | Developing a UHPLC-QTOF-MS and Automated Library Search Method for Screening Drugs and Toxic Compounds in Postmortem Specimens |
| Q34976113 | Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices |
| Q30643818 | Development and screening of a polyketide virtual library for drug leads against a motilide pharmacophore |
| Q37121907 | Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus. |
| Q28543164 | Development and validation of a luminescence-based, medium-throughput assay for drug screening in Schistosoma mansoni |
| Q33558923 | Development of Chemical Compound Libraries for In Silico Drug Screening |
| Q66393219 | Development of Diagnostics and Treatment of Urological Cancers |
| Q38729596 | Development of Leishmania donovani stably expressing DsRed for flow cytometry-based drug screening using chalcone thiazolyl-hydrazone as a new antileishmanial target |
| Q34435796 | Development of a Novel Screening Strategy Designed to Discover a New Class of HIV Drugs |
| Q37172794 | Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment. |
| Q40095970 | Development of a UPLC-MS/MS method for the determination of ten anticancer drugs in hospital and urban wastewaters, and its application for the screening of human metabolites assisted by information-dependent acquisition tool (IDA) in sewage samples |
| Q42942538 | Development of a dot-blot assay for screening monoclonal antibodies to low-molecular-mass drugs |
| Q43071445 | Development of a drug screening platform based on engineered heart tissue |
| Q40405708 | Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors |
| Q36133389 | Development of a high throughput drug screening assay to identify compounds that protect oligodendrocyte viability and differentiation under inflammatory conditions |
| Q39027555 | Development of a high-throughput antiviral assay for screening inhibitors of chikungunya virus and generation of drug-resistant mutations in cultured cells |
| Q31109321 | Development of a keratinocyte-based screening model for antipsoriatic drugs using green fluorescent protein under the control of an endogenous promoter |
| Q38993529 | Development of a magnetic 3D spheroid platform with potential application for high-throughput drug screening |
| Q33214401 | Development of a multi-target screening analysis for 301 drugs using a QTrap liquid chromatography/tandem mass spectrometry system and automated library searching |
| Q34622598 | Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine. |
| Q39608263 | Development of a novel immunoassay to detect interactions with the transactivation domain of p53: application to screening of new drugs |
| Q39028833 | Development of a novel multi-layer microfluidic device towards characterization of drug metabolism and cytotoxicity for drug screening |
| Q35566939 | Development of a phenotypic high-content assay to identify pharmacoperone drugs for the treatment of primary hyperoxaluria type 1 by high-throughput screening |
| Q39415618 | Development of a reporter bovine viral diarrhea virus and initial evaluation of its application for high throughput antiviral drug screening |
| Q41933768 | Development of a semi-automated image-based high-throughput drug screening system |
| Q39667113 | Development of a simple system for screening anti-hepatitis C virus drugs utilizing mutants capable of vigorous replication |
| Q36034475 | Development of a vestibular schwannoma xenograft zebrafish model for in vivo antitumor drug screening. |
| Q39227736 | Development of an adolescent alcohol and other drug abuse screening scale: Personal Experience Screening Questionnaire |
| Q33763772 | Development of an assay for Complex I/Complex III of the respiratory chain using solid supported membranes and its application in mitochondrial toxicity screening in drug discovery |
| Q36219372 | Development of an in vitro drug screening assay using Schistosoma haematobium schistosomula |
| Q41495514 | Development of an in vitro drug screening system for Mycobacterium leprae based on the determination of the intrabacterial sodium to potassium ratio of individual bacterial organisms |
| Q37278489 | Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening |
| Q33369294 | Development of high-throughput screening system for osteogenic drugs using a cell-based sensor |
| Q39529613 | Development of human tumor cell line panels for use in disease-oriented drug screening |
| Q36977946 | Development of selective blockers for Ca²(+)-activated Cl channel using Xenopus laevis oocytes with an improved drug screening strategy |
| Q43924385 | Development of solubility screening methods in drug discovery |
| Q40244380 | Development of specific dengue virus 2'-O- and N7-methyltransferase assays for antiviral drug screening. |
| Q30992027 | Development of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressants. |
| Q34543936 | Development, validation and pilot screening of an in vitro multi-cellular three-dimensional cancer spheroid assay for anti-cancer drug testing |
| Q44388445 | Diagnostic accuracy of a two-item Drug Abuse Screening Test (DAST-2). |
| Q44584626 | Diagnostic accuracy of a two-item screen for drug use developed from the alcohol, smoking and substance involvement screening test (ASSIST). |
| Q43073185 | Diagnostic approach to drug-screening tests for fatal diabetic ketoacidosis: forensic autopsy of a methamphetamine abuser |
| Q43628528 | Diagnostic validity of the drug abuse screening test in the assessment of DSM-III drug disorders |
| Q39532681 | Dielectrophoresis-based cellular microarray chip for anticancer drug screening in perfusion microenvironments. |
| Q41765005 | Differentiation from human pluripotent stem cells of cortical neurons of the superficial layers amenable to psychiatric disease modeling and high-throughput drug screening |
| Q33943741 | Discovering novel neuroactive drugs through high-throughput behavior-based chemical screening in the zebrafish |
| Q36300489 | Discovery of BVDU as a promising Drug for autoimmune diseases Therapy by Dendritic-cell-based functional screening |
| Q38777885 | Discovery of Novel Tricyclic Thiazepine Derivatives as Anti-Drug-Resistant Cancer Agents by Combining Diversity-Oriented Synthesis and Converging Screening Approach |
| Q35747414 | Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells |
| Q36063668 | Discovery of a novel ROCK2 inhibitor with anti-migration effects via docking and high-content drug screening |
| Q43591789 | Discovery of a quorum-sensing inhibitor of drug-resistant staphylococcal infections by structure-based virtual screening |
| Q38876767 | Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains |
| Q33322333 | Discovery of new antitumoral and antibacterial drugs from brazilian plant extracts using high throughput screening. |
| Q34048491 | Discovery of novel anti-inflammatory drug-like compounds by aligning in silico and in vivo screening: the nitroindazolinone chemotype |
| Q38585751 | Discovery of novel drug targets and their functions using phenotypic screening of natural products |
| Q33686745 | Discovery of phosphatidylinositol 3-kinase inhibitory compounds from the Screening Committee of Anticancer Drugs (SCADS) library |
| Q38107799 | Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells |
| Q35463524 | Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. |
| Q35221680 | Disease-modifying anti-rheumatic drugs: strategies for screening |
| Q39121692 | Disparities and guideline adherence in drugs of abuse screening in intracerebral hemorrhage |
| Q43291087 | Disposable microfluidic device with ultraviolet detection for highly resolved screening of illicit drugs |
| Q33944843 | Diversity screening versus focussed screening in drug discovery |
| Q38564024 | Docking and Virtual Screening Strategies for GPCR Drug Discovery |
| Q34364227 | Docking and scoring in virtual screening for drug discovery: methods and applications |
| Q37296002 | Docking, virtual high throughput screening and in silico fragment-based drug design |
| Q37644425 | Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB. |
| Q44673298 | Does brain slices from pentylenetetrazole-kindled mice provide a more predictive screening model for antiepileptic drugs? |
| Q38177927 | Does urine drug abuse screening help for managing patients? A systematic review |
| Q39289099 | Dopamine receptors in bovine retina : characterization of the 3H-spiroperidol binding and its use for screening dopamine receptor affinity of drugs |
| Q40095650 | Dosage and Dose Schedule Screening of Drug Combinations in Agent-Based Models Reveals Hidden Synergies |
| Q36221907 | Droplet Microfluidic System with On-Demand Trapping and Releasing of Droplet for Drug Screening Applications. |
| Q34905068 | Drosophila melanogaster as a model system for drug discovery and pathway screening |
| Q43720412 | Drug & alcohol testing. Screening for safety. |
| Q39915817 | Drug Abuse Screening Programs: Detection Procedures, Development Costs, Street-Sample Analysis, and Field Tests |
| Q26745421 | Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies |
| Q37687204 | Drug Literacy in Iran: the Experience of Using "The Single Item Health Literacy Screening (SILS) Tool". |
| Q35570951 | Drug Repositioning for Preeclampsia Therapeutics by In Vitro Screening: Phosphodiesterase-5 Inhibitor Vardenafil Restores Endothelial Dysfunction via Induction of Placental Growth Factor |
| Q36052648 | Drug Repurposing Screening Identifies Novel Compounds That Effectively Inhibit Toxoplasma gondii Growth |
| Q39951925 | Drug Screening |
| Q39781689 | Drug Screening in Cell Cultures |
| Q38956362 | Drug Screening in Neonates |
| Q38536894 | Drug Screening to Treat Early-Onset Eye Diseases: Can Zebrafish Expedite the Discovery? |
| Q39044390 | Drug Therapy for Gender Transitions and Health Screenings in Transgender Older Adults |
| Q39252459 | Drug abuse screening of childbearing-age women in Alabama public health clinics |
| Q40682777 | Drug abuse screening with immunoassays: unexpected cross-reactivities and other pitfalls |
| Q36610906 | Drug activity screening based on microsomes-hydrogel system in predicting metabolism induced antitumor effect of oroxylin A |
| Q43636743 | Drug addiction is not an independent risk factor for oncogenic human papillomavirus infections or high-grade cervical intraepithelial neoplasia: case-control study nested within the Latin American Screening study cohort. |
| Q27691343 | Drug and bioactive molecule screening based on a bioelectrical impedance cell culture platform |
| Q38822734 | Drug cytotoxicity and signaling pathway analysis with three-dimensional tumor spheroids in a microwell-based microfluidic chip for drug screening. |
| Q34172502 | Drug discovery and development for spinal muscular atrophy: lessons from screening approaches and future challenges for clinical development |
| Q28477551 | Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening |
| Q38833961 | Drug discovery for hearing loss: Phenotypic screening of chemical compounds on primary cultures of the spiral ganglion |
| Q36319438 | Drug discovery for male subfertility using high-throughput screening: a new approach to an unsolved problem. |
| Q27306843 | Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening |
| Q33203372 | Drug identification through in vivo screening of chemical libraries |
| Q44487332 | Drug interaction screening--a screen or a sieve? |
| Q34781774 | Drug library screening against metronidazole-sensitive and metronidazole-resistant Trichomonas vaginalis isolates |
| Q36794431 | Drug quality screening in developing countries: establishment of an appropriate laboratory in Swaziland |
| Q34536280 | Drug repositioning by structure-based virtual screening |
| Q34583175 | Drug screening and criminal prosecution of pregnant women |
| Q36801208 | Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer |
| Q35863525 | Drug screening boosted by hyperpolarized long-lived states in NMR |
| Q40800682 | Drug screening by enzyme immunoassay (EMIT) and thin-layer chromatography (Drug Skreen). |
| Q40942836 | Drug screening by enzyme immunoassay with the American Monitor KDA |
| Q42820289 | Drug screening for ALS using patient-specific induced pluripotent stem cells |
| Q33698510 | Drug screening for Huntington's disease and other neurodegenerative disorders |
| Q64064116 | Drug screening for Pelizaeus-Merzbacher disease by quantifying the total levels and membrane localization of PLP1 |
| Q28486224 | Drug screening for autophagy inhibitors based on the dissociation of Beclin1-Bcl2 complex using BiFC technique and mechanism of eugenol on anti-influenza A virus activity |
| Q30476012 | Drug screening for hearing loss: using the zebrafish lateral line to screen for drugs that prevent and cause hearing loss |
| Q28533608 | Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells |
| Q38726308 | Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs |
| Q41871259 | Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment |
| Q33845739 | Drug screening in a zebrafish model of Duchenne muscular dystrophy. |
| Q41375467 | Drug screening in biological fluids. The need for a systematic approach. |
| Q39662431 | Drug screening in hospital clinical laboratories |
| Q40599911 | Drug screening in the athletic setting |
| Q39662436 | Drug screening in the workplace |
| Q39629864 | Drug screening in the workplace--scientific and legal issues |
| Q41490334 | Drug screening of cancer cell lines and human primary tumors using droplet microfluidics. |
| Q39948677 | Drug screening of neuroprotective agents on an organotypic-based model of spinal cord excitotoxic damage |
| Q39244538 | Drug screening of newborns by meconium analysis: a large-scale, prospective, epidemiologic study |
| Q30846580 | Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation. |
| Q35688079 | Drug screening strategy for human membrane proteins: from NMR protein backbone structure to in silica- and NMR-screened hits |
| Q39290861 | Drug screening study using glioma stem-like cells |
| Q33600870 | Drug screening to identify suppressors of GFAP expression |
| Q34631498 | Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity |
| Q28820973 | Drug screening using model systems: some basics |
| Q31807947 | Drug screening versus history in detection of substance use in ED psychiatric patients. |
| Q33872987 | Drug screening--beyond the bottleneck |
| Q30424238 | Drug screening: A MuSIC-al way to identify drug pairs |
| Q27340222 | Drug screening: zebrafish as a tool for studying epileptic-related chemical compounds |
| Q36082949 | Drug search for leishmaniasis: a virtual screening approach by grid computing. |
| Q37790718 | Drug target identification for neuronal apoptosis through a genome scale screening |
| Q40871549 | Drug usage screening criteria |
| Q37899741 | Drug use and screening in pediatric trauma |
| Q37426012 | Drug use during pregnancy: validating the Drug Abuse Screening Test against physiological measures |
| Q38516538 | Drug use in patients admitted to a university trauma center: results of limited (rather than comprehensive) toxicology screening |
| Q33822546 | Drug use trends in a nuclear power facility: data from a random screening program. |
| Q33822548 | Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation Spectroscopy |
| Q33866060 | Drug-eluting microarrays for cell-based screening of chemical-induced apoptosis |
| Q38120873 | Drug-excipient compatibility screening--role of thermoanalytical and spectroscopic techniques |
| Q38022660 | Drug-induced liver steatosis and phospholipidosis: cell-based assays for early screening of drug candidates |
| Q42251100 | Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study |
| Q35090837 | Drug-induced sensitization of adenylyl cyclase: assay streamlining and miniaturization for small molecule and siRNA screening applications |
| Q34349819 | Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening. |
| Q34276296 | Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer |
| Q37722926 | Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response |
| Q40264963 | Drug-symptom networking: Linking drug-likeness screening to drug discovery |
| Q30986175 | Druggability indices for protein targets derived from NMR-based screening data |
| Q36616697 | Drugs and the frog retina. Effect of dopaminergic agents on the pigment screening of light- and dark-adapted frogs |
| Q33887048 | Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept |
| Q38005548 | Drugs-of-abuse testing. Screening and confirmation |
| Q38667371 | Dual centrifugation - A new technique for nanomilling of poorly soluble drugs and formulation screening by an DoE-approach |
| Q38087705 | Duchenne muscular dystrophy drug discovery - the application of utrophin promoter activation screening |
| Q27314878 | Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids |
| Q30700065 | Early discovery drug screening using mass spectrometry |
| Q35282570 | Early human screening of medications to treat drug addiction: novel paradigms and the relevance of pharmacogenetics |
| Q37599990 | Echinococcus metacestodes as laboratory models for the screening of drugs against cestodes and trematodes. |
| Q44283187 | Editorial (Hot topic: Pharmacophore mapping and high throughput screening in drug discovery). |
| Q35189272 | Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme |
| Q44268458 | Effect of signal interference from dosing excipients on pharmacokinetic screening of drug candidates by liquid chromatography/mass spectrometry |
| Q44672957 | Effects of identification and usefulness of the Lie Scale of the Drug Use Screening Inventory (DUSI-R) in the assessment of adolescent drug use. |
| Q37717412 | Effects of marketed antiepileptic drugs and placebo in the human photosensitivity screening protocol |
| Q40462745 | Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core struc |
| Q41693959 | Effects of vasodilators on microcirculation of the rat cremaster muscle: a microscopic method for screening drugs |
| Q41503596 | Efficacy of drug screening in forensic autopsy: retrospective investigation of routine toxicological findings |
| Q42485760 | Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA. |
| Q34550486 | Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells |
| Q33932549 | Efficient screening of cytochrome P450 BM3 mutants for their metabolic activity and diversity toward a wide set of drug-like molecules in chemical space |
| Q35129381 | Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase |
| Q34650852 | Electrochemical and spectroscopic characterisation of amphetamine-like drugs: application to the screening of 3,4-methylenedioxymethamphetamine (MDMA) and its synthetic precursors. |
| Q37655347 | Electronic screening of medical records to detect inpatients at risk of drug-related problems |
| Q39090025 | Elisa protocol for rapid screening of potential anti-tubercular drugs based on antigenic reactivity of mycobacterial ES-31 serine protease - a drug target supported by axenic culture of Mycobacterium tuberculosis H37 Ra strain in the presence of inh |
| Q38672564 | Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug Screening |
| Q39148400 | Emergency department alcohol and drug screening for Illinois pediatric trauma patients, 1999 to 2009. |
| Q35813370 | Emerging Approaches to GPCR Ligand Screening for Drug Discovery |
| Q41104146 | Emerging from a crisis in anticancer drug discovery? Screening versus design: confessions of an optimistic fence-sitter |
| Q37789852 | Emerging roles for β-arrestin-1 in the control of the pancreatic β-cell function and mass: new therapeutic strategies and consequences for drug screening |
| Q39678217 | Employee drug screening: issues to be resolved in implementing a program |
| Q36421944 | Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies |
| Q39142461 | Engineered muscle tissues for disease modeling and drug screening applications |
| Q64096475 | Engineering Microfluidic Organoid-on-a-Chip Platforms |
| Q38191718 | Engineering Xenopus embryos for phenotypic drug discovery screening |
| Q27318558 | Engineering a Brain Cancer Chip for High-throughput Drug Screening |
| Q37913577 | Engineering and screening the N-terminus of chemokines for drug discovery |
| Q42820949 | Engineering cell-compatible paper chips for cell culturing, drug screening, and mass spectrometric sensing |
| Q38172965 | Engineering three-dimensional cardiac microtissues for potential drug screening applications |
| Q44755754 | Enhanced oral bioavailability of poorly absorbed drugs. I. Screening of absorption carrier for the ceftriaxone complex |
| Q41032156 | Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs |
| Q40644853 | Enhancing alcohol and other drug (AOD) screening by emergency nurses |
| Q37239731 | Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates. |
| Q30405622 | Enhancing reproducibility in cancer drug screening: how do we move forward? |
| Q43625135 | Enzyme-linked immunosorbent assay (ELISA) for the specific detection of apoptotic cells and its application to rapid drug screening |
| Q34084746 | Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes |
| Q42949372 | Erratum to "Microfluidic System Based High Throughput Drug Screening System for Curcumin/TRAIL Combinational Chemotherapy in Human Prostate Cancer PC3 Cells" [Biomol. Ther. 22 (2014) 355-362]. |
| Q42748850 | Establishment and application of a screening anti-HIV-1 drug model targeted nuclear trafficking of virus RNA |
| Q34559456 | Establishment of HRAS(G12V) transgenic medaka as a stable tumor model for in vivo screening of anticancer drugs |
| Q38853703 | Establishment of a Three-dimensional Floating Cell Culture System for Screening Drugs Targeting KRAS-mediated Signaling Molecules. |
| Q36492612 | Establishment of a cell model for screening antibody drugs against rheumatoid arthritis with ADCC and CDC. |
| Q39370163 | Establishment of a cell-based drug screening model for identifying agonists of human peroxisome proliferator-activated receptor gamma (PPARγ). |
| Q40173695 | Establishment of a cell-based drug screening model for identifying down-regulators of Protein Tyrosine Phosphatase 1B expression |
| Q40284049 | Establishment of a cell-based drug screening system for identifying selective down-regulators of mPGES-1. |
| Q39361030 | Establishment of a pancreatic β cell proliferation model in vitro and a platform for diabetes drug screening |
| Q34648879 | Establishment of a panel of reference Trypanosoma evansi and Trypanosoma equiperdum strains for drug screening. |
| Q38924755 | Establishment of a rapid drug screening system based on embryonic stem cells |
| Q37563199 | Establishment of an allo-transplantable hamster cholangiocarcinoma cell line and its application for in vivo screening of anti-cancer drugs. |
| Q44796074 | Establishment of drug screening model based on transcriptional regulation of estrogen responsive element |
| Q39804949 | Estimating the coverage of a targeted mobile tuberculosis screening programme among illicit drug users and homeless persons with truncated models |
| Q34385857 | Ethical aspects of workplace urine screening for drug abuse |
| Q34762595 | Evaluating the predictivity of virtual screening for ABL kinase inhibitors to hinder drug resistance |
| Q37775670 | Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. |
| Q38753542 | Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis |
| Q36851555 | Evaluation of California's Alcohol and Drug Screening and Brief Intervention Project for Emergency Department Patients |
| Q43642944 | Evaluation of Madison 109 lung carcinoma as a model for screening antitumor drugs |
| Q41315473 | Evaluation of a Community Pharmacy-Based Screening Questionnaire to Identify Patients at Risk for Drug Therapy Problems |
| Q40355014 | Evaluation of a computerized drug interaction screening system |
| Q34058390 | Evaluation of a fluorescence-based method for antibabesial drug screening |
| Q33580969 | Evaluation of a range of anti-proliferative assays for the preclinical screening of anti-psoriatic drugs: a comparison of colorimetric and fluorimetric assays with the thymidine incorporation assay |
| Q42835470 | Evaluation of a screening method by liquid chromatography-tandem mass spectrometry for estimating effect of drugs on the activation and β-oxidation of fatty acids in mitochondria |
| Q44389826 | Evaluation of an immunobiosensor for the on-site testing of veterinary drug residues at an abattoir. Screening for sulfamethazine in pigs |
| Q43966237 | Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications |
| Q30405065 | Evaluation of enzyme inhibition data in screening for new drugs |
| Q40306339 | Evaluation of geriatric patients with special reference to clinical trials of so-called nootropic drugs. I. General considerations and screening |
| Q44487309 | Evaluation of immunochemical drug screenings of whole blood samples. A retrospective optimization of cutoff levels after confirmation-analysis on GC-MS and HPLC-DAD. |
| Q37397994 | Evaluation of indole-based probes for high-throughput screening of drug binding to human serum albumin: Analysis by high-performance affinity chromatography |
| Q39310651 | Evaluation of layers of the rat airway epithelial cell line RL-65 for permeability screening of inhaled drug candidates. |
| Q38203697 | Evaluation of methods of detecting cell reactive oxygen species production for drug screening and cell cycle studies |
| Q43904801 | Evaluation of monolithic and sub 2 microm particle packed columns for the rapid screening for illicit drugs--application to the determination of drug contamination on Irish euro banknotes |
| Q43242431 | Evaluation of on-site oral fluid screening using Drugwipe-5(+), RapidSTAT and Drug Test 5000 for the detection of drugs of abuse in drivers. |
| Q44776422 | Evaluation of six computerized drug interaction screening programs |
| Q34328659 | Evaluation of the BBMEC model for screening the CNS permeability of drugs |
| Q34038593 | Evaluation of the identification power of RPLC analyses in the screening for drug compounds |
| Q40289866 | Evaluation of the on-site immunoassay drug-screening device Triage-TOX in routine forensic autopsy |
| Q40313557 | Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies |
| Q43333571 | Evaluation of the toxic effects of four anti-cancer drugs in plant bioassays and its potency for screening in the context of waste water reuse for irrigation. |
| Q41962768 | Evaluation of Δ(9) -tetrahydrocannabinol detection using DrugWipe5S(®) screening and oral fluid quantification after Quantisal™ collection for roadside drug detection via a controlled study with chronic cannabis users |
| Q37852146 | Ex vivo screening of prospective peptide drugs: new approaches. |
| Q35877759 | Exemplifying the Screening Power of Mass Spectrometry Imaging over Label-Based Technologies for Simultaneous Monitoring of Drug and Metabolite Distributions in Tissue Sections |
| Q39575411 | Experience with a drug screening program at a school of pharmacy |
| Q40802302 | Experimental and computational screening models for the prediction of intestinal drug absorption |
| Q39887085 | Experimental animal integumental models for screening potential dermatologic drugs. |
| Q41202669 | Experimental animal models of arterial thrombosis and the screening of platelet-inhibiting, anti-thrombotic drugs: a review |
| Q36715881 | Experimental techniques for developing new drugs acting on dementia (5)--Screening method in drug evaluation on neurite regeneration in primary cultured neurons |
| Q27653434 | Exploiting Structural Analysis, in Silico Screening, and Serendipity To Identify Novel Inhibitors of Drug-Resistant Falciparum Malaria |
| Q35453467 | Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer |
| Q36393559 | Exploiting high-throughput ion channel screening technologies in integrated drug discovery |
| Q38168968 | Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments |
| Q33945252 | Exploratory analysis of cell-based screening data for phenotype identification in drug-siRNA study. |
| Q38174399 | Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies. |
| Q38309541 | Exploring the potential mechanism and screening small molecule drugs for glaucoma by using bioinformatics approach |
| Q40469200 | Exploring the role of different drug transport routes in permeability screening. |
| Q35241686 | Exploring weak ligand-protein interactions by long-lived NMR states: improved contrast in fragment-based drug screening |
| Q35270807 | Expression of an Mg2+-dependent HIV-1 RNase H construct for drug screening |
| Q36885436 | Expression of an epitope tagged human C5a receptor and antibody-mediated immobilization of detergent-solubilized receptor for drug discovery screening |
| Q35039801 | FRET-based calcium imaging: a tool for high-throughput/content phenotypic drug screening in Alzheimer disease |
| Q30667479 | Factors Influencing Uptake of Rapid HIV and Hepatitis C Screening Among Drug Misusing Adult Emergency Department Patients: Implications for Future HIV/HCV Screening Interventions |
| Q37972644 | Facts and fiction: cellular models for high throughput screening for HIV-1 reactivating drugs |
| Q31070929 | Fast gradient elution reversed-phase liquid chromatography with diode-array detection as a high-throughput screening method for drugs of abuse. II. Data analysis |
| Q43298143 | Fast-growing, non-infectious and intracellularly surviving drug-resistant Mycobacterium aurum: a model for high-throughput antituberculosis drug screening |
| Q99956863 | Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer |
| Q36413374 | Feasibility and Acceptability of Screening and Brief Interventions to Address Alcohol and Other Drug Use among Patients Presenting for Emergency Services in Cape Town, South Africa |
| Q43235364 | Feasibility evaluation of 3 automated cellular drug screening assays on a robotic workstation |
| Q34661407 | Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay |
| Q39365706 | Feasibility of implementing cell-based pathway reporter assays in early high-throughput screening assay cascades for antibody drug discovery |
| Q33193088 | Femtomole Immunodetection of Synthetic and Endogenous Amyloid-β Oligomers and Its Application to Alzheimer's Disease Drug Candidate Screening |
| Q37052900 | Fertility drug use and mammographic breast density in a mammography screening cohort of premenopausal women |
| Q42984796 | FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study |
| Q36308248 | Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis |
| Q40513219 | Financial viability of screening for drugs of abuse. |
| Q34400159 | Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. |
| Q38910094 | Finding new drugs to enhance anion secretion in cystic fibrosis: Toward suitable systems for better drug screening. Report on the pre-conference meeting to the 12th ECFS Basic Science Conference, Albufeira, 25-28 March 2015. |
| Q34646772 | Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it. |
| Q44360288 | Findings of ten years of clinical drug screening |
| Q35688544 | Flexible and waterproof micro-sensors to uncover zebrafish circadian rhythms: The next generation of cardiac monitoring for drug screening |
| Q33291702 | Flow cytometry for drug discovery, receptor pharmacology and high-throughput screening |
| Q26796399 | Fluorescence anisotropy (polarization): from drug screening to precision medicine |
| Q35545682 | Fluorescence assays for monitoring RNA-ligand interactions and riboswitch-targeted drug discovery screening |
| Q33489703 | Fluorescence assays for screening combinatorial libraries of drug candidates |
| Q41467248 | Fluorescence polarization assays in high-throughput screening and drug discovery: a review |
| Q34139889 | Fluorescent TEM-1 β-lactamase with wild-type activity as a rapid drug sensor for in vitro drug screening |
| Q38260166 | Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases |
| Q33240546 | Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling |
| Q34223234 | Fluorine local environment: from screening to drug design |
| Q43557275 | Fluorometric screening for metabolism-based drug--drug interactions |
| Q35748198 | Flux assays in high throughput screening of ion channels in drug discovery |
| Q28484164 | Focused Screening and Treatment (FSAT): a PCR-based strategy to detect malaria parasite carriers and contain drug resistant P. falciparum, Pailin, Cambodia |
| Q42179451 | Folding fan mode counter-current chromatography offers fast blind screening for drug discovery. Case study: finding anti-enterovirus 71 agents from Anemarrhena asphodeloides |
| Q28485179 | Formalization, annotation and analysis of diverse drug and probe screening assay datasets using the BioAssay Ontology (BAO) |
| Q36384043 | Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening |
| Q39043214 | Fragment screening and druggability assessment for the CBP/p300 KIX domain through protein-observed 19F NMR spectroscopy |
| Q37840332 | Fragment screening to predict druggability (ligandability) and lead discovery success. |
| Q35074986 | Fragment-based Shape Signatures: a new tool for virtual screening and drug discovery |
| Q34595676 | Fragment-based drug discovery using a multidomain, parallel MD-MM/PBSA screening protocol |
| Q40065981 | Frequency-dependent drug screening using optogenetic stimulation of human iPSC-derived cardiomyocytes. |
| Q35931675 | From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity |
| Q34982258 | From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials |
| Q39733401 | From contact investigation to tuberculosis screening of drug addicts and homeless persons in Rotterdam |
| Q33392561 | From rapid in vitro screening to rapid in vivo screening in the drug discovery process |
| Q41833220 | Fully automated screening of veterinary drugs in milk by turbulent flow chromatography and tandem mass spectrometry |
| Q33780121 | Functional drug screening assay reveals potential glioma therapeutics |
| Q35084389 | Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion. |
| Q37017706 | Functional nucleic acids in high throughput screening and drug discovery |
| Q37156891 | Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs |
| Q41054042 | Fusion of green fluorescent protein with the Zeocin-resistance marker allows visual screening and drug selection of transfected eukaryotic cells |
| Q30428276 | Future trends in screening technology for drug discovery |
| Q36483067 | G proteins in drug screening: from analysis of receptor-G protein specificity to manipulation of GPCR-mediated signalling pathways |
| Q32159805 | G-protein-coupled receptors in Saccharomyces cerevisiae: high-throughput screening assays for drug discovery |
| Q38975844 | GENIUS In Silico Screening Technology for HCV Drug Discovery |
| Q42943017 | GPC Spin Column HPLC–ESI-MS Methods for Screening Drugs Noncovalently Bound to Proteins |
| Q43050158 | Gas chromatography-mass spectrometric method for the screening and quantification of illicit drugs and their metabolites in human urine using solid-phase extraction and trimethylsilyl derivatization |
| Q43087272 | Gene expression profile analysis of T lymphocytes involved in pathogenesis of severe aplastic anemia by using bioinformatics method as a novel way of drug screening |
| Q36412671 | Gene expression profiling in the discovery, optimization and development of novel drugs: one universal screening platform |
| Q43288298 | General unknown screening procedure for the characterization of human drug metabolites in forensic toxicology: applications and constraints |
| Q37756278 | Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening |
| Q30850695 | Generation and evaluation of putative neuroregenerative drugs. Part 2: screening virtual libraries of novel polyketides which possess the binding domain of rapamycin |
| Q28547585 | Generation of SNCA Cell Models Using Zinc Finger Nuclease (ZFN) Technology for Efficient High-Throughput Drug Screening |
| Q40516689 | Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening |
| Q39052831 | Generation of human pluripotent stem cell-derived hepatocyte-like cells for drug toxicity screening |
| Q39896116 | Genetic Screening of Compounds Used in Drug Abuse Treatment I. Naltrexone Hydrochloride |
| Q37630978 | Genetic interventions in mammalian cells; applications and uses in high-throughput screening and drug discovery |
| Q34580738 | Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils |
| Q36441268 | Genetic screening reveals a link between Wnt signaling and antitubulin drugs |
| Q37599219 | Genome Sequences of Diverse Human Cytomegalovirus Strains with Utility in Drug Screening and Vaccine Evaluation. |
| Q34053717 | Genome rearrangement of influenza virus for anti-viral drug screening |
| Q43865514 | Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. |
| Q36789580 | Genomic and proteomic screening of apoptosis mitochondrial regulators for drug target discovery. |
| Q31095308 | Genomic drug discovery for apoptosis regulation using a new computer screening amino acid complement wave method |
| Q31070577 | Genomics strategies for antifungal drug discovery--from gene discovery to compound screening |
| Q39226193 | Genotype-selective combination therapies for melanoma identified by high-throughput drug screening |
| Q38450409 | Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe |
| Q41189239 | Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program |
| Q37314426 | Graph wavelet alignment kernels for drug virtual screening. |
| Q37368245 | HCS-Neurons: identifying phenotypic changes in multi-neuron images upon drug treatments of high-content screening |
| Q36046167 | HER2 Targeting Peptides Screening and Applications in Tumor Imaging and Drug Delivery |
| Q39906829 | HO-1-u-1 model for screening sublingual drug delivery--influence of pH, osmolarity and permeation enhancer |
| Q39866912 | HPLC analysis of lipoproteins in culture medium of hepatoma cells: an in vitro system for screening antihyperlipidemic drugs |
| Q39418224 | Hair growth inhibition as a method of screening drugs for local antimitotic activity |
| Q38710078 | Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs |
| Q37416000 | Healthcare system-wide implementation of opioid-safety guideline recommendations: the case of urine drug screening and opioid-patient suicide- and overdose-related events in the Veterans Health Administration |
| Q39196823 | HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved. |
| Q38961609 | HepaRG cell line as an in vitro model for screening drug-drug interactions mediated by metabolic induction: amiodarone used as a model substance |
| Q42703170 | HepaRG culture in tethered spheroids as an in vitro three-dimensional model for drug safety screening |
| Q40204531 | Hepatic organoids for microfluidic drug screening |
| Q44273548 | Hepatitis C virus screening in drug users in an addiction out-patient unit |
| Q36166651 | Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes |
| Q38028547 | Heterodimerisation of G protein-coupled receptors: implications for drug design and ligand screening |
| Q35214824 | Hierarchical virtual screening approaches in small molecule drug discovery |
| Q33239100 | High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening |
| Q38824126 | High efficacy vasopermeability drug candidates identified by screening in an ex ovo chorioallantoic membrane model. |
| Q36292759 | High fat plus high cholesterol diet lead to hepatic steatosis in zebrafish larvae: a novel model for screening anti-hepatic steatosis drugs |
| Q43578085 | High performance affinity chromatography (HPAC) as a high-throughput screening tool in drug discovery to study drug-plasma protein interactions |
| Q40470979 | High performance in silico virtual drug screening on many-core processors. |
| Q30429074 | High quality drug screening by capillary electrophoresis: a review |
| Q35932100 | High throughput drug screening |
| Q40137552 | High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds |
| Q33357361 | High throughput functional screening of an ion channel library for drug safety and efficacy |
| Q33910529 | High throughput gene expression screening: its emerging role in drug discovery |
| Q39198526 | High throughput identification and quantification of anabolic steroid esters by atmospheric solids analysis probe mass spectrometry for efficient screening of drug preparations |
| Q36948480 | High throughput physiological screening of iPSC-derived cardiomyocytes for drug development. |
| Q27339765 | High throughput ratio imaging to profile caspase activity: potential application in multiparameter high content apoptosis analysis and drug screening |
| Q37973421 | High throughput screening (HTS) in identification new ligands and drugable targets of G protein-coupled receptors (GPCRs). |
| Q28542489 | High throughput screening for anti-Trypanosoma cruzi drug discovery |
| Q34433680 | High throughput screening for drug discovery of autophagy modulators |
| Q38999747 | High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy |
| Q28483402 | High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery |
| Q33251878 | High throughput screening in drug discovery. |
| Q34792390 | High throughput screening in duchenne muscular dystrophy: from drug discovery to functional genomics |
| Q37739503 | High throughput screening methodologies classified for major drug target classes according to target signaling pathways |
| Q33416607 | High throughput screening of physicochemical properties and in vitro ADME profiling in drug discovery |
| Q39253982 | High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model |
| Q38157498 | High-Content Screening in hPSC-Neural Progenitors Identifies Drug Candidates that Inhibit Zika Virus Infection in Fetal-like Organoids and Adult Brain. |
| Q35867471 | High-Resolution Mass Spectrometry for Untargeted Drug Screening |
| Q39037445 | High-Throughput Lipolysis in 96-Well Plates for Rapid Screening of Lipid-Based Drug Delivery Systems |
| Q36865175 | High-Throughput Screening for Drugs that Modulate Intermediate Filament Proteins |
| Q36071927 | High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity. |
| Q38372256 | High-Throughput, Multiplex Genotyping Directly from Blood or Dried Blood Spot without DNA Extraction for the Screening of Multiple G6PD Gene Variants at Risk for Drug-Induced Hemolysis |
| Q38673430 | High-content drug screening for rare diseases |
| Q33835153 | High-content drug screening with engineered musculoskeletal tissues |
| Q31132684 | High-content screening and profiling of drug activity in an automated centrosome-duplication assay |
| Q34167197 | High-content screening data management for drug discovery in a small- to medium-size laboratory: results of a collaborative pilot study focused on user expectations as indicators of effectiveness. |
| Q36297052 | High-content screening of clinically tested anticancer drugs identifies novel inhibitors of human MRP1 (ABCC1). |
| Q39634258 | High-content screening of drug-induced cardiotoxicity using quantitative single cell imaging cytometry on microfluidic device |
| Q41687456 | High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. |
| Q38383132 | High-content screening technology for studying drug-induced hepatotoxicity in cell models. |
| Q33312213 | High-content single-cell drug screening with phosphospecific flow cytometry |
| Q28473663 | High-content, image-based screening for drug targets in yeast |
| Q28476233 | High-performance drug discovery: computational screening by combining docking and molecular dynamics simulations |
| Q42037172 | High-speed screening and QSAR analysis of human ATP-binding cassette transporter ABCB11 (bile salt export pump) to predict drug-induced intrahepatic cholestasis |
| Q36990518 | High-speed screening and quantitative SAR analysis of human ABC transporter ABCG2 for molecular modeling of anticancer drugs to circumvent multidrug resistance |
| Q39626327 | High-throughput 3-D cell-based proliferation and cytotoxicity assays for drug screening and bioprocess development |
| Q28534624 | High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells |
| Q38088365 | High-throughput and in silico screenings in drug discovery. |
| Q33507489 | High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth |
| Q30433183 | High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells |
| Q43602056 | High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. |
| Q35945841 | High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor |
| Q30988504 | High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells. |
| Q33402196 | High-throughput in vivo genetic and drug screening using femtosecond laser nano-surgery, and microfluidics |
| Q30402235 | High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations |
| Q43655654 | High-throughput microsomal stability assay for screening new chemical entities in drug discovery |
| Q39066311 | High-throughput screening (HTS) of anticancer drug efficacy on a micropillar/microwell chip platform |
| Q34378937 | High-throughput screening approaches for investigating drug metabolism and pharmacokinetics |
| Q33552169 | High-throughput screening for TLR3-IFN regulatory factor 3 signaling pathway modulators identifies several antipsychotic drugs as TLR inhibitors |
| Q39404815 | High-throughput screening for anti-influenza A virus drugs and study of the mechanism of procyanidin on influenza A virus-induced autophagy |
| Q33321838 | High-throughput screening for daunorubicin-mediated drug resistance identifies mometasone furoate as a novel ABCB1-reversal agent |
| Q40920298 | High-throughput screening for drug discovery |
| Q33302249 | High-throughput screening for fatty acid uptake inhibitors in humanized yeast identifies atypical antipsychotic drugs that cause dyslipidemias |
| Q44522113 | High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method |
| Q33932117 | High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery |
| Q34824028 | High-throughput screening normalized to biological response: application to antiviral drug discovery |
| Q35208534 | High-throughput screening of FDA-approved drugs using oxygen biosensor plates reveals secondary mitofunctional effects |
| Q33910080 | High-throughput screening of PLGA thin films utilizing hydrophobic fluorescent dyes for hydrophobic drug compounds |
| Q35079712 | High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assay |
| Q33235621 | High-throughput screening of biocatalytic activity: applications in drug discovery |
| Q33275409 | High-throughput screening of cellular features using high-resolution light-microscopy; application for profiling drug effects on cell adhesion |
| Q42913863 | High-throughput screening of dendrimer-binding drugs. |
| Q35894135 | High-throughput screening of drug-lipid membrane interactions via counter-propagating second harmonic generation imaging |
| Q43894479 | High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. |
| Q39911943 | High-throughput screening platform for anticancer therapeutic drug cytotoxicity. |
| Q35353325 | High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease. |
| Q42827268 | High-throughput screening system for identifying phototoxic potential of drug candidates based on derivatives of reactive oxygen metabolites |
| Q37222804 | High-throughput screening technologies for drug glucuronidation profiling |
| Q44560574 | High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes |
| Q38826826 | High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. |
| Q38900070 | High-throughput screening with nanoimprinting 3D culture for efficient drug development by mimicking the tumor environment |
| Q40835835 | High-throughput synthesis and screening of platinum drug candidates |
| Q39009487 | High-throughput untargeted screening of veterinary drug residues and metabolites in tilapia using high resolution orbitrap mass spectrometry |
| Q34679959 | High-throughput virtual screening for drug discovery in parallel |
| Q43718094 | Highly sensitive capillary electrophoresis-mass spectrometry for rapid screening and accurate quantitation of drugs of abuse in urine |
| Q43508192 | History and new development of screening and evaluation methods of anticancer drugs used in vivo and in vitro |
| Q30904660 | Hit triage using efficiency indices after screening of compound libraries in drug discovery |
| Q38028514 | How can high-throughput screening deliver drugs to treat atherosclerosis? |
| Q43630348 | How far can virtual screening take us in drug discovery? |
| Q33925459 | Hsp90 inhibitors and drugs from fragment and virtual screening. |
| Q42008727 | Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4. |
| Q27346581 | Human Vascular Microphysiological System for in vitro Drug Screening |
| Q44773631 | Human acidic mammalian chitinase as a novel target for anti-asthma drug design using in silico screening |
| Q43120536 | Human and murine embryonic stem cell-derived cardiomyocytes serve together as a valuable model for drug safety screening |
| Q34460195 | Human flavin-containing monooxygenase 3 on graphene oxide for drug metabolism screening. |
| Q38871403 | Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening. |
| Q30625616 | Human iPSC-based cardiac microphysiological system for drug screening applications. |
| Q39050993 | Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening |
| Q30586653 | Human induced pluripotent stem cell-derived cardiomyocytes as an in vitro model for coxsackievirus B3-induced myocarditis and antiviral drug screening platform |
| Q39953732 | Human organ culture: applications in the screening of teratogenic drugs |
| Q37950950 | Human pluripotent stem cells for disease modelling and drug screening |
| Q37931912 | Human pluripotent stem cells for genetic disease modeling and drug screening. |
| Q64057372 | Human three-dimensional in vitro model of hepatic zonation to predict zonal hepatotoxicity |
| Q42193034 | Human tyrosinase produced in insect cells: a landmark for the screening of new drugs addressing its activity. |
| Q33894635 | Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening |
| Q42815563 | Hydrogel-based diffusion chip with Electric Cell-substrate Impedance Sensing (ECIS) integration for cell viability assay and drug toxicity screening. |
| Q42170262 | Hydrophilic matrices: application of Placket-Burman screening design to model the effect of POLYOX-carbopol blends on drug release |
| Q34626216 | Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity |
| Q41475999 | Hypercholesterolemia in ExHC rats and lipid-lowering drug: a screening method for new hypocholesterolemic agents. |
| Q34123122 | Hypothesis testing in high-throughput screening for drug discovery. |
| Q38813118 | IPEC-J2 MDR1, a Novel High-Resistance Cell Line with Functional Expression of Human P-glycoprotein (ABCB1) for Drug Screening Studies. |
| Q64091347 | Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes |
| Q35225281 | Identification and characterization of human Rad51 inhibitors by screening of an existing drug library |
| Q33874959 | Identification and characterization of the new designer drug 4'-methylethcathinone (4-MEC) and elaboration of a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) screening method for seven different methcathinone analogs |
| Q36105916 | Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening |
| Q37293444 | Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma. |
| Q35989976 | Identification of Drug-Like Inhibitors of Insulin-Regulated Aminopeptidase Through Small-Molecule Screening |
| Q37168704 | Identification of Multiple Cryptococcal Fungicidal Drug Targets by Combined Gene Dosing and Drug Affinity Responsive Target Stability Screening |
| Q38681868 | Identification of Multiple Druggable Secondary Sites by Fragment Screening against DC-SIGN. |
| Q38677621 | Identification of Novel Vacuolin-1 Analogues as Autophagy Inhibitors by Virtual Drug Screening and Chemical Synthesis. |
| Q34677203 | Identification of Potential Antituberculosis Drugs Through Docking and Virtual Screening |
| Q39061415 | Identification of a cell line producing high levels of TSLP: advantages for screening of anti-allergic drugs |
| Q43834622 | Identification of a novel chemical potentiator and inhibitors of UCH-L1 by in silico drug screening |
| Q35282969 | Identification of a novel inhibitor of dengue virus protease through use of a virtual screening drug discovery Web portal |
| Q33786075 | Identification of a novel scaffold for allosteric inhibition of wild type and drug resistant HIV-1 reverse transcriptase by fragment library screening. |
| Q36643383 | Identification of active Plasmodium falciparum calpain to establish screening system for Pf-calpain-based drug development |
| Q35627436 | Identification of anti-inflammatory fractions of Geranium wilfordii using tumor necrosis factor-alpha as a drug target on Herbochip® - an array-based high throughput screening platform |
| Q33370734 | Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries |
| Q34677728 | Identification of compounds with potential antibacterial activity against Mycobacterium through structure-based drug screening |
| Q30371457 | Identification of druggable targets for radiation mitigation using a small interfering RNA screening assay |
| Q28478963 | Identification of genes affecting the toxicity of anti-cancer drug bortezomib by genome-wide screening in S. pombe |
| Q34407398 | Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. |
| Q36284083 | Identification of inappropriate drug prescribing by computerized, retrospective DUR screening in Korea |
| Q39432161 | Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome |
| Q41946056 | Identification of new antimalarial drugs by linear discriminant analysis and topological virtual screening |
| Q35996715 | Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening |
| Q39836825 | Identification of non-muscle myosin heavy chain as a substrate for Cdk5 and tool for drug screening |
| Q34546554 | Identification of novel antimycobacterial chemical agents through the in silico multi-conformational structure-based drug screening of a large-scale chemical library |
| Q34942905 | Identification of novel compounds against an R294K substitution of influenza A (H7N9) virus using ensemble based drug virtual screening |
| Q35065902 | Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings |
| Q35604788 | Identification of novel pathways and molecules able to down-regulate PHOX2B gene expression by in vitro drug screening approaches in neuroblastoma cells |
| Q35100832 | Identification of novel potential antibiotics against Staphylococcus using structure-based drug screening targeting dihydrofolate reductase |
| Q31002197 | Identification of novel potential antibiotics for tuberculosis by in silico structure-based drug screening |
| Q33853600 | Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM. |
| Q41904886 | Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study |
| Q36275846 | Identification of several high-risk HPV inhibitors and drug targets with a novel high-throughput screening assay |
| Q34310151 | Identifications small molecules inhibitor of p53-mortalin complex for cancer drug using virtual screening |
| Q35545643 | Identifying differentially expressed genes and screening small molecule drugs for lapatinib-resistance of breast cancer by a bioinformatics strategy |
| Q30982375 | Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data |
| Q41694630 | Identifying putative drug targets and potential drug leads: starting points for virtual screening and docking |
| Q40993237 | Identifying small-molecule lead compounds: the screening approach to drug discovery |
| Q39655929 | Image-based chemical screening identifies drug efflux inhibitors in lung cancer cells |
| Q33604028 | Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease |
| Q33772068 | Imaged-based high-throughput screening for anti-angiogenic drug discovery |
| Q33283786 | Immobilized P2X2 purinergic receptor stationary phase for chromatographic determination of pharmacological properties and drug screening |
| Q43729332 | Immobilized artificial membrane chromatography with mass spectrometric detection: a rapid method for screening drug-membrane interactions |
| Q44262474 | Immunochemical screening and liquid chromatographic-tandem mass spectrometric confirmation of drug residues in edible tissues of calves injected with a therapeutic dose of the synthetic glucocorticoids dexamethasone and flumethasone |
| Q40347835 | Impact of Urine Drug Screening on No Shows and Dropouts among Chronic Pain Patients: A Propensity-Matched Cohort Study |
| Q35135407 | Impact of a brief training on medical resident screening for alcohol misuse and illicit drug use. |
| Q42081670 | Impact of drug screening in suspected overdose |
| Q36716473 | Impact of hot and humid tropical conditions on Toxi-Lab thin-layer chromatographic systems for the screening of basic and neutral drugs |
| Q44669332 | Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators |
| Q37703542 | Impact of new technologies for cellular screening along the drug value chain |
| Q30985881 | Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data |
| Q33323467 | Impact of novel screening technologies on ion channel drug discovery |
| Q39739453 | Implementing screening, brief intervention, and referral for alcohol and drug use: the trauma service perspective |
| Q28396456 | Importance of Urinary Drug Screening in the Multiple Sleep Latency Test and Maintenance of Wakefulness Test |
| Q37414073 | Improved behavioral response as a valid biomarker for drug screening program in transgenic rodent models of tauopathies |
| Q35275203 | Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe |
| Q40242001 | Improved toxicogenomic screening for drug-induced phospholipidosis using a multiplexed quantitative gene expression ArrayPlate assay |
| Q39371099 | Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivo screening of antileishmanial drugs |
| Q36858894 | Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014. |
| Q38084626 | Improving adverse drug event detection in critically ill patients through screening intensive care unit transfer summaries |
| Q31034164 | Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits |
| Q43220459 | Improving toxicity screening and drug development by using genetically defined strains |
| Q41643903 | In Silico Investigation of a HIV-1 Vpr Inhibitor Binding Site: Potential for Virtual Screening and anti-HIV Drug Design. |
| Q36094897 | In Silico Predictions of Drug - Drug Interactions Caused by CYP1A2, 2C9 and 3A4 Inhibition - a Comparative Study of Virtual Screening Performance |
| Q39554945 | In Silico Receptorome Screening of Antipsychotic Drugs |
| Q39314986 | In Silico Screening of Nonsteroidal Anti-Inflammatory Drugs and Their Combined Action on Prostaglandin H Synthase-1. |
| Q28817785 | In silico Approach for Anti-Thrombosis Drug Discovery: P2Y1R Structure-Based TCMs Screening |
| Q42826496 | In silico Screening and Evaluation of the Anticonvulsant Activity of Docosahexaenoic Acid-Like Molecules in Experimental Models of Seizures |
| Q37706134 | In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma |
| Q33428166 | In silico fragment screening by replica generation (FSRG) method for fragment-based drug design |
| Q38370634 | In silico identification of potential drug compound against Peroxisome proliferator-activated receptor-gamma by virtual screening and toxicity studies for the treatment of Diabetic Nephropathy |
| Q33399778 | In silico methods for predicting metabolism and mass fragmentation applied to quetiapine in liquid chromatography/time-of-flight mass spectrometry urine drug screening |
| Q41243043 | In silico model of the human ClC-Kb chloride channel: pore mapping, biostructural pathology and drug screening |
| Q36840592 | In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling |
| Q43683821 | In silico screening of drugs to find potential gamma-secretase inhibitors using pharmacophore modeling, QSAR and molecular docking studies |
| Q36385556 | In silico structure-based drug screening of novel antimycobacterial pharmacophores by DOCK-GOLD tandem screening |
| Q34440373 | In silico study and validation of phosphotransacetylase (PTA) as a putative drug target for Staphylococcus aureus by homology-based modelling and virtual screening. |
| Q35200578 | In silico virtual screening approaches for anti-viral drug discovery |
| Q36612258 | In vitro ADME medium/high-throughput screening in drug preclinical development. |
| Q43080976 | In vitro and in vivo experimental models for drug screening and development for Chagas disease |
| Q34661494 | In vitro assays for new drug screening: comparison of a thymidine incorporation assay with the human tumor colony-forming assay |
| Q40322881 | In vitro assays in preclinical antineoplastic drug screening. |
| Q43752048 | In vitro bioassays for anticancer drug screening: effects of cell concentration and other assay parameters on growth inhibitory activity |
| Q28331628 | In vitro cultivation of Cryptosporidium parvum and screening for anticryptosporidial drugs |
| Q34263018 | In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery |
| Q35531225 | In vitro screening for drug repositioning |
| Q39360061 | In vitro screening for drug-induced depression and/or suicidal adverse effects: a new toxicogenomic assay based on CE-SSCP analysis of HTR2C mRNA editing in SH-SY5Y cells |
| Q38850871 | In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells. |
| Q36572626 | In vitro screening of drug metabolism during drug development: can we trust the predictions? |
| Q39695348 | In vitro screening of new drugs and analogues--specificity and selectivity |
| Q27693191 | In vitro screening of psychoactive drugs |
| Q34721678 | In vitro screening of psychoactive drugs by [(35)S]GTPgammaS binding in rat brain membranes |
| Q39529837 | In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma. |
| Q37320150 | In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery |
| Q41444042 | In vitro sensitivity screening system for human cancers to drugs and hypertermia (42 degrees C) |
| Q36602062 | In vivo and in vitro mechanisms of radiation sensitization, drug synthesis and screening: can we learn it all from the high dose data? |
| Q33242912 | In vivo drug screening in human skin using femtosecond laser multiphoton tomography |
| Q27305075 | In vivo imaging of trypanosome-brain interactions and development of a rapid screening test for drugs against CNS stage trypanosomiasis |
| Q38028652 | In vivo models of cardiac diseases: application to drug development and screening |
| Q33487840 | In vivo pharmacokinetic screening in cassette dosing experiments; the use of on-line Pprospekt liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry technology in drug discovery |
| Q39396060 | In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach |
| Q37707220 | In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening |
| Q39230904 | In-silico drug screening and potential target identification for hepatocellular carcinoma using Support Vector Machines based on drug screening result |
| Q36660891 | In-silico screening of Schistosoma mansoni Sirtuin1 inhibitors for prioritization of drug candidates |
| Q42840452 | In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier. |
| Q42904714 | Incorporation of multicellular spheroids into 3-D polymeric scaffolds provides an improved tumor model for screening anticancer drugs |
| Q28247246 | Increasing speed and throughput when using HPLC-MS/MS systems for drug metabolism and pharmacokinetic screening |
| Q37120351 | Indication of nerve growth factor binding components from herbal extracts by HerboChip: a platform for drug screening on a chip. |
| Q42678871 | Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis |
| Q63246820 | Induced Pluripotent Stem Cells: A Powerful Neurodegenerative Disease Modeling Tool for Mechanism Study and Drug Discovery |
| Q37988757 | Induced pluripotent stem cell research: a revolutionary approach to face the challenges in drug screening. |
| Q36633022 | Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseases |
| Q26828408 | Induced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screening |
| Q26865689 | Induced pluripotent stem cells as a disease modeling and drug screening platform |
| Q43061149 | Infant race affects application of clinical guidelines when screening for drugs of abuse in newborns. |
| Q35112883 | Infl ammatory Response of Tumor-Activated Hepatic Sinusoidal Endothelium as a Target for the Screening of Metastasis Chemopreventive Drugs |
| Q36454748 | Influence of a three-dimensional, microarray environment on human cell culture in drug screening systems |
| Q42091676 | Influence of non-steroidal anti-inflammatory drugs on the outcome of faecal occult blood tests in screening for colorectal cancer |
| Q63246645 | Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx-DDB1 Interaction |
| Q42202117 | Inhibition of aconitine-induced mortality in the conscious rat: a screening test for antiarrhythmic drugs |
| Q41610657 | Initial screening for carcinogenicity of commonly used drugs |
| Q43121088 | Inkjet printing methodologies for drug screening |
| Q30712463 | Integrated acquisition of analytical and biopharmaceutical screening data for beta-adrenergic-drugs employing diversified macrocycle supported potentiometric detection in HPLC systems |
| Q30886901 | Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery. |
| Q38840391 | Integrating High-Dimensional Transcriptomics and Image Analysis Tools into Early Safety Screening: Proof of Concept for a New Early Drug Development Strategy |
| Q38842097 | Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy |
| Q39943706 | Integrating Project ASSERT: a screening, intervention, and referral to treatment program for unhealthy alcohol and drug use into an urban emergency department |
| Q33882211 | Integrating virtual screening and combinatorial chemistry for accelerated drug discovery. |
| Q37277338 | Integration of ligand-based drug screening with structure-based drug screening by combining maximum volume overlapping score with ligand docking |
| Q38891843 | Integration of protein tethering in a rapid and label-free SERS screening platform for drugs of abuse. |
| Q31134010 | Integration of virtual screening into the drug discovery process |
| Q34149937 | Interest of animal models in the preclinical screening of anti-osteoarthritic drugs |
| Q33435097 | Interference by venlafaxine ingestion in the detection of tramadol by liquid chromatography linked to tandem mass spectrometry for the screening of illicit drugs in human urine |
| Q39320904 | Interleukin-4-transgenic hu-PBL-SCID mice: a model for the screening of antiviral drugs and immunotherapeutic agents against X4 HIV-1 viruses |
| Q43900707 | Internet-based screening and brief intervention for illicit drug users: a randomized controlled trial with 12-month follow-up |
| Q41255699 | Interviewing and Urine Drug Toxicology Screening in a Pediatric Pain Management Center: An Analysis of Analgesic Nonadherence and Aberrant Behaviors in Adolescents and Young Adults |
| Q43542092 | Intracranial transplantation of human hematopoietic cell lines in nude mice: a preclinical screening model for cytostatic drugs. |
| Q36002329 | Intramers and aptamers: applications in protein-function analyses and potential for drug screening |
| Q33870160 | Intravenous drug abuse is an indication for antepartum screening for RH alloimmunization. A case report and review of literature |
| Q44431331 | Introduction of mass psychology of animals to pharmacology. 2. New screening method of drugs acting on the central nervous system |
| Q36800397 | Invertebrate animal models of diseases as screening tools in drug discovery |
| Q39063825 | Investigating the therapeutic potential of herbal leads against drug resistant Listeria monocytogenes by computational virtual screening and in vitro assays. |
| Q41683093 | Investigation of the antimicrobial activity of soy peptides by developing a high throughput drug screening assay. |
| Q33359104 | Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds |
| Q36058287 | Invited Commentary: Screening for hepatitis B in the immigrant population and individuals who are in need of immunosuppressive drug therapy. |
| Q40226151 | Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. |
| Q34503331 | Is LC-MS suitable for a comprehensive screening of drugs and poisons in clinical toxicology? |
| Q27681373 | Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein–Protein Interactions? |
| Q36858280 | Is this urine really negative? A systematic review of tampering methods in urine drug screening and testing |
| Q34401331 | Isolating genes involved with genotoxic drug response in the nematode Caenorhabditis elegans using genome-wide RNAi screening |
| Q40126214 | Isolation and maintenance of a strain of Entamoeba histolytica Schaudinn, 1903 and the possibility of its utilization in screening of drugs |
| Q44544140 | Isolation of drugs active against mammalian prions using a yeast-based screening assay |
| Q34500109 | Isotopic pattern and accurate mass determination in urine drug screening by liquid chromatography/time-of-flight mass spectrometry |
| Q40604171 | Karyotypic complexity of the NCI-60 drug-screening panel. |
| Q33215051 | Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection |
| Q38680657 | Kidney-on-a-Chip Technology for Drug-Induced Nephrotoxicity Screening. |
| Q64278335 | Kinome-Wide RNA Interference Screening Identifies Mitogen-Activated Protein Kinases and Phosphatidylinositol Metabolism as Key Factors for Rabies Virus Infection |
| Q35235014 | Kiosk versus in-person screening for alcohol and drug use in the emergency department: patient preferences and disclosure |
| Q34327708 | LC-MS vs. GC-MS, online extraction systems, advantages of technology for drug screening assays |
| Q38994703 | LC-QTOF MS screening of more than 1,000 licit and illicit drugs and their metabolites in wastewater and surface waters from the area of Bogotá, Colombia. |
| Q35570159 | LOCAL KERNEL CANONICAL CORRELATION ANALYSIS WITH APPLICATION TO VIRTUAL DRUG SCREENING. |
| Q39159961 | Lab-on-a-Chip for anticancer drug screening using quantum dots probe based apoptosis assay |
| Q28487553 | Label-free recognition of drug resistance via impedimetric screening of breast cancer cells |
| Q37856304 | Label-free screening assays: a strategy for finding better drug candidates |
| Q42912184 | Label-free screening of drug-protein interactions by time-resolved Fourier transform infrared spectroscopic assays exemplified by Ras interactions |
| Q36064224 | Labeling the Stroma of a Patient-Derived Orthotopic Xenograft (PDOX) Mouse Model of Undifferentiated Pleomorphic Soft-Tissue Sarcoma With Red Fluorescent Protein for Rapid Non-Invasive Imaging for Drug Screening. |
| Q40898501 | Laboratory tests for rapid screening of drugs of abuse in the workplace: a review |
| Q35805872 | Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet Syndrome(1,2,3). |
| Q44600874 | Large-Volume Injection Gas Chromatography-Mass Spectrometry for Automated Broad-Spectrum Drug Screening in Horse Urine |
| Q39491082 | Large-scale drug screening against Babesia divergens parasite using a fluorescence-based high-throughput screening assay. |
| Q34596420 | Large-scale recordings for drug screening in neural circuit systems |
| Q36834733 | Laser light scattering bioassay for veterinary drug residues in food producing animals. 3. Screening bovine tissues for drug residues |
| Q63248437 | Late Neurological Consequences of Zika Virus Infection: Risk Factors and Pharmaceutical Approaches |
| Q27672398 | Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design |
| Q40276020 | Leishmania (Viannia) panamensis: an in vitro assay using the expression of GFP for screening of antileishmanial drug. |
| Q39085580 | Leishmania amastigotes as targets for drug screening. |
| Q36003229 | Leishmania tarentolae: purification and characterization of tubulin and its suitability for antileishmanial drug screening |
| Q42836783 | Less common "doping" agents and substances encountered during routine screening for drugs |
| Q37829496 | Lessons from (patho)physiological tissue stiffness and their implications for drug screening, drug delivery and regenerative medicine |
| Q33309109 | Lessons learnt from assembling screening libraries for drug discovery for neglected diseases |
| Q27667103 | Leveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomallei |
| Q28302776 | Ligand docking and structure-based virtual screening in drug discovery |
| Q33848744 | Ligand specificity, privileged substructures and protein druggability from fragment-based screening. |
| Q44695513 | Ligand-selective signaling and high-content screening for GPCR drugs |
| Q33911356 | Limited utility of routine drug screening in trauma patients |
| Q36075396 | Linking tumor cell cytotoxicity to mechanism of drug action: an integrated analysis of gene expression, small-molecule screening and structural databases |
| Q42798666 | Lipid multilayer microarrays for in vitro liposomal drug delivery and screening |
| Q38699252 | Lipid-lowering drugs and risk of new-onset diabetes: a cohort study using Japanese healthcare data linked to clinical data for health screening |
| Q34400730 | Lipophilicity screening of novel drug-like compounds and comparison to clog P. |
| Q43846426 | Liposome electrokinetic chromatography based in vitro model for early screening of the drug-induced phospholipidosis risk |
| Q43637462 | Liquid chromatography high-resolution TOF analysis: investigation of MSE for broad-spectrum drug screening |
| Q36331104 | Liquid chromatography-high resolution-tandem mass spectrometry using Orbitrap technology for comprehensive screening to detect drugs and their metabolites in blood plasma. |
| Q37342241 | Liquid chromatography-mass spectrometry in in vitro drug metabolite screening. |
| Q34482424 | Liquid chromatography-quadrupole time-of-flight mass spectrometry for screening in vitro drug metabolites in humans: investigation on seven phenethylamine-based designer drugs. |
| Q30573300 | Live multicellular tumor spheroid models for high-content imaging and screening in cancer drug discovery |
| Q28546859 | MLViS: A Web Tool for Machine Learning-Based Virtual Screening in Early-Phase of Drug Discovery and Development |
| Q41343108 | Macrophage-like RAW 264 cell line and time-resolved fluoroimmunoassay (TRFIA) as tools in screening drug effects on cytokine secretion |
| Q44191064 | Managed care plans' requirements for screening for alcohol, drug, and mental health problems in primary care |
| Q33337913 | Marine natural product libraries for high-throughput screening and rapid drug discovery |
| Q36419709 | Mass ligand binding screening for receptor antagonists: prototype new drugs and blind alleys |
| Q40805253 | Mass ligand-binding screening strategies for identification of leads for new drug discovery. |
| Q33338340 | Mass receptor screening for new drugs |
| Q33300712 | Mass spectrometric techniques for label-free high-throughput screening in drug discovery |
| Q33717850 | Measuring respiration of cultured cell with oxygen electrode as a metabolic indicator for drug screening |
| Q28071848 | Mechanically produced schistosomula as a higher-throughput tools for phenotypic pre-screening in drug sensitivity assays: current research and future trends |
| Q37149411 | MedusaScore: an accurate force field-based scoring function for virtual drug screening |
| Q38594740 | Mesenchymal-mode migration assay and antimetastatic drug screening with high-throughput microfluidic channel networks |
| Q37189197 | Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes |
| Q43109191 | Metabolic screening in children receiving antipsychotic drug treatment |
| Q37135583 | Metabolite profiling studies in Saccharomyces cerevisiae: an assisting tool to prioritize host targets for antiviral drug screening |
| Q34081089 | Metabolomic high-content nuclear magnetic resonance-based drug screening of a kinase inhibitor library |
| Q37026573 | Metabolomics guides rational development of a simplified cell culture medium for drug screening against Trypanosoma brucei. |
| Q40843885 | Metal based drugs: design, synthesis and in-vitro antimicrobial screening of Co(II), Ni(II), Cu(II) and Zn(II) complexes with some new carboxamide derived compounds: crystal structures of N-[ethyl(propan-2-yl)carbamothioyl]thiophene-2-carboxamide an |
| Q44444451 | Method for the screening of drugs active against Giardia intestinalis |
| Q36638820 | Methods for the prediction of protein-ligand binding sites for structure-based drug design and virtual ligand screening |
| Q43932020 | Methods of screening anticancer drugs in the soviet union |
| Q44786399 | Michigan assessment-screening test for alcohol and drugs (MAST/AD): evaluation in a clinical sample |
| Q40087568 | Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii |
| Q35826421 | Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies. |
| Q30464008 | Microengineering methods for cell-based microarrays and high-throughput drug-screening applications |
| Q37421604 | Microfabricated electrospun collagen membranes for 3-D cancer models and drug screening applications. |
| Q34039836 | Microfluidic System Based High Throughput Drug Screening System for Curcumin/TRAIL Combinational Chemotherapy in Human Prostate Cancer PC3 Cells |
| Q38806522 | Microfluidic cell chips for high-throughput drug screening. |
| Q42078619 | Microfluidic cell culture and its application in high-throughput drug screening: cardiotoxicity assay for hERG channels |
| Q40947222 | Microfluidic cell-phoresis enabling high-throughput analysis of red blood cell deformability and biophysical screening of antimalarial drugs |
| Q37352735 | Microfluidic co-culture system for cancer migratory analysis and anti-metastatic drugs screening |
| Q30426039 | Microfluidics-assisted in vitro drug screening and carrier production |
| Q37337055 | Microfluidics-enabled method to identify modes of Caenorhabditis elegans paralysis in four anthelmintics |
| Q42042125 | Microfluidics: Emerging prospects for anti-cancer drug screening |
| Q38851260 | Micropatterned co-culture of cardiac myocytes on fibrous scaffolds for predictive screening of drug cardiotoxicities |
| Q43864651 | Microplate screening for apoptosis with antibody to single-stranded DNA distinguishes anticancer drugs from toxic chemicals |
| Q38713292 | Microprinted tumor spheroids enable anti-cancer drug screening |
| Q35890716 | Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates |
| Q34163313 | Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons |
| Q38820083 | Microtechnology-based organ systems and whole-body models for drug screening |
| Q42820442 | Minimizing DILI risk in drug discovery - A screening tool for drug candidates |
| Q42043842 | Model for high-throughput screening of multitarget drugs in chemical neurosciences: synthesis, assay, and theoretic study of rasagiline carbamates. |
| Q38139523 | Modeling colorectal cancer as a 3-dimensional disease in a dish: the case for drug screening using organoids, zebrafish, and fruit flies. |
| Q38028513 | Models and screening assays for drug discovery in osteoporosis |
| Q36353071 | Models of epileptogenesis in adult animals available for antiepileptogenesis drug screening |
| Q34974378 | Modulators of the microRNA biogenesis pathway via arrayed lentiviral enabled RNAi screening for drug and biomarker discovery |
| Q36516889 | Molecular descriptors and methods for ligand based virtual high throughput screening in drug discovery |
| Q34977641 | Molecular dynamics-based virtual screening: accelerating the drug discovery process by high-performance computing |
| Q43561902 | Molecular mechanism of cyclosporine A drug interactions: inducers and inhibitors of cytochrome P450 screening in primary cultures of human hepatocytes |
| Q44520886 | More economical use of chromatographic plates for drug screening |
| Q36070734 | Multi-analyte procedures for screening for and quantification of drugs in blood, plasma, or serum by liquid chromatography-single stage or tandem mass spectrometry (LC-MS or LC-MS/MS) relevant to clinical and forensic toxicology |
| Q40387119 | Multi-class, multi-residue analysis of trace veterinary drugs in milk by rapid screening and quantification using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry |
| Q33328225 | Multi-class, multi-residue liquid chromatography/tandem mass spectrometry screening and confirmation methods for drug residues in milk |
| Q64103530 | MultiBac: Baculovirus-Mediated Multigene DNA Cargo Delivery in Insect and Mammalian Cells |
| Q41109573 | Multicomponent High-throughput Drug Screening via Inkjet Printing to Verify the Effect of Immunosuppressive Drugs on Immune T Lymphocytes. |
| Q33430934 | Multicomponent screening for drugs of abuse: direct analysis of urine by LC-MS-MS. |
| Q41622608 | Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening |
| Q35985227 | Multilayered, Hyaluronic Acid-Based Hydrogel Formulations Suitable for Automated 3D High Throughput Drug Screening of Cancer-Stromal Cell Cocultures. |
| Q35872435 | Multiple target drug cocktail design for attacking the core network markers of four cancers using ligand-based and structure-based virtual screening methods |
| Q30878938 | Multiplex gene expression analysis for high-throughput drug discovery: screening and analysis of compounds affecting genes overexpressed in cancer cells |
| Q35212116 | Multiplexed phosphospecific flow cytometry enables large-scale signaling profiling and drug screening in blood platelets |
| Q39103079 | Multiresidue Screening of Veterinary Drugs in Meat, Milk, Egg, and Fish Using Liquid Chromatography Coupled with Ion Trap Time-of-Flight Mass Spectrometry |
| Q27690666 | Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases |
| Q41697020 | Multiwell capillarity-based microfluidic device for the study of 3D tumour tissue-2D endothelium interactions and drug screening in co-culture models |
| Q41599256 | NCI's anticancer drug screening program may not be selecting for clinically active compounds. |
| Q40011673 | NEED FOR SCREENING FOR ALCOHOL AND DRUGS IN EMERGENCY TRAUMA UNITS. |
| Q33681479 | NMR screening and hit validation in fragment based drug discovery |
| Q33536469 | NMR screening in drug discovery. |
| Q35548727 | NMR screening in fragment-based drug design: a practical guide |
| Q34149352 | NMR-based screening in drug discovery |
| Q35209034 | Nails are a potential alternative matrix to hair for drug analysis in general unknown screenings by liquid-chromatography quadrupole time-of-flight mass spectrometry |
| Q28390779 | Nanotechnology in drug delivery: the need for more cell culture based studies in screening |
| Q37861778 | Natural products of dietary origin as lead compounds in virtual screening and drug design |
| Q38014956 | Navigating tuberculosis drug discovery with target-based screening |
| Q33937467 | Network target for screening synergistic drug combinations with application to traditional Chinese medicine |
| Q28601372 | Network-based in silico drug efficacy screening |
| Q39791234 | Neurotoxicity screening of (illicit) drugs using novel methods for analysis of microelectrode array (MEA) recordings. |
| Q44372677 | New advances in pain management drug screening and confirmation |
| Q42121275 | New approach for high-throughput screening of drug activity on Plasmodium liver stages |
| Q38225001 | New approaches for NMR screening in drug discovery |
| Q29615418 | New colorimetric cytotoxicity assay for anticancer-drug screening |
| Q40979436 | New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening |
| Q44151953 | New screening system for selection of anticancer drugs for treatment of human colorectal cancer |
| Q43531822 | New strategies in ion channel screening for drug discovery: are there ways to improve its productivity? |
| Q36034635 | New targets and screening approaches in antimicrobial drug discovery |
| Q42495773 | New technologies in drug metabolism and toxicity screening: organ-to-organ interaction |
| Q39607835 | New uses for old drugs: pharmacophore-based screening for the discovery of P-glycoprotein inhibitors |
| Q34977552 | Newborn hearing screening in neonates exposed to psychoactive drugs |
| Q28551492 | Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial |
| Q39695416 | Non-invasive detection of cellular bioelectricity based on carbon nanotube devices for high-throughput drug screening |
| Q41404998 | Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial |
| Q36055324 | Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial |
| Q37395586 | Nondisclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection |
| Q28271902 | Nonmevalonate terpene biosynthesis enzymes as antiinfective drug targets: substrate synthesis and high-throughput screening methods |
| Q44787120 | Nonprescription drug screening. Dyclonine hydrochloride |
| Q44308671 | Nonprescription drug screening. Pseudoephedrine |
| Q43943461 | Nosocomial Pseudomonas pickettii bacteremias traced to narcotic tampering. A case for selective drug screening of health care personnel |
| Q35652155 | Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening |
| Q36370492 | Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties |
| Q30541176 | Novel Phenotypic Fluorescent Three-Dimensional Platforms for High-throughput Drug Screening and Personalized Chemotherapy |
| Q36837580 | Novel analytical procedures for screening of drug residues in water, waste water, sediment and sludge |
| Q34100267 | Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP) |
| Q38112184 | Novel approaches to glioma drug design and drug screening. |
| Q34550212 | Novel approaches to models of Alzheimer's disease pathology for drug screening and development |
| Q33226756 | Novel approaches to plant drug discovery based on high throughput pharmacological screening and genetic manipulation |
| Q28830471 | Novel high throughput pooled shRNA screening identifies NQO1 as a potential drug target for host directed therapy for tuberculosis |
| Q35937856 | Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: a computational approach in drug design |
| Q30662767 | Novel paradigms for drug discovery: computational multitarget screening |
| Q28087793 | Novel screening techniques for ion channel targeting drugs |
| Q33758781 | Novel small-molecule inhibitors of arylamine N-acetyltransferases: drug discovery by high-throughput screening. |
| Q36467362 | Nuclear magnetic resonance-based screening methods for drug discovery |
| Q40028907 | Numerical analysis of an immunochromatographic test strip reader in abused drugs screening |
| Q35101307 | Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis |
| Q33258230 | Observational study design |
| Q34887838 | Off-rate screening for selection of high-affinity anti-drug antibodies |
| Q36952095 | Optical chemical biosensors for high-throughput screening of drugs. |
| Q43571879 | Optical density ratios of human immunodeficiency virus screening tests from HIV-seronegative intravenous drug abusers |
| Q43462180 | Optimal experimental design for assessment of enzyme kinetics in a drug discovery screening environment. |
| Q28546732 | Optimization of a Fluorescence-Based Assay for Large-Scale Drug Screening against Babesia and Theileria Parasites |
| Q39168691 | Optogenetic methods in drug screening: technologies and applications |
| Q44261993 | Oral fluid testing for drugs of abuse: positive prevalence rates by Intercept immunoassay screening and GC-MS-MS confirmation and suggested cutoff concentrations |
| Q35781608 | Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening - exemplified for cardiovascular drugs |
| Q63431939 | Organ-on-a-Chip for Cancer and Immune Organs Modeling |
| Q38137976 | Organ-on-a-chip technology and microfluidic whole-body models for pharmacokinetic drug toxicity screening |
| Q38741010 | Organic cation rhodamines for screening organic cation transporters in early stages of drug development |
| Q38898338 | Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling |
| Q34802808 | Orthotopic transplantation of retinoblastoma cells into vitreous cavity of zebrafish for screening of anticancer drugs |
| Q37963199 | Outpatient adverse drug events identified by screening electronic health records. |
| Q30393585 | Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I. |
| Q30396946 | Overview on the current status on virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part II. |
| Q34675679 | Overview: the art of cancer drug screening: molecular target versus milieu-based screens. |
| Q41335260 | Oxidative stress and lens opacity: an overall approach to screening anticataractous drugs |
| Q35057007 | P1 and P1' para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease. |
| Q31033451 | PEG based resins for protease drug discovery synthesis, screening and analysis of combinatorial on-bead libraries |
| Q35112942 | PET Screening of Anticancer Drugs: A Faster Route to Drug/Target Evaluations In Vivo |
| Q40637027 | Pap smear screening, pap smear abnormalities and psychosocial risk factors among women in a residential alcohol and drug rehabilitation facility. |
| Q35570425 | Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells |
| Q28486252 | Parallel screening of wild-type and drug-resistant targets for anti-resistance neuraminidase inhibitors |
| Q34279501 | Parasite-based screening and proteome profiling reveal orlistat, an FDA-approved drug, as a potential anti Trypanosoma brucei agent |
| Q28833697 | Parkinson disease drug screening based on the interaction between D(2) dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresis |
| Q38260639 | Pathology consultation on urine compliance testing and drug abuse screening |
| Q38440139 | Pathophysiologically relevant in vitro tumor models for drug screening |
| Q28067569 | Patient Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Development and Screening In Catecholaminergic Polymorphic Ventricular Tachycardia |
| Q38221457 | Patient aberrant drug taking behaviors in a large family medicine residency program: a retrospective chart review of screening practices, incidence, and predictors |
| Q36409821 | Patient-Specific Drug Screening Using a Human Induced Pluripotent Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Type 2. |
| Q43841197 | Pattern of mycobacterial resistance to four anti-tuberculosis drugs in pulmonary tuberculosis patients in the state of Qatar after the implementation of DOTS and a limited expatriate screening programme |
| Q30500502 | Patterned cardiomyocytes on microelectrode arrays as a functional, high information content drug screening platform |
| Q38813543 | Patterning hypoxic multicellular spheroids in a 3D matrix - a promising method for anti-tumor drug screening |
| Q31108870 | Peptide ligands in antibacterial drug discovery: use as inhibitors in target validation and target-based screening |
| Q40135000 | Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells |
| Q37994798 | Peptides as drugs: from screening to application. |
| Q35999174 | Per-residue energy decomposition pharmacophore model to enhance virtual screening in drug discovery: a study for identification of reverse transcriptase inhibitors as potential anti-HIV agents |
| Q36964408 | Perceptions of drug users regarding hepatitis C screening and care: a qualitative study |
| Q42379039 | Performance and consistency of a fluorescence-based high-throughput screening assay for use in Babesia drug screening in mice |
| Q43871710 | Performance evaluation of on-site oral fluid drug screening devices in normal police procedure in Germany |
| Q44135536 | Performance evaluation of the DrugWipe® 5/5+ on-site oral fluid screening device |
| Q34038764 | Performance evaluation of three liquid chromatography mass spectrometry methods for broad spectrum drug screening |
| Q39277702 | Perfusion enhanced polydimethylsiloxane based scaffold cell culturing system for multi-well drug screening platform. |
| Q38020229 | Perinatal illicit drug screening practices in mother-newborn dyads at a university hospital serving rural/semi-urban communities: translation of research to quality improvement. |
| Q38573892 | Perinatal screening for illicit drugs: policies in hospitals in a large metropolitan area |
| Q26999370 | Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening |
| Q37737041 | Perspectives of liquid chromatography coupled to low- and high-resolution mass spectrometry for screening, identification, and quantification of drugs in clinical and forensic toxicology. |
| Q41668153 | Pharmaceutical industry screening for new antiepileptic drugs. |
| Q40533703 | Pharmaceutical screening: from off-the-wall to off-the-shelf. The many routes to successful drug discovery |
| Q34453112 | Pharmacogenetic screening and therapeutic drugs |
| Q37974124 | Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era. |
| Q34350966 | Pharmacokinetic herb-drug interactions: are preventive screenings necessary and appropriate? |
| Q33487027 | Pharmacokinetic screening for the selection of new drug discovery candidates is greatly enhanced through the use of liquid chromatography-atmospheric pressure ionization tandem mass spectrometry |
| Q42463156 | Pharmacological profile of brain-derived neurotrophic factor (BDNF) splice variant translation using a novel drug screening assay: a "quantitative code" |
| Q38226581 | Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery |
| Q39008696 | Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 inhibitors. |
| Q33885419 | Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment |
| Q33255029 | Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model |
| Q36039949 | Phenotype-first screening for the identification of novel drug targets |
| Q26771369 | Phenotypic Screening Approaches to Develop Aurora Kinase Inhibitors: Drug Discovery Perspectives |
| Q35889090 | Phenotypic Screening of Drug Library in Actively Differentiating Mouse Embryonic Stem Cells. |
| Q36125734 | Phenotypic Screening of Small-Molecule Inhibitors: Implications for Therapeutic Discovery and Drug Target Development in Traumatic Brain Injury |
| Q38984689 | Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma |
| Q34429484 | Phenotypic screening in cancer drug discovery - past, present and future |
| Q37799854 | Phenotypic screening strategies for neurodegenerative diseases: a pathway to discover novel drug candidates and potential disease targets or mechanisms |
| Q38904862 | Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration. |
| Q38126962 | Physical and virtual screening methods for marine toxins and drug discovery targeting nicotinic acetylcholine receptors |
| Q37576495 | Physician tobacco screening and advice to quit among U.S. adolescents - National Survey on Drug Use and Health, 2013. |
| Q36865292 | Phytochemical Screening and Antimicrobial Activity of Some Medicinal Plants Against Multi-drug Resistant Bacteria from Clinical Isolates |
| Q40703516 | Pilot Study: Combining Formal and Peer Education with FibroScan to Increase HCV Screening and Treatment in Persons who use Drugs |
| Q37440391 | Planning multi-arm screening studies within the context of a drug development program |
| Q33301828 | Plasmodium falciparum: functional mitochondrial ADP/ATP transporter in Escherichia coli plasmic membrane as a tool for selective drug screening |
| Q61797618 | Plasmodium palmitoylation machinery engineered in for high-throughput screening of palmitoyl acyl-transferase inhibitors |
| Q38091765 | Pluripotency and targeted reprogramming: strategies, disease modeling and drug screening |
| Q38569334 | Pluripotent stem cells as a cellular model for skin: relevance for physiopathology, cell/gene therapy and drug screening |
| Q38235190 | Pluripotent stem cells as a platform for cardiac arrhythmia drug screening |
| Q38932077 | Pluripotent stem cells for disease modeling and drug screening: new perspectives for treatment of cystic fibrosis? |
| Q33435425 | Pooling in high-throughput drug screening. |
| Q43469301 | Population screening of risky alcohol and drug use via Internet and Interactive Voice Response (IVR): a feasibility and psychometric study in a random sample |
| Q35970376 | Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping control. |
| Q37718843 | Post processing of protein-compound docking for fragment-based drug discovery (FBDD): in-silico structure-based drug screening and ligand-binding pose prediction |
| Q44340380 | Poster 45 Utilization and Management of Urine Drug Screening for Opioid Medications |
| Q34003928 | Postmortem drug screening by non-targeted and targeted ultra-performance liquid chromatography-mass spectrometry technology |
| Q40880405 | Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use. |
| Q34701024 | Potassium channels: gene family, therapeutic relevance, high-throughput screening technologies and drug discovery. |
| Q36403490 | Potential Broad Spectrum Inhibitors of the Coronavirus 3CLpro: A Virtual Screening and Structure-Based Drug Design Study |
| Q39998926 | Potential application as screening and drug designing tools of cytoarchitectural deficiencies present in three animal models of schizophrenia |
| Q36804572 | Potential application of embryonic stem cells in Parkinson's disease: drug screening and cell therapy |
| Q34453023 | Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method |
| Q37846001 | Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method |
| Q33500799 | Potential efficacy of fumagillin in intestinal microsporidiosis due to Enterocytozoon bieneusi in patients with HIV infection: results of a drug screening study. The French Microsporidiosis Study Group |
| Q37940945 | Potential impact of drug effects, availability, pharmacokinetics, and screening on estimates of drugs implicated in cases of assault |
| Q33203790 | Potentiometric quasi-array employing calixarene derivatives for the high-throughput similarity/diversity screening of beta-adrenergic and beta-blocking chiral drugs by HPLC. |
| Q42671775 | Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trials |
| Q44410318 | Precise gas chromatography with retention time locking in comprehensive toxicological screening for drugs in blood |
| Q41684883 | Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective |
| Q37040225 | Preclinical screening of in vivo interactions between myelopoietic growth factors and antitumour drugs for therapy of myeloid leukaemia patients (review). |
| Q42628073 | Predicting combinative drug pairs towards realistic screening via integrating heterogeneous features |
| Q33301559 | Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach |
| Q43203128 | Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition |
| Q36689081 | Prediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump |
| Q37619170 | Predictive Validity of the Beers and Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) Criteria to Detect Adverse Drug Events, Hospitalizations, and Emergency Department Visits in the United States |
| Q40399513 | Predictive Value of Positive Drug Screening Results in an Urban Outpatient Population |
| Q40987219 | Predictive validity of the Drug Lifestyle Screening Interview: a two-year follow-up |
| Q39401592 | Preemployment drug screening at the Johns Hopkins Hospital, 1989 and 1991. |
| Q39246197 | Preemployment drug screening in a large metropolitan medical center: a one-month trial |
| Q42011216 | Preemployment drug screening. The epidemiologic issues |
| Q31168171 | Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs |
| Q43579642 | Preliminary screening for antiviral AIDS drugs. II. Report on fiscal year 1989 |
| Q41148330 | Prenatal screening for illegal drugs. Dilemma for the nurse-midwife |
| Q40667101 | Prescription drugs associated with false-positive results when using faecal immunochemical tests for colorectal cancer screening |
| Q28486101 | Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009) |
| Q34387810 | Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. |
| Q39788426 | Prevalence of multiple drug resistance and screening of enterotoxin (stn) gene in Salmonella enterica serovars from water sources in Lagos, Nigeria |
| Q39640712 | Prevention of Hospital-Acquired Adverse Drug Reactions in Older People Using Screening Tool of Older Persons' Prescriptions and Screening Tool to Alert to Right Treatment Criteria: A Cluster Randomized Controlled Trial |
| Q39729427 | Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening |
| Q39442440 | Primary and secondary drug screening assays for Friedreich ataxia |
| Q37824151 | Primary cells and stem cells in drug discovery: emerging tools for high-throughput screening |
| Q38250275 | Primary human papillomavirus screening for cervical cancer in the United States-US Food and Drug Administration approval, clinical trials, and where we are today |
| Q38392178 | Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screening. |
| Q34815390 | Problem alcohol use among problem drug users in primary care: a qualitative study of what patients think about screening and treatment |
| Q44773460 | Problems related to screening tests for drug addiction at the workplace |
| Q37980229 | Procathepsin D as a tumor marker, anti-cancer drug or screening agent |
| Q39886523 | Procedure for identification and characterization of drugs efficient against mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models |
| Q43428867 | Production of ultraviolet-light-induced skin erythema in the hairless rat: a comparison with the haired rat in screening for anti-inflammatory drugs |
| Q44125156 | Progress toward virtual screening for drug side effects. |
| Q28324388 | Prolongation of rat cardiac allograft survival by donor pretreatment. Screening of antineoplastic drugs |
| Q42700625 | Promising toxicological biomarkers for the diagnosis of liver injury types: Bile acid metabolic profiles and oxidative stress marker as screening tools in drug development |
| Q37921341 | Promoting adult hippocampal neurogenesis: a novel strategy for antidepressant drug screening |
| Q41548921 | Propagation of Waldenström's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model. |
| Q33719385 | Prospects for drug screening using the reverse two-hybrid system |
| Q40316207 | Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial |
| Q34283636 | Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial |
| Q36651883 | Protein NMR-based screening in drug discovery |
| Q30414525 | Protein reporter bioassay systems for the phenotypic screening of candidate drugs: a mouse platform for anti-aging drug screening |
| Q35397776 | Protein-protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays |
| Q41559923 | Proteome mining for drug target identification in Listeria monocytogenes strain EGD-e and structure-based virtual screening of a candidate drug target penicillin binding protein 4. |
| Q36021850 | Proteome-wide drug screening using mass spectrometric imaging of bead-arrays |
| Q38603615 | Protocol for fast screening of multi-target drug candidates: Application to Alzheimer's disease |
| Q41523758 | Protocols for the routine screening of drug sensitivity in the human parasite Trichomonas vaginalis |
| Q37219517 | Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening |
| Q36740589 | Psychometric evaluation of the alcohol use disorders identification test and short drug abuse screening test with psychiatric patients in India |
| Q44190207 | Psychometric properties of the Brazilian version of the drug use screening inventory |
| Q39181873 | Psychotropic drugs as potential antitumor agents: a selective screening study |
| Q39539730 | QSAR Modelling of CYP3A4 Inhibition as a Screening Tool in the Context of DrugDrug Interaction Studies |
| Q41193471 | QSAR-assisted virtual screening of lead-like molecules from marine and microbial natural sources for antitumor and antibiotic drug discovery. |
| Q33294677 | Qualitative screening for basic drugs in autopsy liver samples by dual-plate overpressured layer chromatography |
| Q43591135 | Qualitative screening for drugs of abuse in hair using GC-MS. |
| Q38676363 | Quality Metrics and Systems Transformation: Are We Advancing Alcohol and Drug Screening in Primary Care? |
| Q38832531 | Quantification of cell viability and rapid screening anti-cancer drug utilizing nanomechanical fluctuation |
| Q33299345 | Quantifying RNA-peptide interaction by single-quantum dot-based nanosensor: an approach for drug screening |
| Q36098066 | Quantitative RT-PCR assay for high-throughput screening (HTS) of drugs against the growth of Cryptosporidium parvum in vitro |
| Q34101536 | Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing |
| Q33424539 | Quantitative screening and matrix effect studies of drug discovery compounds in monkey plasma using fast-gradient liquid chromatography/tandem mass spectrometry |
| Q36558399 | Quantitative screening for anticestode drugs based on changes in baseline enzyme secretion by Taenia crassiceps |
| Q42076166 | Quantitative serum toxic screening in the management of suspected drug overdose |
| Q38129020 | Quantum dot approaches for target-based drug screening and multiplexed active biosensing |
| Q30979591 | RAMPED-UP NMR: multiplexed NMR-based screening for drug discovery. |
| Q33971652 | RNA as a drug target: methods for biophysical characterization and screening |
| Q39844705 | RNA catalyst as a reporter for screening drugs against RNA editing in trypanosomes |
| Q34029015 | RNAi screening identifies HAT1 as a potential drug target in esophageal squamous cell carcinoma |
| Q36754233 | Radiolabeling of Mycobacterium leprae lipids within schwannoma cells, a potential drug screening system |
| Q43547220 | Radioligand binding assays in the drug discovery process: potential pitfalls of high throughput screenings |
| Q38685105 | Radioligand binding to intact cells as a tool for extended drug screening in a representative physiological context |
| Q35616791 | Raman micro spectroscopy for in vitro drug screening: subcellular localisation and interactions of doxorubicin. |
| Q43204290 | Random drug testing in schools fails screening criteria |
| Q33712846 | Randomized clinical trial of the effects of screening and brief intervention for illicit drug use: the Life Shift/Shift Gears study |
| Q36811736 | Randomized controlled trial to evaluate screening and brief intervention for drug-using multiethnic emergency and trauma department patients |
| Q39507365 | Rapid CO breath test screening of drugs for protective effects on ribavirin-induced hemolysis in a rabbit model: a pilot study |
| Q41604745 | Rapid complementation assay for anti-HIV-1 drug screening and analysis of envelope protein function |
| Q33345948 | Rapid fluorescent assay for screening drugs on Leishmania amastigotes |
| Q42323219 | Rapid identification and drug susceptibility screening of ESAT-6 secreting Mycobacteria by a NanoELIwell assay |
| Q43215903 | Rapid in vitro screening of drug-metal ion interactions |
| Q34823666 | Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice |
| Q34613593 | Rapid permeability screening in drug discovery to predict human intestinal absorption |
| Q33425283 | Rapid pharmacokinetic screening for the selection of new drug discovery candidates using a generic isocratic liquid chromatography--atmospheric pressure ionization tandem mass spectrometry method |
| Q33686753 | Rapid prototyping of concave microwells for the formation of 3D multicellular cancer aggregates for drug screening. |
| Q44309151 | Rapid screening and characterization of drug metabolites using a new quadrupole-linear ion trap mass spectrometer |
| Q33439783 | Rapid screening and characterization of drug metabolites using multiple ion monitoring dependent product ion scan and postacquisition data mining on a hybrid triple quadrupole-linear ion trap mass spectrometer |
| Q33517144 | Rapid screening and confirmation of drugs and toxic compounds in biological specimens using liquid chromatography/ion trap tandem mass spectrometry and automated library search |
| Q33455694 | Rapid screening and determination of designer drugs in saliva by a nib-assisted paper spray-mass spectrometry and separation technique |
| Q43734275 | Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity |
| Q35786304 | Rapid screening of anti-infective drug products for counterfeits using Raman spectral library-based correlation methods |
| Q36763401 | Rapid screening of drug-protein binding using high-performance affinity chromatography with columns containing immobilized human serum albumin |
| Q43987106 | Rapid screening of drugs of abuse in human urine by high-performance liquid chromatography coupled with high resolution and high mass accuracy hybrid linear ion trap-Orbitrap mass spectrometry |
| Q44748665 | Rapid screening procedure based on headspace solid-phase microextraction and gas chromatography-mass spectrometry for the detection of many recreational drugs in hair |
| Q39963381 | Rapid wide-scope screening of drugs of abuse, prescription drugs with potential for abuse and their metabolites in influent and effluent urban wastewater by ultrahigh pressure liquid chromatography-quadrupole-time-of-flight-mass spectrometry. |
| Q34408489 | Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer |
| Q26786512 | Rat Ultrasonic Vocalizations and Behavioral Neuropharmacology: From the Screening of Drugs to the Study of Disease |
| Q39434698 | Rational drug design of antineoplastic agents using 3D-QSAR, cheminformatic, and virtual screening approaches |
| Q36695853 | Rational screening of oligonucleotide combinatorial libraries for drug discovery |
| Q28482250 | Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort study |
| Q39008246 | Real-time investigation of human topoisomerase I reaction kinetics using an optical sensor: a fast method for drug screening and determination of active enzyme concentrations |
| Q38838000 | Recent Developments of Three-Dimensional Paper-Based Electrochemical Devices for Cancer Cell Detection and Anticancer Drug Screening. |
| Q38073317 | Recent advances in in vivo screening for antiarrhythmic drugs |
| Q38252759 | Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors. |
| Q35743496 | Recent development and application of virtual screening in drug discovery: an overview |
| Q38104820 | Recent trends and future prospects in computational GPCR drug discovery: from virtual screening to polypharmacology. |
| Q35653355 | Receptor-based virtual screening protocol for drug discovery. |
| Q36133296 | Receptorome screening for CNS drug discovery. |
| Q37657158 | Receptorome screening: a powerful, facile approach to better understand and engineer drugs. |
| Q59350388 | Recombinant Lassa Virus Expressing Green Fluorescent Protein as a Tool for High-Throughput Drug Screens and Neutralizing Antibody Assays |
| Q39002283 | Recreational drug use and chemsex among HIV-infected in-patients: a unique screening opportunity |
| Q35664315 | Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production |
| Q36875696 | Reference ranges for screening preclinical drug safety data |
| Q38798795 | Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells |
| Q41589552 | Regulation of smooth muscle alpha-actin promoter in ras-transformed cells: usefulness for setting up reporter gene-based assay system for drug screening |
| Q36518879 | Reliability of Identification Techniques for Drugs of Abuse in a Urine Screening Program and Drug Excretion Data |
| Q40166866 | Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies. |
| Q29248487 | Repositioning approved drugs for the treatment of problematic cancers using a screening approach. |
| Q43909637 | Response to comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells". |
| Q35018958 | Retrospect and prospect of virtual screening in drug discovery |
| Q35282259 | Revisiting de novo drug design: receptor based pharmacophore screening. |
| Q38060778 | Riboswitch-based antibacterial drug discovery using high-throughput screening methods |
| Q33290242 | Risky use of alcohol, drugs and cigarettes in a psychosis unit: a 1 1/2 year follow-up of stability and changes after initial screening |
| Q33374261 | Robust and systematic drug screening method using chemical arrays and the protein library: identification of novel inhibitors of carbonic anhydrase II. |
| Q35137591 | Role of ADME characteristics in drug discovery and their in silico evaluation: in silico screening of chemicals for their metabolic stability |
| Q35681868 | Role of Open Source Tools and Resources in Virtual Screening for Drug Discovery |
| Q38125595 | Role of urine drug screening in the medical clearance of pediatric psychiatric patients: is there one? |
| Q39251393 | Routine Drug Screening for Patients in the Emergency Department of a State Psychiatric Hospital: A Naturalistic Cohort Study |
| Q43038141 | Routine practice HCV infection screening with saliva samples: multicentric study in an intravenous drug user population |
| Q38433186 | Routine screening for syphilis is justified in patients admitted to psychiatric, alcohol, and drug rehabilitation wards of the Veterans Administration Medical Center |
| Q38630580 | Routine screening of blood and urine for severe reactions to anticonvulsant drugs in asymptomatic patients is of doubtful value |
| Q44010046 | SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. |
| Q65368973 | SBIRT Implementation for Adolescents in Urban Federally Qualified Health Centers |
| Q33866136 | SCN8A encephalopathy: Research progress and prospects |
| Q35495232 | SCREENING OF DRUGS FOR TRIAL IN HUMAN LEPROSY |
| Q31040678 | SERS assisted ultra-fast peptidic screening: a new tool for drug discovery. |
| Q35423302 | Scaffold hopping with virtual screening from IP3 to a drug-like partial agonist of the inositol trisphosphate receptor. |
| Q43153706 | Screening DNA-targeted anticancer drug in vitro based on the drug-conjugated DNA by resonance light scattering technique |
| Q35960314 | Screening Ingredients from Herbs against Pregnane X Receptor in the Study of Inductive Herb-Drug Interactions: Combining Pharmacophore and Docking-Based Rank Aggregation. |
| Q36021810 | Screening North American plant extracts in vitro against Trypanosoma brucei for discovery of new antitrypanosomal drug leads |
| Q33691241 | Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma |
| Q43335514 | Screening adulteration of polypropylene bottles with postconsumer recycled plastics for oral drug package by near-infrared spectroscopy |
| Q36734255 | Screening an elderly population for verifiable adverse drug reactions. Methodological approach and initial data of the Berlin Aging Study (BASE). |
| Q36270523 | Screening and Characterization of Drugs That Protect Corneal Endothelial Cells Against Unfolded Protein Response and Oxidative Stress |
| Q40157880 | Screening and Characterization of Enzyme Inhibitors as Drug Candidates |
| Q35721741 | Screening and Identification of Inhibitors Against Glutathione Synthetase, A Potential Drug Target of Plasmodium falciparum |
| Q41202652 | Screening and assessment of antiinflammatory drugs |
| Q36688593 | Screening and brief intervention for alcohol and other drug use in primary care: associations between organizational climate and practice |
| Q27347865 | Screening and brief intervention for drug use in primary care: the ASPIRE randomized clinical trial |
| Q34177139 | Screening and brief intervention for unhealthy drug use in primary care settings: randomized clinical trials are needed. |
| Q34116604 | Screening and brief intervention for unhealthy drug use: little or no efficacy |
| Q30461937 | Screening and characterization of antiepileptic drugs with rapidly recurring hippocampal seizures in rats |
| Q33398902 | Screening and cloning of multi-drug resistant genes in HL-60/MDR cells |
| Q34374699 | Screening and confirmation of 62 drugs of abuse and metabolites in urine by ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry |
| Q28320600 | Screening and confirmation of drugs in urine: interference of hordenine with the immunoassays and thin layer chromatography methods |
| Q31116250 | Screening and determination of drugs in human saliva utilizing microextraction by packed sorbent and liquid chromatography-tandem mass spectrometry |
| Q36853288 | Screening and identification of drugs in human hair by high-performance liquid chromatography-photodiode-array UV detection and gas chromatography-mass spectrometry after solid-phase extraction. A powerful tool in forensic medicine |
| Q38980481 | Screening and identification of inhibitors against influenza A virus from a US drug collection of 1280 drugs |
| Q36342321 | Screening and interventions for alcohol and drug problems in medical settings: what works? |
| Q41370019 | Screening and personalizing nootropic drugs and cognitive modulator regimens in silico |
| Q35603610 | Screening and prevention of alcohol and drug use disorders in women |
| Q36682338 | Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance |
| Q34106875 | Screening and selective quantification of illicit drugs in wastewater by mixed-mode solid-phase extraction and quadrupole-time-of-flight liquid chromatography-mass spectrometry |
| Q42252450 | Screening anti-southern rice black-streaked dwarf virus drugs based on S7-1 gene expression in rice suspension cells |
| Q36520996 | Screening applications in drug discovery based on microfluidic technology. |
| Q39387222 | Screening candidate anticancer drugs for brain tumor chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues |
| Q36873402 | Screening chemical libraries for nucleic-acid-binding drugs by in vitro selection: a test case with lividomycin |
| Q28486133 | Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference |
| Q40042037 | Screening current and future diagnosis of psychiatric disorders using the Revised Drug Use Screening Inventory |
| Q33259890 | Screening designs for drug development |
| Q40225809 | Screening determination of four amphetamine-type drugs in street-grade illegal tablets and urine samples by portable capillary electrophoresis with contactless conductivity detection. |
| Q30558954 | Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays |
| Q40356909 | Screening drug-like compounds by docking to homology models: a systematic study. |
| Q38624938 | Screening drug-target interactions with positive-unlabeled learning |
| Q31039509 | Screening drugs for metabolic stability using pulsed ultrafiltration mass spectrometry |
| Q36351468 | Screening existing drugs for neurodegeneration: The National Institute of Neurologic Disorders and Stroke (NINDS) model |
| Q34147370 | Screening for HIV, HBV and HCV markers among drug users in treatment in rural south-east England |
| Q35715116 | Screening for Hepatitis C in injecting drug users: a cost utility analysis |
| Q28072176 | Screening for Potential Drug Targets by Comprehensive Identification of Disease-specific Antigens Incorporated into Immune Complexes in Patients with Immunological Diseases |
| Q35547694 | Screening for a gene deletion mutant whose temperature sensitivity is suppressed by FK506 in budding yeast and its application for a positive screening for drugs inhibiting calcineurin. |
| Q36934704 | Screening for adolescent alcohol and drug use in pediatric health-care settings: predictors and implications for practice and policy |
| Q38256069 | Screening for adverse drug events in older adults: the impact of interventions |
| Q30470746 | Screening for alcohol and drug abuse |
| Q35920320 | Screening for alcohol and drug use disorders among adults in primary care: a review |
| Q44126808 | Screening for alcohol and drug use in pregnancy |
| Q33434788 | Screening for amphetamine and amphetamine-type drugs in doping analysis by liquid chromatography/mass spectrometry |
| Q44492230 | Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry |
| Q28485108 | Screening for and verification of novel mutations associated with drug resistance in the HIV type 1 subtype B(') in China |
| Q28377275 | Screening for anti-HIV drugs that can combine virucidal and virustatic activities synergistically |
| Q36069853 | Screening for antifungal drugs |
| Q42232217 | Screening for antiretroviral drug resistance among treatment-naive human immunodeficiency virus type 1-infected individuals in Lebanon. |
| Q40112327 | Screening for at-risk alcohol use and drug use in an emergency department: integration of screening questions into electronic triage forms achieves high screening rates. |
| Q43277525 | Screening for atypical suicide risk with person fit statistics among people presenting to alcohol and other drug treatment |
| Q31147430 | Screening for basic drugs in 2-mL urine samples by dual-plate overpressured layer chromatography and comparison with gas chromatography-mass spectrometry |
| Q44075359 | Screening for basic drugs in hair of drug addicts by liquid chromatography/time-of-flight mass spectrometry |
| Q40520560 | Screening for central nervous system-stimulating drugs in human plasma by liquid chromatography with mass spectrometric detection. |
| Q36274123 | Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory |
| Q35668192 | Screening for disease-markers and investigating drug effects by proteome profiling: can it meet expectations? |
| Q44294982 | Screening for drug abuse among adolescents in clinical and correctional settings using the Problem-Oriented Screening Instrument for Teenagers |
| Q36657445 | Screening for drug abuse among medical and nonmedical users of prescription drugs in a probability sample of college students |
| Q34488439 | Screening for drug and alcohol abuse among older adults using a modified version of the CAGE. |
| Q41638877 | Screening for drug and alcohol abuse in a general medical population |
| Q28535165 | Screening for drug and alcohol use disorders and their association with HIV-related sexual risk behaviors among men who have sex with men in Peru |
| Q39212268 | Screening for drug-induced hepatotoxicity in primary mouse hepatocytes using acetaminophen, amiodarone, and cyclosporin a as model compounds: an omics-guided approach |
| Q34009338 | Screening for drug-resistant Candida yeasts with chromogenic agar |
| Q39978511 | Screening for drugs in oral fluid: drug driving and illicit drug use in a sample of Queensland motorists. |
| Q40220472 | Screening for drugs in oral fluid: illicit drug use and drug driving in a sample of Queensland motorists |
| Q30778804 | Screening for drugs in serum by electrospray ionization/collision-induced dissociation and library searching |
| Q36882102 | Screening for drugs of abuse (II): Cannabinoids, lysergic acid diethylamide, buprenorphine, methadone, barbiturates, benzodiazepines and other drugs. |
| Q43749347 | Screening for drugs of abuse in urine samples from a drug addiction center |
| Q40547514 | Screening for drugs of abuse. I: Opiates, amphetamines and cocaine |
| Q37048200 | Screening for drugs of abuse: hair as an alternative matrix: a review for the medical toxicologist |
| Q27022334 | Screening for drugs of abuse: which matrix, oral fluid or urine? |
| Q35065174 | Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. |
| Q43725135 | Screening for hepatitis C in injecting and ex-injecting drug users in North East Essex |
| Q34194499 | Screening for human ADME/Tox drug properties in drug discovery |
| Q30619552 | Screening for illicit and medicinal drugs in whole blood using fully automated SPE and ultra-high-performance liquid chromatography with TOF-MS with data-independent acquisition |
| Q41996533 | Screening for illicit drug use in a military obstetric population |
| Q40903642 | Screening for illicit drugs in pooled human urine and urinated soil samples and studies on the stability of urinary excretion products of cocaine, MDMA, and MDEA in wastewater by hyphenated mass spectrometry techniques. |
| Q39391720 | Screening for illicit drugs in the newborn infant. Position statement of the Texas Pediatric Society Committee on Fetus and Newborn. |
| Q42080641 | Screening for molluscicidal activity in crude drugs |
| Q35182580 | Screening for noise in gene expression identifies drug synergies |
| Q41138579 | Screening for novel drug effects with a microphysiometer: a potent effect of clofilium unrelated to potassium channel blockade |
| Q33233385 | Screening for peptide drugs from the natural repertoire of biodiverse protein folds |
| Q34898761 | Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance |
| Q39709217 | Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays |
| Q41584247 | Screening for possible drug carcinogenicity: second report of findings |
| Q40466609 | Screening for prostate cancer. Implications for drug therapy. |
| Q36381116 | Screening for reactive intermediates and toxicity assessment in drug discovery |
| Q44523259 | Screening for risk factors for adolescent alcohol and drug use. |
| Q34211026 | Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis |
| Q30457489 | Screening for substance abuse risk in cancer patients using the Opioid Risk Tool and urine drug screen |
| Q40571927 | Screening for supra-additive effects of cytotoxic drugs and gamma irradiation in an in vitro model for hepatocellular carcinoma |
| Q37529605 | Screening for the drug-phospholipid interaction: correlation to phospholipidosis |
| Q40243708 | Screening for the metabolic syndrome in Australia: a national survey of psychiatrists' attitudes and reported practice in patients prescribed antipsychotic drugs |
| Q35214888 | Screening for the potential of a drug candidate to cause idiosyncratic drug reactions |
| Q34681176 | Screening for unhealthy alcohol and other drug use by health educators: do primary care clinicians document screening results? |
| Q41370052 | Screening hallucinogenic drugs II. Systematic study of two behavioral tests |
| Q40792300 | Screening in a cell-based assay for inhibitors of microglial nitric oxide production reveals calmodulin-regulated protein kinases as potential drug discovery targets |
| Q35572940 | Screening injecting drug users for sexually transmitted infections and blood borne viruses using street outreach and self collected sampling |
| Q33984475 | Screening instruments for detecting illicit drug use/abuse that could be useful in general hospital wards: a systematic review |
| Q28818367 | Screening lifespan-extending drugs in Caenorhabditis elegans via label propagation on drug-protein networks |
| Q28219577 | Screening method for nonsteroidal antiinflammatory drugs based on the cyclooxygenase 2 pathway activated by serum-free stimulation in A549 cells |
| Q30985971 | Screening method for seventy psychoactive drugs or drug metabolites in serum based on high-performance liquid chromatography--electrospray ionization mass spectrometry |
| Q41744330 | Screening methods for drugs and heavy metals in Chinese patent medicines |
| Q34204506 | Screening methods for influenza antiviral drug discovery |
| Q40910909 | Screening microbial metabolites for new drugs--theoretical and practical issues |
| Q40740252 | Screening of Chinese and Mongolian herbal drugs for anti-human immunodeficiency virus type 1 (HIV-1) activity |
| Q30659755 | Screening of Chinese herbal drug extracts for inhibitory activity on nitric oxide production and identification of an active compound of Zanthoxylum bungeanum. |
| Q33374552 | Screening of DHFR-binding drugs by MALDI-TOFMS. |
| Q28553125 | Screening of Drug Metabolizing Enzymes for the Ginsenoside Compound K In Vitro: An Efficient Anti-Cancer Substance Originating from Panax Ginseng |
| Q28831086 | Screening of Drugs Inhibiting In vitro Oligomerization of Cu/Zn-Superoxide Dismutase with a Mutation Causing Amyotrophic Lateral Sclerosis |
| Q38156719 | Screening of FDA-Approved Drugs for Inhibitors against Japanese Encephalitis Virus Infection |
| Q40089278 | Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens |
| Q41331748 | Screening of Polyacetylenic Alcohols in Crude Drugs Using the ELISA for Panaxytriol |
| Q37049385 | Screening of Undiagnosed Hypothyroidism in Elderly Persons with Diabetes according to Age-Specific Reference Intervals for Serum Thyroid Stimulating Hormone and the Impact of Antidiabetes Drugs |
| Q28833169 | Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C |
| Q38959101 | Screening of alternative drugs to the tumor suppressor miR-375 in esophageal squamous cell carcinoma using the connectivity map. |
| Q33236010 | Screening of an annotated compound library for drug activity in a resistant myeloma cell line |
| Q44089784 | Screening of anti-inflammatory drugs |
| Q39559602 | Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma |
| Q34420330 | Screening of antifungal azole drugs and agrochemicals with an adapted alamarBlue-based assay demonstrates antibacterial activity of croconazole against Mycobacterium ulcerans |
| Q39634126 | Screening of antiviral drugs for hepadna virus infection in Pekin ducks: a review |
| Q38738796 | Screening of cardiovascular risk factors in patients with schizophrenia and patients treated with antipsychotic drugs: are we equally exhaustive as with the general population? |
| Q39502943 | Screening of differentially expressed genes and small molecule drugs of pediatric allergic asthma with DNA microarray. |
| Q34318051 | Screening of drug candidates for their drug--drug interaction potential |
| Q40559996 | Screening of drug metabolizing enzymes for fusidic acid and its interactions with isoform-selective substrates in vitro |
| Q36068745 | Screening of drug resistent gene by cyclical packaging rescue of hepatocellular carcinoma retroviral cDNA libraries |
| Q42199786 | Screening of drugs and chemicals by wide-bore capillary gas chromatography with flame ionization and nitrogen phosphorus detectors |
| Q42646320 | Screening of drugs and their assessment for use against the strobilate stage of Echinococcus |
| Q33251285 | Screening of drugs and toxic compounds with liquid chromatography-linear ion trap tandem mass spectrometry |
| Q39694086 | Screening of drugs for activity against Mycobacterium leprae. |
| Q43178224 | Screening of drugs in equine plasma using automated on-line solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry. |
| Q41199937 | Screening of drugs inhibiting Epstein-Barr virus replication |
| Q35585501 | Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1 |
| Q39348663 | Screening of five drugs for efficacy against Babesia felis in experimentally infected cats. |
| Q38090671 | Screening of liver-targeted drugs |
| Q44758844 | Screening of methylenedioxyamphetamine- and piperazine-derived designer drugs in urine by LC-MS/MS using neutral loss and precursor ion scan |
| Q43639304 | Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice |
| Q38089144 | Screening of natural products for drug discovery |
| Q36284934 | Screening of over 100 drugs in horse urine using automated on-line solid-phase extraction coupled to liquid chromatography-high resolution mass spectrometry for doping control |
| Q34818828 | Screening of phage-displayed human liver cDNA library against doxorubicin with drug-immobilized monolithic polyacrylamide cryogel |
| Q43687016 | Screening of psychotropic drugs in human hair based on high-performance thin-layer chromatography and microliquid extraction |
| Q34899322 | Screening of species of the endophytic fungus Phomopsis for the production of the anticancer drug taxol |
| Q33843241 | Screening of the Antimicrobial Activity against Drug Resistant Bacteria of Photorhabdus and Xenorhabdus Associated with Entomopathogenic Nematodes from Mae Wong National Park, Thailand. |
| Q28249005 | Screening of the hypoglycemic effect of eight Vietnamese herbal drugs |
| Q34975426 | Screening of type I and II drug binding to human cytochrome P450-3A4 in nanodiscs by localized surface plasmon resonance spectroscopy |
| Q38787168 | Screening of unapproved drugs using portable Raman spectroscopy. |
| Q33927565 | Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice |
| Q33727159 | Screening patients for alcohol, tobacco, and other drug misuse: the role of brief interventions |
| Q34441859 | Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. |
| Q42730418 | Screening pregnant young adults for alcohol and drug use: a pilot study |
| Q41277483 | Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up |
| Q42254674 | Screening procedure using chicks infected with the sporozoites of Plasmodium gallinaceum in an antimalarial drug development programme |
| Q34106439 | Screening procedures for simultaneous detection of several drug classes used for high throughput toxicological analyses and doping control. A review. |
| Q36953885 | Screening psychiatric patients for illicit drug use disorders and problems |
| Q42786719 | Screening remand prisoners for drug misuse would be improved by training doctors better |
| Q35775608 | Screening retreatment tuberculosis patients for drug resistance in mid-west Nepal: how well are we doing? |
| Q34975777 | Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections |
| Q27343160 | Screening system for drug-induced arrhythmogenic risk combining a patch clamp and heart simulator |
| Q39477040 | Screening system for xenosiderophores as potential drug delivery agents in mycobacteria |
| Q37855923 | Screening technologies for ion channel drug discovery |
| Q43247975 | Screening the Drug Resistance Property Among Aerobic Pathogenic Microorganisms of Dental Caries in North-Western Indian Population: A Preliminary Study |
| Q42932365 | Screening the Drug Sensitivity Genes Related to GEM and CDDP in the Lung Cancer Cell-lines |
| Q38695331 | Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery. |
| Q36544945 | Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'. |
| Q35784309 | Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery |
| Q36483085 | Screening the receptorome yields validated molecular targets for drug discovery |
| Q34548337 | Screening the receptorome: an efficient approach for drug discovery and target validation |
| Q43997248 | Screening the yeast "disruptome" for mutants affecting resistance to the immunosuppressive drug, mycophenolic acid |
| Q42408746 | Screening urged for hepatitis C but drug costs are prohibitive |
| Q39793646 | Screening urine for drugs of abuse in the emergency department: do test results affect physicians' patient care decisions? |
| Q38765515 | Screening with Quantification for 64 Drugs and Metabolites in Human Urine using UPLC-MS-MS Analysis and a Threshold Accurate Calibration |
| Q42933823 | Screening α-glucosidase inhibitors from traditional Chinese drugs by capillary electrophoresis with electrophoretically mediated microanalysis |
| Q40044357 | Screening, brief intervention, and referral to treatment (SBIRT) for alcohol and other drug use among adolescents: evaluation of a pediatric residency curriculum |
| Q34859268 | Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later |
| Q33629006 | Screening, isolation and optimization of anti-white spot syndrome virus drug derived from marine plants |
| Q33629022 | Screening, isolation and optimization of anti-white spot syndrome virus drug derived from terrestrial plants |
| Q27658729 | Screening-based discovery of drug-likeO-GlcNAcase inhibitor scaffolds |
| Q64246506 | Searching for new cytotoxic agents based on chromen-4-one and chromane-2,4-dione scaffolds |
| Q43972938 | Seed finding in golden hamsters: a potential animal model for screening anxiolytic drugs |
| Q37149641 | Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules |
| Q34660618 | Selected culture and drug-susceptibility testing methods for drug-resistant Mycobacterium tuberculosis screening in resource-constrained settings |
| Q31141271 | Selection of Drugs to Test the Specificity of the Tg.AC Assay by Screening for Induction of the gadd153 Promoter in Vitro |
| Q33616604 | Selection of in silico drug screening results by using universal active probes (UAPs). |
| Q31109328 | Selective cytotoxicity evaluation in anticancer drug screening of fractionated plant extracts |
| Q39137130 | Selective metabolic effects of gold nanorods on normal and cancer cells and their application in anticancer drug screening |
| Q35765278 | Selectivity screening and subsequent data evaluation strategies in liquid chromatography: the example of 12 antineoplastic drugs |
| Q34051836 | Self-reported cannabis use is inconsistent with the results from drug-screening in youth at ultra high-risk for psychosis in Colorado |
| Q28477499 | Self-reported risks for multiple-drug resistance among new tuberculosis cases: implications for drug susceptibility screening and treatment |
| Q34626314 | Sense and sensibility: the use of cell death biomarker assays in high-throughput anticancer drug screening and monitoring treatment responses |
| Q40846119 | Sensitive sentinel mutation screening reveals differential underestimation of transmitted HIV drug resistance among demographic groups |
| Q34749914 | Serial pediatric symptom checklist screening in children with prenatal drug exposure |
| Q37870675 | Sexually transmitted diseases in Manitoba: evaluation of physician treatment practices, STD drug utilization, and compliance with screening and treatment guidelines |
| Q41991292 | Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs |
| Q39044937 | Silicate fiber-based 3D cell culture system for anticancer drug screening |
| Q37113284 | Silicone breast implants and magnetic resonance imaging screening for rupture: do U.S. Food and Drug Administration recommendations reflect an evidence-based practice approach to patient care? |
| Q40321482 | Silkworm fungal infection model for identification of virulence genes in pathogenic fungus and screening of novel antifungal drugs. |
| Q37999103 | Simple and efficient model systems of screening anti-Toxoplasma drugs in vitro |
| Q34201426 | Simple and general criterion for "in silico" screening of candidate HIV drugs |
| Q40815903 | Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. |
| Q39067203 | Simple colorimetric trypanothione reductase-based assay for high-throughput screening of drugs against Leishmania intracellular amastigotes |
| Q39652498 | Simple fibroblast-based assay for screening of new antimicrobial drugs against Mycobacterium tuberculosis |
| Q39157890 | Simultaneous Screening and Quantification of Basic, Neutral and Acidic Drugs in Blood Using UPLC-QTOF-MS. |
| Q41883054 | Simultaneous Screening of 177 Drugs of Abuse in Urine Using Ultra-performance Liquid Chromatography with Tandem Mass Spectrometry in Drug-intoxicated Patients |
| Q44026701 | Simultaneous screening and detection of drugs in small blood samples and bloodstains |
| Q44341653 | Simultaneous screening and quantification of 25 opioid drugs in post-mortem blood and urine by liquid chromatography-tandem mass spectrometry |
| Q43268353 | Simultaneous screening and quantification of 29 drugs of abuse in oral fluid by solid-phase extraction and ultraperformance LC-MS/MS. |
| Q43198674 | Simultaneous screening and quantification of 52 common pharmaceuticals and drugs of abuse in hair using UPLC-TOF-MS. |
| Q43715600 | Simultaneous screening and quantitation of 18 antihistamine drugs in blood by liquid chromatography ionspray tandem mass spectrometry |
| Q44574363 | Simultaneous screening for 238 drugs in blood by liquid chromatography-ion spray tandem mass spectrometry with multiple-reaction monitoring |
| Q34102468 | Simultaneous screening for and determination of 128 date-rape drugs in urine by gas chromatography-electron ionization-mass spectrometry |
| Q33433558 | Simultaneously quantifying parent drugs and screening for metabolites in plasma pharmacokinetic samples using selected reaction monitoring information-dependent acquisition on a QTrap instrument |
| Q33294641 | Single drop microextraction as a concentrating probe for rapid screening of low molecular weight drugs from human urine in atmospheric-pressure matrix-assisted laser desorption/ionization mass spectrometry |
| Q37205515 | Single-bead, single-molecule, single-cell fluorescence: technologies for drug screening and target validation |
| Q37635528 | Skin Diseases in Laboratory Mice: Approaches to Drug Target Identification and Efficacy Screening. |
| Q30541089 | Small molecule drug screening in Drosophila identifies the 5HT2A receptor as a feeding modulation target |
| Q34029188 | Small molecule screening in zebrafish: an in vivo approach to identifying new chemical tools and drug leads |
| Q34784242 | Small molecule screening in zebrafish: swimming in potential drug therapies |
| Q43035262 | Small scale screening to determine the ability of different polymers to inhibit drug crystallization upon rapid solvent evaporation. |
| Q36890133 | Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake |
| Q33805140 | Snake venom: From fieldwork to the clinic: Recent insights into snake biology, together with new technology allowing high-throughput screening of venom, bring new hope for drug discovery |
| Q36989980 | Solid electrodes in electroanalytical chemistry: present applications and prospects for high throughput screening of drug compounds |
| Q36356303 | Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening |
| Q39393192 | Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer's disease drug candidates |
| Q36601823 | Stably transformed insect cell lines: tools for expression of secreted and membrane-anchored proteins and high-throughput screening platforms for drug and insecticide discovery |
| Q28534035 | Stage-regulated GFP Expression in Trypanosoma cruzi: applications from host-parasite interactions to drug screening |
| Q43924755 | Standardization of an in vitro drug screening assay by use of cryopreserved and characterized Pneumocystis carinii populations |
| Q38003414 | Stem cells as a novel tool for drug screening and treatment of degenerative diseases |
| Q36903246 | Stem cells as screening tools in drug discovery |
| Q37866053 | Stem cells for drug screening |
| Q42038314 | Stem cells in drug screening for neurodegenerative disease |
| Q38160462 | Stem cells: a model for screening, discovery and development of drugs |
| Q41191017 | Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs |
| Q34567213 | Strategies for absorption screening in drug discovery and development |
| Q31156013 | Strategies for the synthesis of novel indole alkaloid-based screening libraries for drug discovery |
| Q40758069 | Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? |
| Q37750881 | Structural ensemble in computational drug screening |
| Q42966308 | Structural modeling of the NS 3 helicase of Tick-borne encephalitis virus and their virtual screening of potent drugs using molecular docking |
| Q37284895 | Structural properties of non-traditional drug targets present new challenges for virtual screening |
| Q39152309 | Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery. |
| Q31074811 | Structure-based approaches to drug design and virtual screening. |
| Q40287512 | Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. |
| Q37481589 | Structure-based drug screening and ligand-based drug screening with machine learning. |
| Q38002626 | Structure-based drug screening for G-protein-coupled receptors |
| Q39430625 | Structure-based model profiles affinity constant of drugs with hPEPT1 for rapid virtual screening of hPEPT1's substrate |
| Q34608711 | Structure-based screening and design in drug discovery |
| Q43865391 | Structure-based screening of inhibitors against KPC-2: designing potential drug candidates against multidrug-resistant bacteria |
| Q35282223 | Structure-based virtual screening for drug discovery: principles, applications and recent advances. |
| Q33242317 | Structure-based virtual screening of chemical libraries for drug discovery |
| Q44197343 | Studies of interferences of apomorphine and its metabolites or decomposition products with immunochemical screening tests for legal and illicit drugs after therapeutic doses of apomorphine |
| Q44221644 | Studies on anti-tumor activity of crude drugs. I. The effects of aqueous extracts of some crude drugs in shortterm screening test. (1) |
| Q28238237 | Studies on identification of drugs of abuse by diode array detection. I. Screening-test and identification of benzodiazepines by HPLC-DAD with ICOS software system |
| Q35941859 | Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients |
| Q43879053 | Suicidality, depression screening, and antiepileptic drugs: reaction to the FDA alert |
| Q43621078 | Sulfa drug screening in yeast: fifteen sulfa drugs compete with p-aminobenzoate in Saccharomyces cerevisiae |
| Q43197229 | Supramolecular self-assembling cyanine as an alternative to ethidium bromide displacement in DNA-drug model interactions during high throughput screening |
| Q35074238 | Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study. |
| Q42228444 | Synthesis of 2-Oxo-1, 2-Dihydroquinoline Chemotype with Multiple Attachment Points as Novel Screening Compounds for Drug Discovery |
| Q36372524 | Synthesis of enantiomerically enriched drug precursors and an insect pheromone via reduction of ketones using commercially available carbonyl reductase screening kit "Chiralscreen® OH". |
| Q38779456 | Synthesis of the vitamin E amino acid esters with an enhanced anticancer activity and in silico screening for new antineoplastic drugs. |
| Q38809785 | Synthesis, biological evaluation, drug-likeness, and in silico screening of novel benzylidene-hydrazone analogues as small molecule anticancer agents |
| Q35565769 | Synthetic tumor networks for screening drug delivery systems |
| Q41278052 | Systematic Comparison of the Performance of Different 2D and 3D Ligand-Based Virtual Screening Methodologies to Discover Anticonvulsant Drugs |
| Q38729732 | Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer |
| Q36067934 | Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer |
| Q34640983 | Systematic evaluation of 640 FDA drugs for their effect on CD4⁺Foxp3⁺ regulatory T cells using a novel cell-based high throughput screening assay |
| Q30784753 | Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets |
| Q28541594 | Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity |
| Q39189373 | Systematic screening for drug-resistant tuberculosis with Xpert(®) MTB/RIF in a referral hospital in Cambodia |
| Q41155440 | Systematic screening for pharmacokinetic interactions during drug development |
| Q39169235 | Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug discovery |
| Q40321706 | T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication |
| Q28476702 | TCM Database@Taiwan: the world's largest traditional Chinese medicine database for drug screening in silico |
| Q37328244 | TPMT and DPD polymorphisms: Efficient screening method for Indian patients considering taking Thiopurine and 5-FU drugs. |
| Q38669024 | Tailored-pharmacophore model to enhance virtual screening and drug discovery: a case study on the identification of potential inhibitors against drug-resistant Mycobacterium tuberculosis (3R)-hydroxyacyl-ACP dehydratases. |
| Q35659453 | Tankyrase 1 Inhibitors with Drug-like Properties Identified by Screening a DNA-Encoded Chemical Library |
| Q38955696 | Tapered microtract array platform for antimigratory drug screening of human glioblastoma multiforme |
| Q40158257 | Target analysis and retrospective screening of veterinary drugs, ergot alkaloids, plant toxins and other undesirable substances in feed using liquid chromatography-high resolution mass spectrometry |
| Q30904633 | Target immobilization and NMR screening of fragments in early drug discovery |
| Q34705805 | Target-based vs. phenotypic screenings in Leishmania drug discovery: A marriage of convenience or a dialogue of the deaf? |
| Q31137259 | Targeted and non-targeted drug screening in whole blood by UHPLC-TOF-MS with data-independent acquisition |
| Q42269922 | Targeted hepatitis C screening among ex-injection drug users in the community |
| Q27680754 | Targeting Low-Druggability Bromodomains: Fragment Based Screening and Inhibitor Design against the BAZ2B Bromodomain |
| Q38889929 | Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening. |
| Q36192485 | Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening |
| Q36439166 | Targeting opioid receptor heterodimers: strategies for screening and drug development |
| Q34111157 | Targeting the proangiogenic VEGF-VEGFR protein-protein interface with drug-like compounds by in silico and in vitro screening |
| Q37309546 | Tau pathology is present in vivo and develops in vitro in sensory neurons from human P301S tau transgenic mice: a system for screening drugs against tauopathies |
| Q41481985 | The Acceptability and Feasibility of Screening for Alcohol and Drug Misuse in a Hospital Emergency Department |
| Q36724064 | The Ascaris suum nicotinic receptor, ACR-16, as a drug target: Four novel negative allosteric modulators from virtual screening. |
| Q37272084 | The C3H/HeJ mouse and DEBR rat models for alopecia areata: review of preclinical drug screening approaches and results. |
| Q35627447 | The Development of Protein Chips for High Throughput Screening (HTS) of Chemically Labeling Small Molecular Drugs |
| Q28818314 | The Development of Screening Methods to Identify Drugs to Limit ER Stress Using Wild-type and Mutant Serotonin Transporter |
| Q38353846 | The Discovery Channel: microfluidics and microengineered systems in drug screening |
| Q43041890 | The Food and Drug Administration approves second West Nile virus screening test for donated blood and organs |
| Q41234591 | The HBV-producing cell line HepG2-4A5: a new in vitro system for studying the regulation of HBV replication and for screening anti-hepatitis B virus drugs |
| Q39212870 | The HLJ1-targeting drug screening identified Chinese herb andrographolide that can suppress tumour growth and invasion in non-small-cell lung cancer. |
| Q42919381 | The N-terminal cytoplasmic region of NCBE displays features of an intrinsic disordered structure and represents a novel target for specific drug screening |
| Q41668148 | The National Institutes of Health Anticonvulsant Drug Development Program: screening for efficacy |
| Q64066030 | The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines |
| Q30468009 | The University of Kansas High-Throughput Screening Laboratory. Part II: enabling collaborative drug-discovery partnerships through cutting-edge screening technology |
| Q30468375 | The University of Kansas High-Throughput Screening laboratory. Part I: meeting drug-discovery needs in the heartland of America with entrepreneurial flair |
| Q33803835 | The Usefulness of the CRAFFT in Screening for Problematic Drug and Alcohol Use Among Youth Living with HIV. |
| Q38677673 | The Utility of Impulsive Bias and Altered Decision Making as Predictors of Drug Efficacy and Target Selection: Rethinking Behavioral Screening for Antidepressant Drugs |
| Q40259787 | The Virtual Screening of the Drug Protein with a Few Crystal Structures Based on the Adaboost-SVM. |
| Q37485947 | The ability of single screening questions for unhealthy alcohol and other drug use to identify substance dependence in primary care |
| Q36739144 | The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery |
| Q33782923 | The application of the Escherichia coli giant spheroplast for drug screening with automated planar patch clamp system |
| Q33323459 | The baculovirus display technology--an evolving instrument for molecular screening and drug delivery |
| Q37767606 | The beautiful cell: high-content screening in drug discovery |
| Q34691718 | The chakragati mouse: a mouse model for rapid in vivo screening of antipsychotic drug candidates. |
| Q41529103 | The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity |
| Q41931865 | The chemotherapy of rodent malaria, XXIII Causal prophylaxis, part II: Practical experience with Plasmodium yoelii nigeriensis in drug screening |
| Q35832370 | The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers |
| Q37764224 | The crystallographic structure of the human adenosine A2A receptor in a high-affinity antagonist-bound state: implications for GPCR drug screening and design |
| Q30465748 | The design and screening of drugs to prevent acquired sensorineural hearing loss |
| Q39790027 | The development and validation of the Indigenous Risk Impact Screen (IRIS): a 13-item screening instrument for alcohol and drug and mental health risk |
| Q42642405 | The development of a staggered parallel separation liquid chromatography/tandem mass spectrometry system with on-line extraction for high-throughout screening of drug candidates in biological fluids |
| Q33782409 | The development of a whole-cell based medium throughput screening system for the discovery of human aldosterone synthase (CYP11B2) inhibitors: old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and h |
| Q41934745 | The development of an FIA-CD strategy for screening sulfated polysaccharides using antimalarial drugs and related species as probes |
| Q38772165 | The development of high-content screening (HCS) technology and its importance to drug discovery |
| Q27490779 | The development, optimization and validation of an assay for high throughput antiviral drug screening against Dengue virus |
| Q27680079 | The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design |
| Q34280814 | The drug abuse screening test |
| Q35825959 | The effect of hypertension and hypercholesterolemia screening with subsequent intervention letter on the use of blood pressure and lipid lowering drugs |
| Q36379854 | The effect of screening for cardio-renal risk factors on drug use in the general population |
| Q41896609 | The efficacy of preemployment drug screening for marijuana and cocaine in predicting employment outcome |
| Q36425978 | The emerging importance of DNA mapping and other comprehensive screening techniques, as tools to identify new drug targets and as a means of (cancer) therapy personalisation. |
| Q41263901 | The epidemiology of drug abuse: current issues. Indicators of drug abuse--urinalysis screening |
| Q33599669 | The establishment of in vitro culture and drug screening systems for a newly isolated strain of Trypanosoma equiperdum |
| Q26341413 | The estimated predictive value of screening for illicit drugs in the workplace |
| Q40525229 | The evolution of workplace drug screening: a medical review officer's perspective |
| Q37291583 | The feasibility and acceptability of screening for hypertension in private drug retail outlets: a pilot study in Mwanza region, Tanzania |
| Q39293011 | The future of cancer research: prevention, screening, vaccines, and tumor-specific drug combos |
| Q33803985 | The gender of cell lines matters when screening for novel anti-cancer drugs |
| Q33984724 | The generation of induced pluripotent stem cells for macular degeneration as a drug screening platform: identification of curcumin as a protective agent for retinal pigment epithelial cells against oxidative stress |
| Q37212382 | The hERG potassium channel and hERG screening for drug-induced torsades de pointes |
| Q41809541 | The hen's fertile egg screening test (HEST): a comparison between the acute toxicity for chick embryos and rodents of 20 drugs |
| Q34557548 | The holistic integration of virtual screening in drug discovery |
| Q40513517 | The hollow fibre model in cancer drug screening: the NCI experience |
| Q37207158 | The impact of diversity-based, high-throughput screening on drug discovery: "chance favours the prepared mind". |
| Q36287029 | The impact of in silico screening in the discovery of novel and safer drug candidates |
| Q39380722 | The importance of screening solid-state phases of a racemic modification of a chiral drug: thermodynamic and structural characterization of solid-state phases of etiracetam. |
| Q43017995 | The influence of aqueous content in small scale salt screening--improving hit rate for weakly basic, low solubility drugs |
| Q43137166 | The malarial drug target Plasmodium falciparum 1-deoxy-D-xylulose-5-phosphate reductoisomerase (PfDXR): development of a 3-D model for identification of novel, structural and functional features and for inhibitor screening |
| Q37522503 | The modern spectrum of rhabdomyolysis: drug toxicity revealed by creatine kinase screening |
| Q34060933 | The multilayered postconfluent cell culture as a model for drug screening |
| Q41298980 | The popliteal lymph node assay in mice: screening of drugs and other chemicals for immunotoxic hazard |
| Q44244917 | The potential of the essential fatty acid-deficient hairless rat as a psoriasis screening model for topical anti-proliferative drugs. |
| Q36053813 | The programmed cell death GLuc PCA library - a powerful tool for pathway discovery and drug screening |
| Q41031188 | The respirophonogram as a means of drug screening (author's transl) |
| Q39322037 | The role of QSAR and virtual screening studies in type 2 diabetes drug discovery. |
| Q36393829 | The role of atelocollagen-based cell transfection array in high-throughput screening of gene functions and in drug discovery |
| Q31000827 | The role of data mining in pharmacovigilance |
| Q38345322 | The role of matrix compliance on cell responses to drugs and toxins: towards predictive drug screening platforms |
| Q43452258 | The screening of selected microorganisms for use as models of mammalian drug metabolism |
| Q43505959 | The screening test of various chemotherapeutic drugs in primary malignant melanoma cells and human malignant melanoma cell line (TM-1). |
| Q34206995 | The significance of drug analysis of sweat in respect to rapid screening for drug abuse |
| Q33486574 | The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure |
| Q36889010 | The substances and choices scale (SACS)--the development and testing of a new alcohol and other drug screening and outcome measurement instrument for young people. |
| Q42385195 | The use of HPLC-Q-TOF-MS for comprehensive screening of drugs and psychoactive substances in hair samples and several "legal highs" products |
| Q34286552 | The use of Xenopus oocytes in drug screening |
| Q33582989 | The use of administrative data as a substitute for individual screening scores in observational studies related to problematic alcohol or drug use. |
| Q35887644 | The use of isolated natural products as scaffolds for the generation of chemically diverse screening libraries for drug discovery |
| Q38037239 | The use of mammalian two-hybrid technologies for high-throughput drug screening |
| Q43152673 | The use of screening instruments for detecting alcohol and other drug use disorders in first-episode psychosis |
| Q41557981 | The use of ultra deep sequencing technique in the screening program on HIV-1 drug resistance mutation among ART-naїve patients in Hunan province |
| Q33771651 | The validity and reliability of the Mandarin Chinese version of the drug abuse screening test among adolescents in Taiwan |
| Q36342116 | The virtual heart as a platform for screening drug cardiotoxicity |
| Q34674770 | The voluntary acceptance of HIV-antibody screening by intravenous drug users |
| Q36608562 | Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole |
| Q38782433 | Thermo-responsive polymer aided spheroid culture in cryogel based platform for high throughput drug screening |
| Q37998087 | Thermodynamic studies for drug design and screening |
| Q28326761 | Thin-layer detection of diazepam and/or chilordiazepoxide alone or in combination with major drugs of abuse in drug abuse urine screening programs |
| Q44777804 | Thiopurine S-methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs |
| Q38568771 | Three dimensional de novo micro bone marrow and its versatile application in drug screening and regenerative medicine |
| Q30575882 | Three dimensional microfluidic cell arrays for ex vivo drug screening with mimicked vascular flow. |
| Q38724273 | Three-dimensional cell culture models for anticancer drug screening: Worth the effort? |
| Q42424639 | Three-dimensional perfused tumour spheroid model for anti-cancer drug screening. |
| Q35754291 | Time-lapse imaging assay using the BioStation CT: a sensitive drug-screening method for three-dimensional cell culture |
| Q40008099 | Tissue dynamics spectroscopy for three-dimensional tissue-based drug screening |
| Q26799470 | Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screening |
| Q34924483 | Toluene has antidepressant-like actions in two animal models used for the screening of antidepressant drugs. |
| Q28188510 | Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity |
| Q36697086 | Toward antituberculosis drugs: in silico screening of synthetic compounds against Mycobacterium tuberculosisl,d-transpeptidase 2 |
| Q44786637 | Toward fully automated high performance computing drug discovery: a massively parallel virtual screening pipeline for docking and molecular mechanics/generalized Born surface area rescoring to improve enrichment. |
| Q33669091 | Toward high-throughput drug screening on a chip-based parallel affinity separation platform. |
| Q41936404 | Toward the virtual screening of potential drugs in the homology modeled NAD+ dependent DNA ligase from Mycobacterium tuberculosis |
| Q40264218 | Towards holistic dual diagnosis care: physical health screening in a Victorian community-based alcohol and drug treatment service |
| Q41640351 | Towards intelligent anticancer drug screening in the post-genome era? |
| Q38279103 | Towards novel therapeutics for HIV through fragment-based screening and drug design |
| Q34487014 | ToxDBScan: Large-scale similarity screening of toxicological databases for drug candidates |
| Q34617246 | Toxicity from the use of niacin to beat urine drug screening |
| Q39346006 | Toxicity of orally inhaled drug formulations at the alveolar barrier: parameters for initial biological screening |
| Q38820849 | Toxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells |
| Q44575390 | Toxicologic screening in poisoning caused by drugs active on the central nervous system using a multiple immuno-enzymatic method |
| Q44115400 | Toxicological screening for drugs of abuse in samples adulterated with household chemicals |
| Q35236698 | Toxicological screening in heroin users: implications for management of drug misuse |
| Q33343575 | Toxicological screening of drugs by microbore high-performance liquid chromatography with photodiode-array detection and ultraviolet spectral library searches |
| Q35683938 | Toxicological screening of human plasma by on-line SPE-HPLC-DAD: identification and quantification of acidic and neutral drugs |
| Q35423794 | Toxicological screening of human plasma by on-line SPE-HPLC-DAD: identification and quantification of basic drugs and metabolites |
| Q30987813 | Toxicological screening of urine for drugs by liquid chromatography/time-of-flight mass spectrometry with automated target library search based on elemental formulas |
| Q39275951 | Toxicology screening in urban trauma patients: drug prevalence and its relationship to trauma severity and management |
| Q38581155 | Toxicophore exploration as a screening technology for drug design and discovery: techniques, scope and limitations |
| Q33623555 | Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer. |
| Q35016736 | Transgenic plants as low-cost platform for chemotherapeutic drugs screening |
| Q38287052 | Transmission of HIV drug resistance: lessons from sensitive screening assays. |
| Q36658131 | Transporter assays using solid supported membranes: a novel screening platform for drug discovery |
| Q28484497 | Trauma activation patients: evidence for routine alcohol and illicit drug screening |
| Q35587600 | Trends in ion channel drug discovery: advances in screening technologies |
| Q26859238 | Trends in protein-based biosensor assemblies for drug screening and pharmaceutical kinetic studies |
| Q33347904 | Trends in total cholesterol screening and in prescribing lipid-lowering drugs in general practice in the period 1994-2003. |
| Q35562454 | Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes |
| Q34750450 | Tumor necrosis factor receptor superfamily 10B (TNFRSF10B): an insight from structure modeling to virtual screening for designing drug against head and neck cancer |
| Q26777335 | Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs |
| Q37349683 | Turning up the pace of ion channel screening in drug discovery |
| Q33204076 | Type I methionine aminopeptidase from Saccharomyces cerevisiae is a potential target for antifungal drug screening. |
| Q28478649 | Tyrosine kinase syk non-enzymatic inhibitors and potential anti-allergic drug-like compounds discovered by virtual and in vitro screening |
| Q39313818 | Ultra rapid in vivo screening for anti-Alzheimer anti-amyloid drugs |
| Q35079731 | Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors |
| Q33806641 | Unbiased screening of polymer libraries to define novel substrates for functional hepatocytes with inducible drug metabolism |
| Q36234079 | Understanding drugs in breast cancer through drug sensitivity screening |
| Q36845382 | Uniform solid-phase extraction procedure for toxicological drug screening in serum and urine by HPLC with photodiode-array detection |
| Q34036311 | Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents |
| Q35103635 | Universal alcohol/drug screening in prenatal care: a strategy for reducing racial disparities? Questioning the assumptions |
| Q43712425 | Universal screening and drug treatment of dyslipidemia in children and adolescents |
| Q35814648 | Universal screening for alcohol and drug use and racial disparities in child protective services reporting |
| Q30952493 | Upscaling and automation of electrophysiology: toward high throughput screening in ion channel drug discovery |
| Q37063195 | Urinary antihypertensive drug metabolite screening using molecular networking coupled to high-resolution mass spectrometry fragmentation |
| Q28298195 | Urine benzodiazepines screening of involuntarily drugged and robbed or raped patients |
| Q40747130 | Urine drug screening and the family physician. |
| Q34626399 | Urine drug screening in adolescents |
| Q34453105 | Urine drug screening in the medical setting |
| Q43148281 | Urine drug screening: a valuable office procedure. |
| Q44348079 | Urine drug screening: opioid risks preclude complete patient autonomy |
| Q37049743 | Urine drug screening: practical guide for clinicians |
| Q40703900 | Use of Chlamydomonas reinhardtii mutants for anticancer drug screening |
| Q39769666 | Use of Freund's adjuvant arthritis test in anti-flammatory drug screening in the rat: value of animal selection and preparation at the breeding center |
| Q42940936 | Use of L4 larvae of Nippostrongylus brasiliensis for the in vivo screening of anthelmintic drugs. |
| Q42948051 | Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening |
| Q37720821 | Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered In Vivo Screening Paradigm for Development of Drugs To Treat Cutaneous Leishmaniasis. |
| Q33857553 | Use of a single alcohol screening question to identify other drug use |
| Q43194763 | Use of an algorithm applied to urine drug screening to assess adherence to an oxycontin regimen. |
| Q40313682 | Use of an online surveillance system for screening drug interactions in prescriptions in community pharmacies |
| Q28193525 | Use of ankle brachial index screening for selecting patients for antiplatelet drug therapy |
| Q35020639 | Use of cartilage derived from murine induced pluripotent stem cells for osteoarthritis drug screening. |
| Q44291465 | Use of high-performance liquid chromatography with diode-array detection after a primary drug screening in patients admitted to the emergency department |
| Q44546030 | Use of human neuroblastoma continuous cell lines for in vitro drug sensitivity screening |
| Q34093306 | Use of isogenic human cancer cells for high-throughput screening and drug discovery |
| Q41670120 | Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial |
| Q33959722 | Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database |
| Q43550101 | Use of standardized screening procedures to identify adverse drug reactions. |
| Q34246255 | Use of tremorine for screening anti-parkinsonian drugs |
| Q37534808 | Using CRISPR/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease. |
| Q38370364 | Using Docker Compose for the Simple Deployment of an Integrated Drug Target Screening Platform |
| Q35636931 | Using Hierarchical Virtual Screening To Combat Drug Resistance of the HIV-1 Protease |
| Q39686509 | Using a computerized drug prescription screening system to trace drug interactions in an outpatient setting. |
| Q31022565 | Using electronic health record data for substance use Screening, Brief Intervention, and Referral to Treatment among adults with type 2 diabetes: Design of a National Drug Abuse Treatment Clinical Trials Network study |
| Q36180934 | Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML |
| Q39034431 | Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies. |
| Q37999094 | Using label-free screening technology to improve efficiency in drug discovery |
| Q33436079 | Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine |
| Q44136597 | Using population screening for recruitment of young adults engaged in illicit drug use: methodological issues and sampling outcomes |
| Q30490605 | Using the pea aphid Acrythociphon pisum as a tool for screening biological responses to chemicals and drugs |
| Q34032565 | Using the zebrafish photomotor response for psychotropic drug screening |
| Q38976598 | Using zebrafish models of leukemia to streamline drug screening and discovery |
| Q36460071 | Utility of an improved model of amyloid-beta (Aβ₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease |
| Q39532720 | Utility of routine drug screening in a psychiatric emergency setting |
| Q35012705 | Utilization and cost effectiveness of standardized testing for screening and confirmation of drugs of abuse in urine. |
| Q38942888 | Utilization of an automated pipetting system in the cell line-based screening of the activity of a DNA-damaging anti-tumour drug. |
| Q40298672 | Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems. |
| Q38722694 | Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures. |
| Q33838630 | Utilizing Zebrafish Visual Behaviors in Drug Screening for Retinal Degeneration |
| Q40256723 | Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription |
| Q34066061 | Validating a firefly luciferase-based high-throughput screening assay for antimalarial drug discovery |
| Q36647089 | Validation of LC-TOF-MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens |
| Q36258417 | Validation of Self-Administered Single-Item Screening Questions (SISQs) for Unhealthy Alcohol and Drug Use in Primary Care Patients |
| Q33456199 | Validation of a screening questionnaire for a human milk bank to determine the presence of illegal drugs, nicotine, and caffeine. |
| Q34026612 | Validation of a short version of the revised drug use screening inventory in a Brazilian sample of adolescents |
| Q34132848 | Validation of novel fluorescence assays for the routine screening of drug susceptibilities of Trichomonas vaginalis |
| Q35758990 | Validation of the Drug Abuse Screening Test (DAST-10): A study on illicit drug use among Chinese pregnant women |
| Q33551732 | Validity of brief screening instrument for adolescent tobacco, alcohol, and drug use. |
| Q43602216 | Validity of screening methods for drugs of abuse in biological fluids I. Heroin in urine |
| Q34271643 | Validity of the CRAFFT in American-Indian and Alaska-Native adolescents: screening for drug and alcohol risk |
| Q42076934 | Value of rapid screening for acetaminophen in all patients with intentional drug overdose |
| Q39020240 | Vertebrate embryos as tools for anti-angiogenic drug screening and function. |
| Q28076767 | Viral hepatitis screening guideline before biological drug use in rheumatic patients |
| Q36087908 | Virtual Screening of Small Drug-Like Compounds Stimulating the Enzymatic Activity of Kallikrein-Related Peptidase 3 (KLK3). |
| Q33528248 | Virtual Screening of potential drug-like inhibitors against Lysine/DAP pathway of Mycobacterium tuberculosis |
| Q39635247 | Virtual compound screening in drug discovery |
| Q34263028 | Virtual darwinian drug design: QSAR inverse problem, virtual combinatorial chemistry, and computational screening |
| Q42382334 | Virtual drug screening for prion diseases: A valuable step? |
| Q41580527 | Virtual high throughput screening of carbapenem derivatives as new generation carbapenemase and penicillin binding protein inhibitors: a hunt to save drug of last resort |
| Q33525137 | Virtual screening and drug design for PDE-5 receptor from traditional Chinese medicine database |
| Q34149028 | Virtual screening and evaluation of Ketol-Acid Reducto-Isomerase (KARI) as a putative drug target for Aspergillosis. |
| Q41835114 | Virtual screening and in vitro assay of potential drug like inhibitors from spices against Glutathione-S-Transferase of Meloidogyne incognita |
| Q39756809 | Virtual screening and in vitro assay of potential drug like inhibitors from spices against glutathione-S-transferase of filarial nematodes |
| Q37066134 | Virtual screening and its integration with modern drug design technologies. |
| Q30977619 | Virtual screening and selection of drug-like compounds to block noggin interaction with bone morphogenetic proteins |
| Q42214607 | Virtual screening following rational drug design based approach for introducing new anti amyloid beta aggregation agent |
| Q33761638 | Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase |
| Q38097356 | Virtual screening in drug design |
| Q33541655 | Virtual screening in drug design and development. |
| Q33294074 | Virtual screening in drug discovery -- a computational perspective |
| Q35892808 | Virtual screening in structure-based drug discovery |
| Q34422811 | Virtual screening methods as tools for drug lead discovery from large chemical libraries |
| Q34626368 | Virtual screening of chemical libraries for drug discovery |
| Q33852942 | Virtual screening of intestinal drug permeability |
| Q28253252 | Virtual screening strategies in drug discovery |
| Q38104785 | Virtual screening strategies in drug discovery: a critical review. |
| Q38250453 | Virtual-screening targeting Human Immunodeficiency Virus type 1 integrase-lens epithelium-derived growth factor/p75 interaction for drug development |
| Q33830275 | Weak affinity chromatography as a new approach for fragment screening in drug discovery |
| Q34421776 | Web-based screening and brief intervention for poly-drug use among teenagers: study protocol of a multicentre two-arm randomized controlled trial |
| Q34337160 | Web-based training for primary care providers on screening, brief intervention, and referral to treatment (SBIRT) for alcohol, tobacco, and other drugs |
| Q31125195 | Weighted gene co-expression network analysis of colorectal cancer liver metastasis genome sequencing data and screening of anti-metastasis drugs |
| Q38444921 | What Can a Urine Drug Screening Immunoassay Really Tell Us? |
| Q42996080 | What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users? |
| Q34410513 | What is the future of (ultra) high performance liquid chromatography coupled to low and high resolution mass spectrometry for toxicological drug screening? |
| Q27902275 | When drug discovery meets web search: Learning to Rank for ligand-based virtual screening |
| Q40765815 | Which place for point-of-care screening tests in the diagnosis of hepatitis C infection among drug users? |
| Q39057684 | Wide-Scope Screening Method for Multiclass Veterinary Drug Residues in Fish, Shrimp, and Eel Using Liquid Chromatography-Quadrupole High-Resolution Mass Spectrometry |
| Q33849179 | Women's perspectives on screening for alcohol and drug use in prenatal care |
| Q23922421 | Work-related injuries in a state trauma registry: relationship between industry and drug screening |
| Q43217727 | Workplace urine screening for drug abuse |
| Q40668405 | Yeast as a Model for Studies on Aβ Aggregation Toxicity in Alzheimer's Disease, Autophagic Responses, and Drug Screening. |
| Q33253398 | Yeast models of human mitochondrial diseases: from molecular mechanisms to drug screening |
| Q42316646 | Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization |
| Q35019498 | Yeast three-hybrid screening for identifying anti-tuberculosis drug targets |
| Q41865521 | ZNStress: a high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis |
| Q38092194 | Zebrafish as a genetic model in pre-clinical drug testing and screening |
| Q38603263 | Zebrafish as an early stage screening tool to study the systemic circulation of nanoparticulate drug delivery systems in vivo |
| Q36546258 | Zebrafish assays for drug toxicity screening |
| Q42704507 | Zebrafish embryotoxicity test for developmental (neuro)toxicity: Demo case of an integrated screening approach system using anti-epileptic drugs |
| Q37846234 | Zebrafish for drug toxicity screening: bridging the in vitro cell-based models and in vivo mammalian models. |
| Q33775916 | Zebrafish models for functional and toxicological screening of nanoscale drug delivery systems: promoting preclinical applications |
| Q31137189 | [Corrigendum] Weighted gene co-expression network analysis of colorectal cancer liver metastasis genome sequencing data and screening of anti-metastasis drugs |
| Q34395018 | [Phenotype-based primary screening for drugs promoting neuronal subtype differentiation in embryonic stem cells with light microscope]. |
| Q64138079 | [Tat-based cell-cell fusion method for screening HIV-1 fusion inhibitors] |
| Q38597179 | iPSC-based drug screening for Huntington's disease |
| Q34824893 | in Silico analysis of Escherichia coli polyphosphate kinase (PPK) as a novel antimicrobial drug target and its high throughput virtual screening against PubChem library |
| Q37436081 | mQC: A Heuristic Quality-Control Metric for High-Throughput Drug Combination Screening. |
| Q33339028 | poolHiTS: a shifted transversal design based pooling strategy for high-throughput drug screening |
| Q37277365 | siRNA Genome Screening Approaches to Therapeutic Drug Repositioning |
| Q28184643 | Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive |